1. Olsson MG, Davidsson S, Muhammad ZD, et al. Increased levels of hemoglobin and
alpha1-microglobulin in Huntington's disease. Front Biosci (Elite Ed) 2012; 4:950-957.
2. Rosenblatt A, Kumar BV, Mo A, et al. Age, CAG repeat length, and clinical progression in
Huntington's disease. Mov Disord 2012; 27:272-276.
3. Hart E, Middelkoop H, Jurgens CK, Witjes-Ané MN, Roos RA. Seven-year clinical followup of premanifest carriers of Huntington's disease. PLoS Curr. 2011 Nov 30;3:RRN1288.
doi: 10.1371/currents.RRN1288.
4. Cubo E, González M, del Puerto I, de Yébenes JG, Arconada OF, Gabriel y Galán JM;
European Huntington's Disease Initiative Study Group Placebo effect characteristics
observed in a single, international, longitudinal study in Huntington's disease. Mov Disord.
2012 Mar;27(3):439-42. doi: 10.1002/mds.24062. Epub 2011 Dec 9.
5. Saft C, Andrich J, Fälker M, Gauda S, Küchler S, Woitalla D, Goetze O.No evidence of
impaired gastric emptying in early Huntington's Disease.PLoS Curr. 2011 Oct
25;3:RRN1284.
6. Vaccarino AL, Sills T, Anderson KE, Borowsky B, Craufurd D, Giuliano J, Goodman L,
Guttman M, Kupchak P, Ho AK, Paulsen JS, C Stout J, van Kammen DP, Evans K.
Assessment of Cognitive Symptoms in Prodromal and Early Huntington Disease. PLoS
Curr. 2011 Oct 25;3:RRN1250.
7. Hubers AA, Reedeker N, Giltay EJ, Roos RA, van Duijn E, van der Mast RC. Suicidality in
Huntington's disease. J Affect Disord. 2012 Feb;136(3):550-7. doi:
10.1016/j.jad.2011.10.031. Epub 2011 Nov 25.
8. Scahill RI, Hobbs NZ, Say MJ, Bechtel N, Henley SM, Hyare H, Langbehn DR, Jones R,
Leavitt BR, Roos RA, Durr A, Johnson H, Lehéricy S, Craufurd D, Kennard C, Hicks SL,
Stout JC, Reilmann R, Tabrizi SJ; the TRACK-HD investigators. Clinical impairment in
premanifest and early Huntington's disease is associated with regionally specific atrophy.
Hum Brain Mapp. 2011 Nov 18. doi: 10.1002/hbm.21449. [Epub ahead of print]
9. Meyer C, Landwehrmeyer B, Schwenke C, Doble A, Orth M, Ludolph AC; EHDI Study
Group. Rate of change in early Huntington's disease: a clinicometric analysis. Mov Disord.
2012 Jan;27(1):118-24. doi: 10.1002/mds.23847. Epub 2011 Nov 17.
10. Patel SS, Jankovic J, Hood AJ, Jeter CB, Sereno AB. Reflexive and volitional saccades:
biomarkers of Huntington disease severity and progression. J Neurol Sci. 2012 Feb
15;313(1-2):35-41. doi: 10.1016/j.jns.2011.09.035. Epub 2011 Oct 21.
11. Gatto E, Parisi V, Persi G, Converso DP, Etcheverry JL, Varela V, Alba L, Fretchel G.
Clinical and genetic characteristics in patients with Huntington's Disease from Argentina.
Parkinsonism Relat Disord. 2012 Feb;18(2):166-9. doi: 10.1016/j.parkreldis.2011.09.011.
Epub 2011 Oct 1.
12. Chen JJ, Salat DH, Rosas HD. Complex relationships between cerebral blood flow and
brain atrophy in early Huntington's disease. Neuroimage. 2012 Jan 16;59(2):1043-51. doi:
10.1016/j.neuroimage.2011.08.112. Epub 2011 Sep 16.
13. Seibert TM, Majid DS, Aron AR, Corey-Bloom J, Brewer JB. Stability of resting fMRI
interregional correlations analyzed in subject-native space: a one-year longitudinal study in
healthy adults and premanifest Huntington's disease. Neuroimage. 2012 Feb 1;59(3):245263. doi: 10.1016/j.neuroimage.2011.08.105. Epub 2011 Sep 10.
14. Vaccarino AL, Sills T, Anderson KE, Endicott J, Giuliano J, Guttman M, Ho AK, Kupchak
P, Paulsen JS, Warner JH, Williams J, Evans K. Assessment of Day-to-Day Functioning in
Prodromal and Early Huntington Disease. PLoS Curr. 2011 Sep 12;3:RRN1262.
15. Aylward EH, Liu D, Nopoulos PC, Ross CA, Pierson RK, Mills JA, Long JD, Paulsen JS;
PREDICT-HD Investigators and Coordinators of the Huntington Study Group.Striatal
volume contributes to the prediction of onset of Huntington disease in incident cases. Biol
Psychiatry. 2012 May 1;71(9):822-8.
16. Williams J, Downing N, Vaccarino AL, Guttman M, Paulsen JS. Self Reports of Day-toDay Function in a Small Cohort of People with Prodromal and Early HD. PLoS Curr. 2011
Aug 11;3:RRN1254. doi: 10.1371/currents.RRN1254.
17. Majerová V, Kalinčík T, Laczó J, Vyhnálek M, Hort J, Bojar M, Růžička E, Roth J.
Disturbance of real space navigation in moderately advanced but not in early Huntington's
disease. J Neurol Sci. 2012 Jan 15;312(1-2):86-91. doi: 10.1016/j.jns.2011.08.016. Epub
2011 Aug 27.
18. Zhang BR, Tian J, Yan YP, Yin XZ, Zhao GH, Wu ZY, Gu WH, Xia K, Tang BS. CCG
polymorphisms in the huntingtin gene have no effect on the pathogenesis of patients with
Huntington's disease in mainland Chinese families. J Neurol Sci. 2012 Jan 15;312(1-2):926. doi: 10.1016/j.jns.2011.08.015. Epub 2011 Aug 27.
19. Vaccarino AL, Anonymous, Anderson KE, Borowsky B, Coccaro E, Craufurd D, Endicott
J, Giuliano J, Groves M, Guttman M, Ho AK, Kupchak P, Paulsen JS, Stanford MS, van
Kammen DP, Watson D, Wu KD, Evans K. Assessing Behavioural Manifestations Prior to
Clinical Diagnosis of Huntington Disease: "Anger and Irritability" and "Obsessions and
Compulsions"PLoS Curr. 2011 Jul 11;3:RRN1241.
20. Wild E, Magnusson A, Lahiri N, Krus U, Orth M, Tabrizi SJ, Björkqvist M. Abnormal
peripheral chemokine profile in Huntington's disease. PLoS Curr. 2011 Apr 13;3:RRN1231.
doi: 10.1371/currents.RRN1231.
21. Ready RE, O'Rourke JJ, Paulsen JS. Quality of Life in Prodromal HD: Qualitative Analyses
of Discourse from Participants and Companions. Neurol Res Int. 2011;2011:958439. doi:
10.1155/2011/958439. Epub 2011 Jul 21.
22. Vaccarino AL, Sills T, Anderson KE, Biglan K, Borowsky B, Giuliano J, Guttman M, Ho
AK, Kennard C, Kupchak P, Landwehrmeyer GB, Michell A, Paulsen JS, Reilmann R, van
Kammen DP, Warner JH, Evans K. Assessment of motor symptoms and functional impact
in prodromal and early huntington disease. Version 2. PLoS Curr. 2011 Jun 14 [revised
2011 Jul 11];2:RRN1244.
23. Jurgens CK, van der Hiele K, Reijntjes RH, van de Wiel L, Witjes-Ané MN, van der Grond
J, Roos RA, Middelkoop HA, van Dijk JG. Basal ganglia volume is strongly related to P3
event-related potential in premanifest Huntington's disease. Eur J Neurol. 2011
Aug;18(8):1105-8. doi: 10.1111/j.1468-1331.2010.03309.x. Epub 2011 Jan 25.
24. Ho AK, Hocaoglu MB; European Huntington's Disease Network Quality of Life Working
Group. Impact of Huntington's across the entire disease spectrum: the phases and stages of
disease from the patient perspective. Clin Genet. 2011 Sep;80(3):235-9. doi:
10.1111/j.1399-0004.2011.01748.x. Epub 2011 Aug 4.
25. Vaccarino AL, Sills T, Anderson KE, Bachoud-Lévi AC, Borowsky B, Craufurd D, Duff K,
Giuliano J, Groves M, Guttman M, Kupchak P, Ho AK, Paulsen JS, Pedersen KF, van
Duijn E, van Kammen DP, Evans K. Assessment of Depression, Anxiety and Apathy in
Prodromal and Early Huntington Disease. PLoS Curr. 2011 Jun 17;3:RRN1242.
26. Kassubek J, Pinkhardt EH, Dietmaier A, Ludolph AC, Landwehrmeyer GB, Huppertz HJ.
Fully automated atlas-based MR imaging volumetry in Huntington disease, compared with
manual volumetry. AJNR Am J Neuroradiol. 2011 Aug;32(7):1328-32. doi:
10.3174/ajnr.A2514. Epub 2011 Jun 16.
27. Brožová H, Stochl J, Klempíř J, Kucharík M, Růžička E, Roth J. A sensitivity comparison
of clinical tests for postural instability in patients with Huntington's disease. Gait Posture.
2011 Jun;34(2):245-7. doi: 10.1016/j.gaitpost.2011.05.006. Epub 2011 Jun 8.
28. Henderson T, Georgiou-Karistianis N, White O, Millist L, Williams DR, Churchyard A,
Fielding J. Inhibitory control during smooth pursuit in Parkinson's disease and Huntington's
disease. Mov Disord. 2011 Aug 15;26(10):1893-9. doi: 10.1002/mds.23757. Epub 2011
May 31.
29. Rosas HD, Reuter M, Doros G, Lee SY, Triggs T, Malarick K, Fischl B, Salat DH, Hersch
SM. A tale of two factors: what determines the rate of progression in Huntington's disease?
A longitudinal MRI study. Mov Disord. 2011 Aug 1;26(9):1691-7. doi:
10.1002/mds.23762. Epub 2011 May 24.
30. Aylward E, Mills J, Liu D, Nopoulos P, Ross CA, Pierson R, Paulsen JS. Association
between Age and Striatal Volume Stratified by CAG Repeat Length in Prodromal
Huntington Disease. PLoS Curr. 2011 May 11;3:RRN1235. doi:
10.1371/currents.RRN1235.
31. Esmaeilzadeh M, Kullingsjö J, Ullman H, Varrone A, Tedroff J. Regional cerebral glucose
metabolism after pridopidine (ACR16) treatment in patients with Huntington disease. Clin
Neuropharmacol. 2011 May-Jun;34(3):95-100. doi: 10.1097/WNF.0b013e31821c31d8.
32. Wolf RC, Grön G, Sambataro F, Vasic N, Wolf ND, Thomann PA, Saft C, Landwehrmeyer
GB, Orth M. Magnetic resonance perfusion imaging of resting-state cerebral blood flow in
preclinical Huntington's disease. J Cereb Blood Flow Metab. 2011 Sep;31(9):1908-18. doi:
10.1038/jcbfm.2011.60. Epub 2011 May 11.
33. Hobbs NZ, Pedrick AV, Say MJ, Frost C, Dar Santos R, Coleman A, Sturrock A, Craufurd
D, Stout JC, Leavitt BR, Barnes J, Tabrizi SJ, Scahill RI. The structural involvement of the
cingulate cortex in premanifest and early Huntington's disease. Mov Disord. 2011 Aug
1;26(9):1684-90. doi: 10.1002/mds.23747. Epub 2011 May 6.
34. Rosenblatt A, Kumar BV, Margolis RL, Welsh CS, Ross CA. Factors contributing to
institutionalization in patients with Huntington's disease. Mov Disord. 2011 Aug
1;26(9):1711-6. doi: 10.1002/mds.23716. Epub 2011 Apr 29.
35. De Tommaso M, Serpino C, Difruscolo O, Cormio C, Sciruicchio V, Franco G, Farella I,
Livrea P. Nociceptive inputs transmission in Huntington's disease: a study by laser evoked
potentials. Acta Neurol Belg. 2011 Mar;111(1):33-40.
36. Gaughwin PM, Ciesla M, Lahiri N, Tabrizi SJ, Brundin P, Björkqvist M. Hsa-miR-34b is a
plasma-stable microRNA that is elevated in pre-manifest Huntington's disease. Hum Mol
Genet. 2011 Jun 1;20(11):2225-37. doi: 10.1093/hmg/ddr111. Epub 2011 Mar 19.
37. Vaccarino AL, Anderson K, Borowsky B, Duff K, Giuliano J, Guttman M, Ho AK, Orth M,
Paulsen JS, Sills T, van Kammen DP, Evans KR; PREDICT-HD and REGISTRY
Investigators Coordinators. An item response analysis of the motor and behavioral
subscales of the unified Huntington's disease rating scale in huntington disease gene
expansion carriers. Mov Disord. 2011 Apr;26(5):877-84. doi: 10.1002/mds.23574. Epub
2011 Mar 2.
38. Klempíř J, Zidovská J, Stochl J, Ing VK, Uhrová T, Roth J. The number of CAG repeats
within the normal allele does not influence the age of onset in Huntington's disease. Mov
Disord. 2011 Jan;26(1):125-9. doi: 10.1002/mds.23436. Epub 2010 Nov 10.
39. Lovrecic L, Slavkov I, Dzeroski S, Peterlin B. ADP-ribosylation factor guanine nucleotideexchange factor 2 (ARFGEF2): a new potential biomarker in Huntington's disease. J Int
Med Res. 2010 Sep-Oct;38(5):1653-62.
40. Dumas EM, van den Bogaard SJ, Ruber ME, Reilman RR, Stout JC, Craufurd D, Hicks SL,
Kennard C, Tabrizi SJ, van Buchem MA, van der Grond J, Roos RA. Early changes in
white matter pathways of the sensorimotor cortex in premanifest Huntington's disease. Hum
Brain Mapp. 2012 Jan;33(1):203-12. doi: 10.1002/hbm.21205. Epub 2011 Jan 24.
41. Panzera R, Salomonczyk D, Pirogovosky E, Simmons R, Goldstein J, Corey-Bloom J,
Gilbert PE. Postural deficits in Huntington's disease when performing motor skills involved
in daily living. Gait Posture. 2011 Mar;33(3):457-61. doi:10.1016/j.gaitpost.2010.12.025.
Epub 2011 Jan 20.
42. Politis M, Pavese N, Tai YF, Kiferle L, Mason SL, Brooks DJ, Tabrizi SJ, Barker RA,
Piccini P. Microglial activation in regions related to cognitive function predicts disease
onset in Huntington's disease: a multimodal imaging study. Hum Brain Mapp. 2011
Feb;32(2):258-70. doi: 10.1002/hbm.21008.
43. Tomasi G, Bertoldo A, Cobelli C, Pavese N, Tai YF, Hammers A, Turkheimer FE. Globaltwo-stage filtering of clinical PET parametric maps: application to [(11)C]-(R)-PK11195.
Neuroimage. 2011 Apr 1;55(3):942-53. doi: 10.1016/j.neuroimage.2010.12.056. Epub 2010
Dec 30.
44. Jesse S, Brettschneider J, Süssmuth SD, Landwehrmeyer BG, von Arnim CA, Ludolph AC,
Tumani H, Otto M. Summary of cerebrospinal fluid routine parameters in
neurodegenerative diseases. J Neurol. 2011 Jun;258(6):1034-41. doi: 10.1007/s00415-0105876-x. Epub 2010 Dec 25.
45. Bombard Y, Palin J, Friedman JM, Veenstra G, Creighton S, Paulsen JS, Bottorff JL,
Hayden MR; Canadian Respond-HD Collaborative Research Group. Factors associated
with experiences of genetic discrimination among individuals at risk for Huntington
disease. Am J Med Genet B Neuropsychiatr Genet. 2011 Jan;156B(1):19-27. doi:
10.1002/ajmg.b.31130. Epub 2010 Nov 10.
46. Panegyres PK, Goh JG. The neurology and natural history of patients with indeterminate
CAG repeat length mutations of the Huntington disease gene. J Neurol Sci. 2011 Feb
15;301(1-2):14-20. doi: 10.1016/j.jns.2010.11.015. Epub 2010 Dec 13.
47. Krogias C, Strassburger K, Eyding J, Gold R, Norra C, Juckel G, Saft C, Ninphius D.
Depression in patients with Huntington disease correlates with alterations of the brain stem
raphe depicted by transcranial sonography. J Psychiatry Neurosci. 2011 May;36(3):187-94.
doi: 10.1503/jpn.100067.
48. Tabrizi SJ, Scahill RI, Durr A, Roos RA, Leavitt BR, Jones R, Landwehrmeyer GB, Fox
NC, Johnson H, Hicks SL, Kennard C, Craufurd D, Frost C, Langbehn DR, Reilmann R,
Stout JC; TRACK-HD Investigators. Biological and clinical changes in premanifest and
early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal
analysis. Lancet Neurol. 2011 Jan;10(1):31-42. doi: 10.1016/S1474-4422(10)70276-3.
Epub 2010 Dec 2.
49. Say MJ, Jones R, Scahill RI, Dumas EM, Coleman A, Santos RC, Justo D, Campbell JC,
Queller S, Shores EA, Tabrizi SJ, Stout JC; TRACK-HD Investigators. Visuomotor
integration deficits precede clinical onset in Huntington's disease. Neuropsychologia. 2011
Jan;49(2):264-70. doi: 10.1016/j.neuropsychologia.2010.11.016. Epub 2010 Nov 20.
50. Bombard Y, Palin J, Friedman JM, Veenstra G, Creighton S, Paulsen JS, Bottorff JL,
Hayden MR; Canadian Respond-HD Collaborative Research Group. Factors associated
with experiences of genetic discrimination among individuals at risk for Huntington
disease. Am J Med Genet B Neuropsychiatr Genet. 2011 Jan;156B(1):19-27. doi:
10.1002/ajmg.b.31130. Epub 2010 Nov 10.
51. Klempíř J, Zidovská J, Stochl J, Ing VK, Uhrová T, Roth J. The number of CAG repeats
within the normal allele does not influence the age of onset in Huntington's disease. Mov
Disord. 2011 Jan;26(1):125-9. doi: 10.1002/mds.23436. Epub 2010 Nov 10.
52. Bechtel N, Scahill RI, Rosas HD, Acharya T, van den Bogaard SJ, Jauffret C, Say MJ,
Sturrock A, Johnson H, Onorato CE, Salat DH, Durr A, Leavitt BR, Roos RA,
Landwehrmeyer GB, Langbehn DR, Stout JC, Tabrizi SJ, Reilmann R. Tapping linked to
function and structure in premanifest and symptomatic Huntington disease. Neurology.
2010 Dec 14;75(24):2150-60. doi: 10.1212/WNL.0b013e3182020123. Epub 2010 Nov 10.
53. Klein A, Sacrey LA, Dunnett SB, Whishaw IQ, Nikkhah G. Proximal movements
compensate for distal forelimb movement impairments in a reach-to-eat task in
Huntington's disease: new insights into motor impairments in a real-world skill. Neurobiol
Dis. 2011 Feb;41(2):560-9. doi: 10.1016/j.nbd.2010.11.002. Epub 2010 Nov 5.
54. Kloos AD, Kegelmeyer DA, Young GS, Kostyk SK. Fall risk assessment using the Tinetti
mobility test in individuals with Huntington's disease. Mov Disord. 2010 Dec
15;25(16):2838-44. doi: 10.1002/mds.23421.
55. Stout JC, Paulsen JS, Queller S, Solomon AC, Whitlock KB, Campbell JC, Carlozzi N,
Duff K, Beglinger LJ, Langbehn DR, Johnson SA, Biglan KM, Aylward EH.
Neurocognitive signs in prodromal Huntington disease. Neuropsychology. 2011
Jan;25(1):1-14. doi: 10.1037/a0020937.
56. Orth M, Handley OJ, Schwenke C, Dunnett SB, Craufurd D, Ho AK, Wild E, Tabrizi SJ,
Landwehrmeyer GB; Investigators of the European Huntington's Disease Network.
Observing Huntington's Disease: the European Huntington's Disease Network's
REGISTRY. Version 2. PLoS Curr. 2010 Sep 28 [revised 2011 Apr 13];2:RRN1184.
57. Aylward EH, Nopoulos PC, Ross CA, Langbehn DR, Pierson RK, Mills JA, Johnson HJ,
Magnotta VA, Juhl AR, Paulsen JS; PREDICT-HD Investigators and Coordinators of
Huntington Study Group. Longitudinal change in regional brain volumes in prodromal
Huntington disease. J Neurol Neurosurg Psychiatry. 2011 Apr;82(4):405-10. doi:
10.1136/jnnp.2010.208264. Epub 2010 Sep 30.
58. Salvatore E, Rinaldi C, Tucci T, Di Maio L, Di Somma C, Savastano S, Lombardi G, Filla
A, Colao A, De Michele G. Growth hormone response to arginine test differentiates
between two subgroups of Huntington's disease patients. J Neurol Neurosurg Psychiatry.
2011 May;82(5):543-7. doi: 10.1136/jnnp.2010.208553. Epub 2010 Sep 30.
59. Jurgens CK, Jasinschi R, Ekin A, Witjes-Ané MN, Middelkoop H, van der Grond J, Roos
RA. MRI T2 Hypointensities in basal ganglia of premanifest Huntington's disease.PLoS
Curr. 2010 Sep 8;2. pii: RRN1173. doi: 10.1371/currents.RRN1173.
60. Reilmann R, Bohlen S, Klopstock T, Bender A, Weindl A, Saemann P, Auer DP,
Ringelstein EB, Lange HW. Grasping premanifest Huntington's disease - shaping new
endpoints for new trials. Mov Disord. 2010 Dec 15;25(16):2858-62. doi:
10.1002/mds.23300.
61. Salomonczyk D, Panzera R, Pirogovosky E, Goldstein J, Corey-Bloom J, Simmons R,
Gilbert PE. Impaired postural stability as a marker of premanifest Huntington's disease.
Mov Disord. 2010 Oct 30;25(14):2428-33. doi: 10.1002/mds.23309.
62. Ginestroni A, Battaglini M, Diciotti S, Della Nave R, Mazzoni LN, Tessa C, Giannelli M,
Piacentini S, De Stefano N, Mascalchi M. Magnetization transfer MR imaging
demonstrates degeneration of the subcortical and cortical gray matter in Huntington disease.
AJNR Am J Neuroradiol. 2010 Nov;31(10):1807-12. doi: 10.3174/ajnr.A2225. Epub 2010
Sep 2.
63. Goldberg A, Schepens SL, Feely SM, Garbern JY, Miller LJ, Siskind CE, Conti GE.
Deficits in stepping response time are associated with impairments in balance and mobility
in people with Huntington disease. J Neurol Sci. 2010 Nov 15;298(1-2):91-5. doi:
10.1016/j.jns.2010.08.002.
64. Gamez J, Lorenzo-Bosquet C, Cuberas-Borrós G, Carmona F, Hernández-Vara J, Castilló J,
Castell-Conesa J. Does reduced [(123)I]-FP-CIT binding in Huntington's disease suggest
pre-synaptic dopaminergic involvement? Clin Neurol Neurosurg. 2010 Dec;112(10):870-5.
doi: 10.1016/j.clineuro.2010.07.014. Epub 2010 Aug 19.
65. Huntington Study Group DOMINO Investigators. A futility study of minocycline in
Huntington's disease. Mov Disord. 2010 Oct 15;25(13):2219-24. doi: 10.1002/mds.23236.
66. van Duijn E, Reedeker N, Giltay EJ, Roos RA, van der Mast RC. Correlates of apathy in
Huntington's disease. J Neuropsychiatry Clin Neurosci. 2010 Summer;22(3):287-94. doi:
10.1176/appi.neuropsych.22.3.287.
67. Soneson C, Fontes M, Zhou Y, Denisov V, Paulsen JS, Kirik D, Petersén A; Huntington
Study Group PREDICT-HD investigators. Early changes in the hypothalamic region in
prodromal Huntington disease revealed by MRI analysis. Neurobiol Dis. 2010
Dec;40(3):531-43. doi: 10.1016/j.nbd.2010.07.013. Epub 2010 Aug 2.
68. Reilmann R, Bohlen S, Klopstock T, Bender A, Weindl A, Saemann P, Auer DP,
Ringelstein EB, Lange HW. Tongue force analysis assesses motor phenotype in premanifest
and symptomatic Huntington's disease. Mov Disord. 2010 Oct 15;25(13):2195-202. doi:
10.1002/mds.23243.
69. Reedeker N, Van Der Mast RC, Giltay EJ, Van Duijn E, Roos RA. Hypokinesia in
Huntington's disease co-occurs with cognitive and global dysfunctioning. Mov Disord.
2010 Aug 15;25(11):1612-8. doi: 10.1002/mds.23136.
70. Peavy GM, Jacobson MW, Goldstein JL, Hamilton JM, Kane A, Gamst AC, Lessig SL, Lee
JC, Corey-Bloom J. Cognitive and functional decline in Huntington's disease: dementia
criteria revisited. Mov Disord. 2010 Jul 15;25(9):1163-9. doi: 10.1002/mds.22953.
71. Paulsen JS, Wang C, Duff K, Barker R, Nance M, Beglinger L, Moser D, Williams JK,
Simpson S, Langbehn D, van Kammen DP; PREDICT-HD Investigators of the Huntington
Study Group. Challenges assessing clinical endpoints in early Huntington disease. Mov
Disord. 2010 Nov 15;25(15):2595-603. doi: 10.1002/mds.23337.
72. Lundin A, Dietrichs E, Haghighi S, Göller ML, Heiberg A, Loutfi G, Widner H, Wiktorin
K, Wiklund L, Svenningsson A, Sonesson C, Waters N, Waters S, Tedroff J. Efficacy and
safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's
disease. Clin Neuropharmacol. 2010 Sep-Oct;33(5):260-4. doi:
10.1097/WNF.0b013e3181ebb285.
73. Rowe KC, Paulsen JS, Langbehn DR, Duff K, Beglinger LJ, Wang C, O'Rourke JJ, Stout
JC, Moser DJ. Self-paced timing detects and tracks change in prodromal Huntington
disease. Neuropsychology. 2010 Jul;24(4):435-42. doi: 10.1037/a0018905.
74. Cavaco S, Anderson SW, Correia M, Magalhaes M, Pereira C, Tuna A, Taipa R, Pinto P,
Pinto C, Cruz R, Lima AB, Castro-Caldas A, da Silva AM, Damasio H. Task-specific
contribution of the human striatum to perceptual-motor skill learning. J Clin Exp
Neuropsychol. 2011 Jan;33(1):51-62. doi: 10.1080/13803395.2010.493144. Epub 2010 Jul
5.
75. Mochel F, Duteil S, Marelli C, Jauffret C, Barles A, Holm J, Sweetman L, Benoist JF,
Rabier D, Carlier PG, Durr A. Dietary anaplerotic therapy improves peripheral tissue
energy metabolism in patients with Huntington's disease. Eur J Hum Genet. 2010
Sep;18(9):1057-60. doi: 10.1038/ejhg.2010.72. Epub 2010 May 26.
76. Della Nave R, Ginestroni A, Tessa C, Giannelli M, Piacentini S, Filippi M, Mascalchi M.
Regional distribution and clinical correlates of white matter structural damage in
Huntington disease: a tract-based spatial statistics study. AJNR Am J Neuroradiol. 2010
Oct;31(9):1675-81. doi: 10.3174/ajnr.A2128. Epub 2010 May 20.
77. Beglinger LJ, O'Rourke JJ, Wang C, Langbehn DR, Duff K, Paulsen JS; Huntington Study
Group Investigators. Earliest functional declines in Huntington disease.Psychiatry Res.
2010 Jul 30;178(2):414-8. doi: 10.1016/j.psychres.2010.04.030. Epub 2010 May 15.
78. Wild EJ, Henley SM, Hobbs NZ, Frost C, MacManus DG, Barker RA, Fox NC, Tabrizi SJ.
Rate and acceleration of whole-brain atrophy in premanifest and early Huntington's disease.
Mov Disord. 2010 May 15;25(7):888-95. doi: 10.1002/mds.22969.
79. Anderson KE, Gehl CR, Marder KS, Beglinger LJ, Paulsen JS; Huntington's Study Group.
Comorbidities of obsessive and compulsive symptoms in Huntington's disease. J Nerv Ment
Dis. 2010 May;198(5):334-8. doi: 10.1097/NMD.0b013e3181da852a.
80. Rizk-Jackson A, Stoffers D, Sheldon S, Kuperman J, Dale A, Goldstein J, Corey-Bloom J,
Poldrack RA, Aron AR. Evaluating imaging biomarkers for neurodegeneration in presymptomatic Huntington's disease using machine learning techniques.Neuroimage. 2011
May 15;56(2):788-96. doi: 10.1016/j.neuroimage.2010.04.273. Epub 2010 May 6.
81. Stoffers D, Sheldon S, Kuperman JM, Goldstein J, Corey-Bloom J, Aron AR. Contrasting
gray and white matter changes in preclinical Huntington disease: an MRI study.Neurology.
2010 Apr 13;74(15):1208-16. doi: 10.1212/WNL.0b013e3181d8c20a.
82. Paulsen JS, Nopoulos PC, Aylward E, Ross CA, Johnson H, Magnotta VA, Juhl A, Pierson
RK, Mills J, Langbehn D, Nance M; PREDICT-HD Investigators and Coordinators of the
Huntington's Study Group (HSG). Striatal and white matter predictors of estimated
diagnosis for Huntington disease.Brain Res Bull. 2010 May 31;82(3-4):201-7. doi:
10.1016/j.brainresbull.2010.04.003. Epub 2010 Apr 10.
83. Hobbs NZ, Barnes J, Frost C, Henley SM, Wild EJ, Macdonald K, Barker RA, Scahill RI,
Fox NC, Tabrizi SJ. Onset and progression of pathologic atrophy in Huntington disease: a
longitudinal MR imaging study. AJNR Am J Neuroradiol. 2010 Jun;31(6):1036-41. doi:
10.3174/ajnr.A2018. Epub 2010 Feb 11.
84. Velasco García MJ, Cobeta I, Martín G, Alonso-Navarro H, Jimenez-Jimenez FJ. Acoustic
analysis of voice in Huntington's disease patients. J Voice. 2011 Mar;25(2):208-17. doi:
10.1016/j.jvoice.2009.08.007. Epub 2010 Feb 4.
85. Auinger P, Kieburtz K, McDermott MP. The relationship between uric acid levels and
Huntington's disease progression. Mov Disord. 2010 Jan 30;25(2):224-8. doi:
10.1002/mds.22907.
86. Gallina P, Paganini M, Lombardini L, Mascalchi M, Porfirio B, Gadda D, Marini M,
Pinzani P, Salvianti F, Crescioli C, Bucciantini S, Mechi C, Sarchielli E, Romoli AM,
Bertini E, Urbani S, Bartolozzi B, De Cristofaro MT, Piacentini S, Saccardi R, Pupi A,
Vannelli GB, Di Lorenzo N. Human striatal neuroblasts develop and build a striatal-like
structure into the brain of Huntington's disease patients after transplantation. Exp Neurol.
2010 Mar;222(1):30-41. doi: 10.1016/j.expneurol.2009.12.005. Epub 2009 Dec 21.
87. Hobbs NZ, Henley SM, Ridgway GR, Wild EJ, Barker RA, Scahill RI, Barnes J, Fox NC,
Tabrizi SJ. The progression of regional atrophy in premanifest and early Huntington's
disease: a longitudinal voxel-based morphometry study. J Neurol Neurosurg Psychiatry.
2010 Jul;81(7):756-63. doi: 10.1136/jnnp.2009.190702. Epub 2009 Dec 1.
88. van Walsem MR, Sundet K, Retterstøl L, Sundseth Ø. A double blind evaluation of
cognitive decline in a Norwegian cohort of asymptomatic carriers of Huntington's disease. J
Clin Exp Neuropsychol. 2010 Jul;32(6):590-8. doi: 10.1080/13803390903337878. Epub
2009 Nov 12.
89. De Souza J, Jones LA, Rickards H. Validation of self-report depression rating scales in
Huntington's disease. Mov Disord. 2010 Jan 15;25(1):91-6. doi: 10.1002/mds.22837.
90. Beglinger LJ, Duff K, Allison J, Theriault D, O'Rourke JJ, Leserman A, Paulsen JS
Cognitive change in patients with Huntington disease on the Repeatable Battery for the
Assessment of Neuropsychological Status. .J Clin Exp Neuropsychol. 2010 Jul;32(6):573-8.
doi: 10.1080/13803390903313564. Epub 2009 Oct 29.
91. Klöppel S, Stonnington CM, Petrovic P, Mobbs D, Tüscher O, Craufurd D, Tabrizi SJ,
Frackowiak RS. Irritability in pre-clinical Huntington's disease.Neuropsychologia. 2010
Jan;48(2):549-57. doi: 10.1016/j.neuropsychologia.2009.10.016. Epub 2009 Oct 28.
92. Pavese N, Politis M, Tai YF, Barker RA, Tabrizi SJ, Mason SL, Brooks DJ, Piccini P.
Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene
carriers. Neurobiol Dis. 2010 Feb;37(2):356-61. doi: 10.1016/j.nbd.2009.10.015. Epub
2009 Oct 22.
93. Rosas HD, Lee SY, Bender AC, Zaleta AK, Vangel M, Yu P, Fischl B, Pappu V, Onorato
C, Cha JH, Salat DH, Hersch SM. Altered white matter microstructure in the corpus
callosum in Huntington's disease: implications for cortical "disconnection".Neuroimage.
2010 Feb 15;49(4):2995-3004. doi: 10.1016/j.neuroimage.2009.10.015. Epub 2009 Oct 19.
94. Mazzoni P, Wexler NS. Parallel explicit and implicit control of reaching. PLoS One. 2009
Oct 22;4(10):e7557. doi: 10.1371/journal.pone.0007557.
95. Aziz NA, Pijl H, Frölich M, Schröder-van der Elst JP, van der Bent C, Roelfsema F, Roos
RA. Growth hormone and ghrelin secretion are associated with clinical severity in
Huntington's disease. Eur J Neurol. 2010 Feb;17(2):280-8. doi: 10.1111/j.14681331.2009.02798.x. Epub 2009 Oct 21.
96. Squitieri F, Falleni A, Cannella M, Orobello S, Fulceri F, Lenzi P, Fornai F. Abnormal
morphology of peripheral cell tissues from patients with Huntington disease.J Neural
Transm. 2010 Jan;117(1):77-83. doi: 10.1007/s00702-009-0328-4. Epub 2009 Oct 16.
97. Jurgens CK, Bos R, Luyendijk J, Witjes-Ané MN, van der Grond J, Middelkoop HA, Roos
RA. Magnetization transfer imaging in 'premanifest' Huntington's disease.J Neurol. 2010
Mar;257(3):426-32. doi: 10.1007/s00415-009-5339-4. Epub 2009 Oct 13.
98. Aziz NA, Jurgens CK, Landwehrmeyer GB; EHDN Registry Study Group, van Roon-Mom
WM, van Ommen GJ, Stijnen T, Roos RA. Normal and mutant HTT interact to affect
clinical severity and progression in Huntington disease. Neurology. 2009 Oct
20;73(16):1280-5. doi: 10.1212/WNL.0b013e3181bd1121. Epub 2009 Sep 23.
99. Xu EH, Tang Y, Li D, Jia JP. Polymorphism of HD and UCHL-1 genes in Huntington's
disease. J Clin Neurosci. 2009 Nov;16(11):1473-7. doi: 10.1016/j.jocn.2009.03.027. Epub
2009 Aug 14.
100. Alonso ME, Ochoa A, Boll MC, Sosa AL, Yescas P, López M, Macias R, Familiar I,
Rasmussen A. Clinical and genetic characteristics of Mexican Huntington's disease patients.
Mov Disord. 2009 Oct 15;24(13):2012-5. doi: 10.1002/mds.22737.
101. Weiss A, Abramowski D, Bibel M, Bodner R, Chopra V, DiFiglia M, Fox J, Kegel K,
Klein C, Grueninger S, Hersch S, Housman D, Régulier E, Rosas HD, Stefani M, Zeitlin S,
Bilbe G, Paganetti P. Single-step detection of mutant huntingtin in animal and human
tissues: a bioassay for Huntington's disease. Anal Biochem. 2009 Dec 1;395(1):8-15. doi:
10.1016/j.ab.2009.08.001. Epub 2009 Aug 6.
102. Marder K, Zhao H, Eberly S, Tanner CM, Oakes D, Shoulson I; Huntington Study
Group. Dietary intake in adults at risk for Huntington disease: analysis of PHAROS
research
participants.Neurology.
2009
Aug
4;73(5):385-92.
doi:
10.1212/WNL.0b013e3181b04aa2.
103. Rao AK, Louis ED, Marder KS. Clinical assessment of mobility and balance impairments
in pre-symptomatic Huntington's disease. Gait Posture. 2009 Oct;30(3):391-3. doi:
10.1016/j.gaitpost.2009.07.006. Epub 2009 Jul 31.
104. Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, Kennard C, Hicks
SL, Fox NC, Scahill RI, Borowsky B, Tobin AJ, Rosas HD, Johnson H, Reilmann R,
Landwehrmeyer B, Stout JC; TRACK-HD investigators. Biological and clinical
manifestations of Huntington's disease in the longitudinal TRACK-HD study: crosssectional analysis of baseline data. Lancet Neurol. 2009 Sep;8(9):791-801. doi:
10.1016/S1474-4422(09)70170-X. Epub 2009 Jul 29.
105. Robert MP, Nachev PC, Hicks SL, Golding CV, Tabrizi SJ, Kennard C. Saccadometry of
conditional rules in presymptomatic Huntington's disease. Ann N Y Acad Sci. 2009
May;1164:444-50. doi: 10.1111/j.1749-6632.2008.03736.x.
106. Pirogovsky E, Goldstein J, Peavy G, Jacobson MW, Corey-Bloom J, Gilbert PE.
Temporal order memory deficits prior to clinical diagnosis in Huntington's disease. J Int
Neuropsychol Soc. 2009 Sep;15(5):662-70. doi: 10.1017/S1355617709990427. Epub 2009
Jul 28.
107. Boesgaard TW, Nielsen TT, Josefsen K, Hansen T, Jørgensen T, Pedersen O, Nørremølle
A, Nielsen JE, Hasholt L. Huntington's disease does not appear to increase the risk of
diabetes mellitus. J Neuroendocrinol. 2009 Sep;21(9):770-6. doi: 10.1111/j.13652826.2009.01898.x. Epub 2009 Jul 7.
108. Biglan KM, Ross CA, Langbehn DR, Aylward EH, Stout JC, Queller S, Carlozzi NE,
Duff K, Beglinger LJ, Paulsen JS; PREDICT-HD Investigators of the Huntington Study
Group. Motor abnormalities in premanifest persons with Huntington's disease: the
PREDICT-HD study. Mov Disord. 2009 Sep 15;24(12):1763-72. doi: 10.1002/mds.22601.
109. Blekher T, Weaver MR, Cai X, Hui S, Marshall J, Jackson JG, Wojcieszek J, Yee RD,
Foroud TM. Test-retest reliability of saccadic measures in subjects at risk for Huntington
disease. Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5707-11. doi: 10.1167/iovs.09-3538.
Epub 2009 Jun 24.
110. Aziz NA, Pijl H, Frölich M, van der Graaf AW, Roelfsema F, Roos RA. Leptin secretion
rate increases with higher CAG repeat number in Huntington's disease patients.Clin
Endocrinol (Oxf). 2010 Aug;73(2):206-11. doi: 10.1111/j.1365-2265.2009.03661.x. Epub
2009 Jun 22.
111. Hobbs NZ, Henley SM, Wild EJ, Leung KK, Frost C, Barker RA, Scahill RI, Barnes J,
Tabrizi SJ, Fox NC.Automated quantification of caudate atrophy by local registration of
serial MRI: evaluation and application in Huntington's disease.Neuroimage. 2009 Oct
1;47(4):1659-65. doi: 10.1016/j.neuroimage.2009.06.003. Epub 2009 Jun
112. Duff K, Beglinger LJ, Theriault D, Allison J, Paulsen JS. Cognitive deficits in
Huntington's disease on the Repeatable Battery for the Assessment of Neuropsychological
Status.J Clin Exp Neuropsychol. 2010 Mar;32(3):231-8. doi: 10.1080/13803390902926184.
Epub 2009 May 29.
113. Klöppel S, Draganski B, Siebner HR, Tabrizi SJ, Weiller C, Frackowiak RS. Functional
compensation of motor function in pre-symptomatic Huntington's disease.Brain. 2009
Jun;132(Pt 6):1624-32. doi: 10.1093/brain/awp081. Epub 2009 Apr 15.
114. Squitieri F, Orobello S, Cannella M, Martino T, Romanelli P, Giovacchini G, Frati L,
Mansi L, Ciarmiello A. Riluzole protects Huntington disease patients from brain glucose
hypometabolism and grey matter volume loss and increases production of neurotrophins.
Eur J Nucl Med Mol Imaging. 2009 Jul;36(7):1113-20. doi: 10.1007/s00259-009-1103-3.
Epub 2009 Mar 11.
115. Warby SC, Montpetit A, Hayden AR, Carroll JB, Butland SL, Visscher H, Collins JA,
Semaka A, Hudson TJ, Hayden MR. CAG expansion in the Huntington disease gene is
associated with a specific and targetable predisposing haplogroup. Am J Hum Genet. 2009
Mar;84(3):351-66. doi: 10.1016/j.ajhg.2009.02.003. Epub 2009 Feb 26.
116. Magnotta VA, Kim J, Koscik T, Beglinger LJ, Espinso D, Langbehn D, Nopoulos P,
Paulsen JS. Diffusion Tensor Imaging in Preclinical Huntington's Disease. Brain Imaging
Behav. 2009 Mar 1;3(1):77-84.
117. Henley SM, Wild EJ, Hobbs NZ, Frost C, MacManus DG, Barker RA, Fox NC, Tabrizi
SJ. Whole-brain atrophy as a measure of progression in premanifest and early Huntington's
disease.Mov Disord. 2009 Apr 30;24(6):932-6. doi: 10.1002/mds.22485.
118. Sritharan A, Egan GF, Johnston L, Horne M, Bradshaw JL, Bohanna I, Asadi H,
Cunnington R, Churchyard AJ, Chua P, Farrow M, Georgiou-Karistianis N. A longitudinal
diffusion tensor imaging study in symptomatic Huntington's disease. J Neurol Neurosurg
Psychiatry. 2010 Mar;81(3):257-62. doi: 10.1136/jnnp.2007.142786. Epub 2009 Feb 22.
119. Squitieri F, Cannella M, Simonelli M, Sassone J, Martino T, Venditti E, Ciammola A,
Colonnese C, Frati L, Ciarmiello A. Distinct brain volume changes correlating with clinical
stage, disease progression rate, mutation size, and age at onset prediction as early
biomarkers of brain atrophy in Huntington's disease. CNS Neurosci Ther. 2009
Winter;15(1):1-11. doi: 10.1111/j.1755-5949.2008.00068.x.
120. Schippling S, Schneider SA, Bhatia KP, Münchau A, Rothwell JC, Tabrizi SJ, Orth M.
Abnormal motor cortex excitability in preclinical and very early Huntington's disease. Biol
Psychiatry. 2009 Jun 1;65(11):959-65. doi: 10.1016/j.biopsych.2008.12.026. Epub 2009
Feb 7.
121. Brandt J, Inscore AB, Ward J, Shpritz B, Rosenblatt A, Margolis RL, Ross CA.
Neuropsychological deficits in Huntington's disease gene carriers and correlates of early
"conversion".
J Neuropsychiatry Clin Neurosci. 2008 Fall;20(4):466-72. doi:
10.1176/appi.neuropsych.20.4.466.
122. Klöppel S, Chu C, Tan GC, Draganski B, Johnson H, Paulsen JS, Kienzle W, Tabrizi SJ,
Ashburner J, Frackowiak RS; PREDICT-HD Investigators of the Huntington Study Group.
Automatic detection of preclinical neurodegeneration: presymptomatic Huntington disease
Neurology. 2009 Feb 3;72(5):426-31. doi: 10.1212/01.wnl.0000341768.28646.b6.
123. Aziz NA, Pijl H, Frölich M, van der Graaf AW, Roelfsema F, Roos RA.Increased
hypothalamic-pituitary-adrenal axis activity in Huntington's disease.J Clin Endocrinol
Metab. 2009 Apr;94(4):1223-8. doi: 10.1210/jc.2008-2543. Epub 2009 Jan 27.
124. Jurgens CK, van de Wiel L, van Es AC, Grimbergen YM, Witjes-Ané MN, van der
Grond J, Middelkoop HA, Roos RA. Basal ganglia volume and clinical correlates in
'preclinical' Huntington's disease.
J Neurol. 2008 Nov;255(11):1785-91. doi:
10.1007/s00415-008-0050-4. Epub 2008 Dec 8.
125. van Oostrom JC, Dekker M, Willemsen AT, de Jong BM, Roos RA, Leenders KL.
Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington's disease. Eur
J Neurol. 2009 Feb;16(2):226-31. doi: 10.1111/j.1468-1331.2008.02390.x. Epub 2008 Dec
9.
126. Weydt P, Soyal SM, Gellera C, Didonato S, Weidinger C, Oberkofler H, Landwehrmeyer
GB, Patsch W. The gene coding for PGC-1alpha modifies age at onset in Huntington's
Disease.Mol Neurodegener. 2009 Jan 8;4:3. doi: 10.1186/1750-1326-4-3.
127. Rao AK, Muratori L, Louis ED, Moskowitz CB, Marder KS. Clinical measurement of
mobility and balance impairments in Huntington's disease: validity and responsiveness.
Gait Posture. 2009 Apr;29(3):433-6. doi: 10.1016/j.gaitpost.2008.11.002. Epub 2008 Dec
25.
128. Dorsey ER, Beck CA, Adams M, Chadwick G, de Blieck EA, McCallum C, Briner L,
Deuel L, Clarke A, Stewart R, Shoulson I; Huntington Study Group TREND-HD
Investigators. Communicating clinical trial results to research participants. Arch Neurol.
2008 Dec;65(12):1590-5. doi: 10.1001/archneurol.2008.503.
129. Huntington Study Group TREND-HD Investigators. Randomized controlled trial of
ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol.
2008 Dec;65(12):1582-9. doi: 10.1001/archneur.65.12.1582.
130. Herishanu YO, Parvari R, Pollack Y, Shelef I, Marom B, Martino T, Cannella M,
Squitieri F. Huntington disease in subjects from an Israeli Karaite community carrying
alleles of intermediate and expanded CAG repeats in the HTT gene: Huntington disease or
phenocopy? J Neurol Sci. 2009 Feb 15;277(1-2):143-6. doi: 10.1016/j.jns.2008.11.005.
Epub 2008 Dec 6.
131. Constantinescu R, Romer M, Oakes D, Rosengren L, Kieburtz K. Levels of the light
subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington's disease.
Parkinsonism Relat Disord. 2009 Mar;15(3):245-8.doi:10.1016/j.parkreldis.2008.05.012.
Epub 2008 Dec 4.
132. Blekher T, Weaver MR, Marshall J, Hui S, Jackson JG, Stout JC, Beristain X,
Wojcieszek J, Yee RD, Foroud TM. Visual scanning and cognitive performance in
prediagnostic and early-stage Huntington's disease. Mov Disord. 2009 Mar 15;24(4):53340. doi: 10.1002/mds.22329.
133. Fasano A, Cadeddu F, Guidubaldi A, Piano C, Soleti F, Zinzi P, Bentivoglio AR. The
long-term effect of tetrabenazine in the management of Huntington disease. Clin
Neuropharmacol. 2008 Nov-Dec;31(6):313-8. doi: 10.1097/WNF.0b013e318166da60.
134. van Duijn E, Kingma EM, Timman R, Zitman FG, Tibben A, Roos RA, van der Mast
RC. Cross-sectional study on prevalences of psychiatric disorders in mutation carriers of
Huntington's disease compared with mutation-negative first-degree relatives. J Clin
Psychiatry. 2008 Nov;69(11):1804-10. Epub 2008 Nov 4.
135. Beglinger LJ, Paulsen JS, Watson DB, Wang C, Duff K, Langbehn DR, Moser DJ,
Paulson HL, Aylward EH, Carlozzi NE, Queller S, Stout JC. Obsessive and compulsive
symptoms in prediagnosed Huntington's disease. J Clin Psychiatry. 2008 Nov;69(11):175865. Epub 2008 Sep 9.
136. Busse ME, Hughes G, Wiles CM, Rosser AE. Use of hand-held dynamometry in the
evaluation of lower limb muscle strength in people with Huntington's disease. J Neurol.
2008 Oct;255(10):1534-40. doi: 10.1007/s00415-008-0964-x. Epub 2008 Aug 2.
137. Dure LS, Quaid K, Beasley TM. A pilot assessment of parental practices and attitudes
regarding risk disclosure and clinical research involving children in Huntington disease
families. Genet Med. 2008 Nov;10(11):811-9. doi: 10.1097/GIM.0b013e31818adb01.
138. Gallina P, Paganini M, Di Rita A, Lombardini L, Moretti M, Vannelli GB, Di Lorenzo N.
Human fetal striatal transplantation in huntington's disease: a refinement of the stereotactic
procedure. Stereotact Funct Neurosurg. 2008;86(5):308-13. doi: 10.1159/000155233. Epub
2008 Sep 15.
139. Gaba A, Zhang K, Moskowitz CB, Boozer CN, Marder K. Harris-Benedict equation
estimations of energy needs as compared to measured 24-h energy expenditure by indirect
calorimetry in people with early to mid-stage Huntington's disease. Nutr Neurosci. 2008
Oct;11(5):213-8. doi: 10.1179/147683008X344129.
140. Wolf RC, Sambataro F, Vasic N, Schönfeldt-Lecuona C, Ecker D, Landwehrmeyer B.
Altered frontostriatal coupling in pre-manifest Huntington's disease: effects of increasing
cognitive load. Eur J Neurol. 2008 Nov;15(11):1180-90. doi: 10.1111/j.14681331.2008.02253.x. Epub 2008 Aug 27.
141. Mancuso M, Kiferle L, Petrozzi L, Nesti C, Rocchi A, Ceravolo R, Orsucci D, Maluccio
MR, Bonuccelli U, Filosto M, Siciliano G, Murri L. Mitochondrial DNA haplogroups do
not influence the Huntington's disease phenotype. Neurosci Lett. 2008 Oct 17;444(1):83-6.
doi: 10.1016/j.neulet.2008.08.013. Epub 2008 Aug 8.
142. Gómez-Ansón B, Alegret M, Muñoz E, Monté GC, Alayrach E, Sánchez A, Boada M,
Tolosa E. Prefrontal cortex volume reduction on MRI in preclinical Huntington's disease
relates to visuomotor performance and CAG number.Parkinsonism Relat Disord. 2009
Mar;15(3):213-9. doi: 10.1016/j.parkreldis.2008.05.010. Epub 2008 Jul 15.
143. Futter MJ, Heckmann JM, Greenberg LJ. Predictive testing for Huntington disease in a
developing country. Clin Genet. 2009 Jan;75(1):92-7. doi: 10.1111/j.13990004.2008.01044.x. Epub 2008 Jun 18.
144. Ravina B, Romer M, Constantinescu R, Biglan K, Brocht A, Kieburtz K, Shoulson I,
McDermott MP. The relationship between CAG repeat length and clinical progression in
Huntington's disease. Mov Disord. 2008 Jul 15;23(9):1223-7. doi: 10.1002/mds.21988.
145. Michell AW, Goodman AO, Silva AH, Lazic SE, Morton AJ, Barker RA. Hand tapping:
a simple, reproducible, objective marker of motor dysfunction in Huntington's disease. J
Neurol. 2008 Aug;255(8):1145-52. doi: 10.1007/s00415-008-0859-x. Epub 2008 May 13.
146. C. Licklederer, G. Wolff, and J. Barth. Mental health and quality of life after genetic
testing for Huntington disease: a long-term effect study in Germany. Am.J.Med.Genet.A
146A (16):2078-2085, 2008.
147. E. Oster, E. R. Dorsey, J. Bausch, A. Shinaman, E. Kayson, D. Oakes, I. Shoulson, and
K. Quaid. Fear of health insurance loss among individuals at risk for Huntington disease.
Am.J.Med.Genet.A 146A (16):2070-2077, 2008.
148. M. Bjorkqvist, E. J. Wild, J. Thiele, A. Silvestroni, R. Andre, N. Lahiri, E. Raibon, R. V.
Lee, C. L. Benn, D. Soulet, A. Magnusson, B. Woodman, C. Landles, M. A. Pouladi, M. R.
Hayden, A. Khalili-Shirazi, M. W. Lowdell, P. Brundin, G. P. Bates, B. R. Leavitt, T.
Moller, and S. J. Tabrizi. A novel pathogenic pathway of immune activation detectable
before clinical onset in Huntington's disease. J.Exp.Med. 205 (8):1869-1877, 2008.
149. S. Almeida, A. B. Sarmento-Ribeiro, C. Januario, A. C. Rego, and C. R. Oliveira.
Evidence of apoptosis and mitochondrial abnormalities in peripheral blood cells of
Huntington's disease patients. Biochem.Biophys.Res.Commun. 374 (4):599-603, 2008.
150. R. C. Wolf, F. Sambataro, N. Vasic, C. Schonfeldt-Lecuona, D. Ecker, and B.
Landwehrmeyer. Aberrant connectivity of lateral prefrontal networks in presymptomatic
Huntington's disease. Exp.Neurol. 213 (1):137-144, 2008.
151. S. Frank, W. Ondo, S. Fahn, C. Hunter, D. Oakes, S. Plumb, F. Marshall, I. Shoulson, S.
Eberly, F. Walker, S. Factor, V. Hunt, A. Shinaman, and J. Jankovic. A study of chorea
after tetrabenazine withdrawal in patients with Huntington disease. Clin.Neuropharmacol.
31 (3):127-133, 2008.
152. Delval, P. Krystkowiak, J. L. Blatt, M. Delliaux, A. Destee, P. Derambure, and L.
Defebvre. [Evolution of locomotion disorders in Huntington's disease]. Neurophysiol.Clin.
38 (2):117-125, 2008.
153. T. M. Jeitner, W. R. Matson, J. E. Folk, J. P. Blass, and A. J. Cooper. Increased levels of
gamma-glutamylamines in Huntington disease CSF. J.Neurochem. 106 (1):37-44, 2008.
154. B. F. O'Donnell, T. M. Blekher, M. Weaver, K. M. White, J. Marshall, X. Beristain, J. C.
Stout, J. Gray, J. M. Wojcieszek, and T. M. Foroud. Visual perception in prediagnostic and
early stage Huntington's disease. J.Int.Neuropsychol.Soc. 14 (3):446-453, 2008.
155. Arnulf, J. Nielsen, E. Lohmann, J. Schieffer, E. Wild, P. Jennum, E. Konofal, M. Walker,
D. Oudiette, S. Tabrizi, and A. Durr. Rapid eye movement sleep disturbances in Huntington
disease. Arch.Neurol. 65 (4):482-488, 2008.
156. N. M. Lalic, J. Maric, M. Svetel, A. Jotic, E. Stefanova, K. Lalic, N. Dragasevic, T.
Milicic, L. Lukic, and V. S. Kostic. Glucose homeostasis in Huntington disease:
abnormalities in insulin sensitivity and early-phase insulin secretion. Arch.Neurol. 65
(4):476-480, 2008.
157. S. M. Henley, E. J. Wild, N. Z. Hobbs, J. D. Warren, C. Frost, R. I. Scahill, G. R.
Ridgway, D. G. MacManus, R. A. Barker, N. C. Fox, and S. J. Tabrizi. Defective emotion
recognition in early HD is neuropsychologically and anatomically generic.
Neuropsychologia 46 (8):2152-2160, 2008.
158. Y. A. Grimbergen, M. J. Knol, B. R. Bloem, B. P. Kremer, R. A. Roos, and M. Munneke.
Falls and gait disturbances in Huntington's disease. Mov Disord. 23 (7):970-976, 2008.
159. J. Craig, H. Hietanen, I. S. Markova, and G. E. Berrios. The Irritability Questionnaire: a
new scale for the measurement of irritability. Psychiatry Res. 159 (3):367-375, 2008.
160. Reuter, Y. F. Tai, N. Pavese, K. R. Chaudhuri, S. Mason, C. E. Polkey, C. Clough, D. J.
Brooks, R. A. Barker, and P. Piccini. Long-term clinical and positron emission tomography
outcome
of
fetal
striatal
transplantation
in
Huntington's
disease.
J.Neurol.Neurosurg.Psychiatry 79 (8):948-951, 2008.
161. D. S. Magazi, A. Krause, V. Bonev, M. Moagi, Z. Iqbal, M. Dludla, and C. H. van der
Meyden. Huntington's disease: genetic heterogeneity in black African patients. S.Afr.Med.J.
98 (3):200-203, 2008.
162. H. D. Rosas, D. H. Salat, S. Y. Lee, A. K. Zaleta, V. Pappu, B. Fischl, D. Greve, N.
Hevelone, and S. M. Hersch. Cerebral cortex and the clinical expression of Huntington's
disease: complexity and heterogeneity. Brain 131 (Pt 4):1057-1068, 2008.
163. M. Teichmann, V. Gaura, J. F. Demonet, F. Supiot, M. Delliaux, C. Verny, P. Renou, P.
Remy, and A. C. Bachoud-Levi. Language processing within the striatum: evidence from a
PET correlation study in Huntington's disease. Brain 131 (Pt 4):1046-1056, 2008.
164. K. Hodl, E. Hodl, D. V. Otti, B. Herranhof, R. Ille, and R. M. Bonelli. Ideomotor limb
apraxia in Huntington's disease: a case-control study. J.Neurol. 255 (3):331-339, 2008.
165. Duff, L. J. Beglinger, M. E. O'Rourke, P. Nopoulos, H. L. Paulson, and J. S. Paulsen.
Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in
Huntington's disease. Ann.Clin.Psychiatry 20 (1):1-3, 2008.
166. E. M. Kingma, Duijn E. van, R. Timman, R. C. van der Mast, and R. A. Roos.
Behavioural problems in Huntington's disease using the Problem Behaviours Assessment.
Gen.Hosp.Psychiatry 30 (2):155-161, 2008.
167. O. Goodman, P. R. Murgatroyd, G. Medina-Gomez, N. I. Wood, N. Finer, A. J. VidalPuig, A. J. Morton, and R. A. Barker. The metabolic profile of early Huntington's disease--a
combined human and transgenic mouse study. Exp.Neurol. 210 (2):691-698, 2008.
168. S. Peretti, F. Ferreri, F. Blanchard, S. Bakchine, C. R. Peretti, A. Dobrescu, V. A.
Chouinard, and G. Chouinard. Normal and pathological aging of attention in
presymptomatic Huntington's, Huntington's and Alzheimer's Disease, and nondemented
elderly subjects. Psychother.Psychosom. 77 (3):139-146, 2008.
169. M. Couette, A. C. Bachoud-Levi, P. Brugieres, E. Sieroff, and P. Bartolomeo. Orienting
of spatial attention in Huntington's Disease. Neuropsychologia 46 (5):1391-1400, 2008.
170. C. Beste, C. Saft, J. Andrich, R. Gold, and M. Falkenstein. Response inhibition in
Huntington's disease-a study using ERPs and sLORETA. Neuropsychologia 46 (5):12901297, 2008.
171. C. Saft, A. Schuttke, C. Beste, J. Andrich, W. Heindel, and B. Pfleiderer. fMRI reveals
altered auditory processing in manifest and premanifest Huntington's disease.
Neuropsychologia 46 (5):1279-1289, 2008.
172. Peltsch, A. Hoffman, I. Armstrong, G. Pari, and D. P. Munoz. Saccadic impairments in
Huntington's disease. Exp.Brain Res. 186 (3):457-469, 2008.
173. Beste, C. Saft, J. Andrich, R. Gold, and M. Falkenstein. Stimulus-response compatibility
in Huntington's disease: a cognitive-neurophysiological analysis. J.Neurophysiol. 99
(3):1213-1223, 2008.
174. Fenney, M. S. Jog, and C. Duval. Bradykinesia is not a "systematic" feature of adultonset Huntington's disease; implications for basal ganglia pathophysiology. Brain Res.
1193:67-75, 2008.
175. Delval, P. Krystkowiak, M. Delliaux, K. Dujardin, J. L. Blatt, A. Destee, P. Derambure,
and L. Defebvre. Role of attentional resources on gait performance in Huntington's disease.
Mov Disord. 23 (5):684-689, 2008.
176. R. E. Ready, M. Mathews, A. Leserman, and J. S. Paulsen. Patient and caregiver quality
of life in Huntington's disease. Mov Disord. 23 (5):721-726, 2008.
177. D. Crupi, M. F. Ghilardi, C. Mosiello, Rocco A. Di, A. Quartarone, and F. Battaglia.
Cortical and brainstem LTP-like plasticity in Huntington's disease. Brain Res.Bull. 75
(1):107-114, 2008.
178. S. Paulsen, D. R. Langbehn, J. C. Stout, E. Aylward, C. A. Ross, M. Nance, M. Guttman,
S. Johnson, M. MacDonald, L. J. Beglinger, K. Duff, E. Kayson, K. Biglan, I. Shoulson, D.
Oakes, and M. Hayden. Detection of Huntington's disease decades before diagnosis: the
Predict-HD study. J.Neurol.Neurosurg.Psychiatry 79 (8):874-880, 2008.
179. C. Stout, M. Weaver, A. C. Solomon, S. Queller, S. Hui, S. A. Johnson, J. Gray, X.
Beristain, J. Wojcieszek, and T. Foroud. Are cognitive changes progressive in prediagnostic
HD? Cogn Behav.Neurol. 20 (4):212-218, 2007.
180. S. Paradiso, B. M. Turner, J. S. Paulsen, R. Jorge, L. L. Ponto, and R. G. Robinson.
Neural bases of dysphoria in early Huntington's disease. Psychiatry Res. 162 (1):73-87,
2008.
181. Fenney, M. S. Jog, and C. Duval. Short-term variability in amplitude and motor
topography of whole-body involuntary movements in Parkinson's disease dyskinesias and
in Huntington's chorea. Clin.Neurol.Neurosurg. 110 (2):160-167, 2008.
182. Gelder B. de, Stock J. Van den, Rde D. Balaguer, and A. C. Bachoud-Levi. Huntington's
disease impairs recognition of angry and instrumental body language. Neuropsychologia 46
(1):369-373, 2008.
183. Beste, C. Saft, J. Andrich, T. Muller, R. Gold, and M. Falkenstein. Time processing in
Huntington's disease: a group-control study. PLoS.ONE. 2 (12):e1263, 2007.
184. S. Kloppel, B. Draganski, C. V. Golding, C. Chu, Z. Nagy, P. A. Cook, S. L. Hicks, C.
Kennard, D. C. Alexander, G. J. Parker, S. J. Tabrizi, and R. S. Frackowiak. White matter
connections reflect changes in voluntary-guided saccades in pre-symptomatic Huntington's
disease. Brain 131 (Pt 1):196-204, 2008.
185. Markianos, M. Panas, N. Kalfakis, and D. Vassilopoulos. Low plasma total cholesterol in
patients with Huntington's disease and first-degree relatives. Mol.Genet.Metab 93 (3):341346, 2008.
186. Klepac, M. Relja, R. Klepac, S. Hecimovic, T. Babic, and V. Trkulja. Oxidative stress
parameters in plasma of Huntington's disease patients, asymptomatic Huntington's disease
gene carriers and healthy subjects : a cross-sectional study. J.Neurol. 254 (12):1676-1683,
2007.
187. Lemay, S. Chouinard, F. Richer, and P. Lesperance. Huntington's disease affects
movement termination. Behav.Brain Res. 187 (1):153-158, 2008.
188. Vitale, S. Marconi, Maio L. Di, Michele G. De, K. Longo, V. Bonavita, and P. Barone.
Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's
chorea: A double blind, randomized cross-over trial. Mov Disord. 22 (16):2359-2364, 2007.
189. Feigin, C. Tang, Y. Ma, P. Mattis, D. Zgaljardic, M. Guttman, J. S. Paulsen, V. Dhawan,
and D. Eidelberg. Thalamic metabolism and symptom onset in preclinical Huntington's
disease. Brain 130 (Pt 11):2858-2867, 2007.
190. Gavazzi, R. D. Nave, R. Petralli, M. A. Rocca, L. Guerrini, C. Tessa, S. Diciotti, M.
Filippi, S. Piacentini, and M. Mascalchi. Combining functional and structural brain
magnetic resonance imaging in Huntington disease. J.Comput.Assist.Tomogr. 31 (4):574580, 2007.
191. R. C. Wolf, N. Vasic, C. Schonfeldt-Lecuona, G. B. Landwehrmeyer, and D. Ecker.
Dorsolateral prefrontal cortex dysfunction in presymptomatic Huntington's disease:
evidence from event-related fMRI. Brain 130 (Pt 11):2845-2857, 2007.
192. Teichmann, E. Dupoux, P. Cesaro, and A. C. Bachoud-Levi. The role of the striatum in
sentence processing: evidence from a priming study in early stages of Huntington's disease.
Neuropsychologia 46 (1):174-185, 2008.
193. N. Witjes-Ane, B. Mertens, J. P. van Vugt, A. C. Bachoud-Levi, G. J. van Ommen, and
R. A. Roos. Longitudinal evaluation of "presymptomatic" carriers of Huntington's disease.
J.Neuropsychiatry Clin.Neurosci. 19 (3):310-317, 2007.
194. Nopoulos, V. A. Magnotta, A. Mikos, H. Paulson, N. C. Andreasen, and J. S. Paulsen.
Morphology of the cerebral cortex in preclinical Huntington's disease. Am.J.Psychiatry 164
(9):1428-1434, 2007.
195. H. Runne, A. Kuhn, E. J. Wild, W. Pratyaksha, M. Kristiansen, J. D. Isaacs, E. Regulier,
M. Delorenzi, S. J. Tabrizi, and R. Luthi-Carter. Analysis of potential transcriptomic
biomarkers for Huntington's disease in peripheral blood. Proc.Natl.Acad.Sci.U.S.A 104
(36):14424-14429, 2007.
196. Bjorkqvist, B. R. Leavitt, J. E. Nielsen, B. Landwehrmeyer, D. Ecker, H. Mulder, P.
Brundin, and A. Petersen. Cocaine- and amphetamine-regulated transcript is increased in
Huntington disease. Mov Disord. 22 (13):1952-1954, 2007.
197. S. Liu, W. L. Cheng, S. J. Kuo, J. Y. Li, B. W. Soong, and Y. H. Wei. Depletion of
mitochondrial DNA in leukocytes of patients with poly-Q diseases. J.Neurol.Sci. 264 (12):18-21, 2008.
198. S. A. Goldman. Disease targets and strategies for the therapeutic modulation of
endogenous neural stem and progenitor cells. Clin.Pharmacol.Ther. 82 (4):453-460, 2007.
199. J. C. van Oostrom, P. E. Sijens, R. A. Roos, and K. L. Leenders. 1H magnetic resonance
spectroscopy in preclinical Huntington disease. Brain Res. 1168:67-71, 2007.
200. Zinzi, D. Salmaso, Grandis R. De, G. Graziani, S. Maceroni, A. Bentivoglio, P. Zappata,
M. Frontali, and G. Jacopini. Effects of an intensive rehabilitation programme on patients
with Huntington's disease: a pilot study. Clin.Rehabil. 21 (7):603-613, 2007.
201. Hogarth, L. Lovrecic, and D. Krainc. Sodium phenylbutyrate in Huntington's disease: a
dose-finding study. Mov Disord. 22 (13):1962-1964, 2007.
202. G. B. Landwehrmeyer, B. Dubois, J. G. de Yebenes, B. Kremer, W. Gaus, P. H. Kraus,
H. Przuntek, M. Dib, A. Doble, W. Fischer, and A. C. Ludolph. Riluzole in Huntington's
disease: a 3-year, randomized controlled study. Ann.Neurol. 62 (3):262-272, 2007.
203. H. H. Ruocco, I. Lopes-Cendes, L. M. Li, and F. Cendes. Evidence of thalamic
dysfunction in Huntington disease by proton magnetic resonance spectroscopy. Mov
Disord. 22 (14):2052-2056, 2007.
204. J. L. Zimbelman, J. S. Paulsen, A. Mikos, N. C. Reynolds, R. G. Hoffmann, and S. M.
Rao. fMRI detection of early neural dysfunction in preclinical Huntington's disease.
J.Int.Neuropsychol.Soc. 13 (5):758-769, 2007.
205. Beste, C. Saft, J. Yordanova, J. Andrich, R. Gold, M. Falkenstein, and V. Kolev.
Functional compensation or pathology in cortico-subcortical interactions in preclinical
Huntington's disease? Neuropsychologia 45 (13):2922-2930, 2007.
206. K. Finke, W. X. Schneider, P. Redel, M. Dose, G. Kerkhoff, H. J. Muller, and P. Bublak.
The capacity of attention and simultaneous perception of objects: a group study of
Huntington's disease patients. Neuropsychologia 45 (14):3272-3284, 2007.
207. N. Becker, R. P. Munhoz, S. Raskin, L. C. Werneck, and H. A. Teive. Non-choreic
movement disorders as initial manifestations of Huntington's disease. Arq Neuropsiquiatr.
65 (2B):402-405, 2007.
208. W. R. Martin, M. Wieler, and C. C. Hanstock. Is brain lactate increased in Huntington's
disease? J.Neurol.Sci. 263 (1-2):70-74, 2007.
209. T. Pekmezovic, M. Svetel, J. Maric, I. Dujmovic-Basuroski, N. Dragasevic, M.
Keckarevic, S. Romac, and V. S. Kostic. Survival of Huntington's disease patients in
Serbia: longer survival in female patients. Eur.J.Epidemiol. 22 (8):523-526, 2007.
210. Klitzman R, Thorne D, Williamson J, Chung W, Marder K. Disclosures of Huntington
disease risk within families: patterns of decision-making and implications. Am J Med Genet
143A(16):1835-49, 2007
211. Ruocco HH, Bonilha L, Li LM, Lopes-Cendes I, Cendes FJ Neurol Neurosurg
Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the
length of the expanded CAG repeat. J Neurol Neurosurg Psychiatry. 79(2):130-5, 2008.
212. Vassos, M. Panas, A. Kladi, and D. Vassilopoulos. Effect of CAG repeat length on
psychiatric disorders in Huntington's disease. J.Psychiatr.Res. 42 (7):544-549, 2008.
213. Vassos, M. Panas, A. Kladi, and D. Vassilopoulos. Higher levels of extroverted hostility
detected in gene carriers at risk for Huntington's disease. Biol.Psychiatry 62 (12):13471352, 2007.
214. Antoniades, P. M. Altham, S. L. Mason, R. A. Barker, and R. Carpenter. Saccadometry: a
new tool for evaluating presymptomatic Huntington patients. Neuroreport 18 (11):11331136, 2007.
215. J. Vymazal, J. Klempir, R. Jech, J. Zidovska, M. Syka, E. Ruzicka, and J. Roth. MR
relaxometry in Huntington's disease: correlation between imaging, genetic and clinical
parameters. J.Neurol.Sci. 263 (1-2):20-25, 2007.
216. S. A. Johnson, J. C. Stout, A. C. Solomon, D. R. Langbehn, E. H. Aylward, C. B. Cruce,
C. A. Ross, M. Nance, E. Kayson, E. Julian-Baros, M. R. Hayden, K. Kieburtz, M.
Guttman, D. Oakes, I. Shoulson, L. Beglinger, K. Duff, E. Penziner, and J. S. Paulsen.
Beyond disgust: impaired recognition of negative emotions prior to diagnosis in
Huntington's disease. Brain 130 (Pt 7):1732-1744, 2007.
217. M. Kipps, A. J. Duggins, E. A. McCusker, and A. J. Calder. Disgust and happiness
recognition correlate with anteroventral insula and amygdala volume respectively in
preclinical Huntington's disease. J.Cogn Neurosci. 19 (7):1206-1217, 2007.
218. Jech, J. Klempir, J. Vymazal, J. Zidovska, O. Klempirova, E. Ruzicka, and J. Roth.
Variation of selective gray and white matter atrophy in Huntington's disease. Mov Disord.
22 (12):1783-1789, 2007.
219. Liao, J. Wang, and P. He. Multi-resolution entropy analysis of gait symmetry in
neurological degenerative diseases and amyotrophic lateral sclerosis. Med.Eng Phys. 30
(3):299-310, 2008.
220. L. Arning, C. Saft, S. Wieczorek, J. Andrich, P. H. Kraus, and J. T. Epplen. NR2A and
NR2B receptor gene variations modify age at onset in Huntington disease in a sex-specific
manner. Hum.Genet. 122 (2):175-182, 2007.
221. C. Turner, J. M. Cooper, and A. H. Schapira. Clinical correlates of mitochondrial
function in Huntington's disease muscle. Mov Disord. 22 (12):1715-1721, 2007.
222. N. Battista, M. Bari, A. Tarditi, C. Mariotti, A. C. Bachoud-Levi, C. Zuccato, A. FinazziAgro, S. Genitrini, M. Peschanski, Donato S. Di, E. Cattaneo, and M. Maccarrone. Severe
deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the
Huntington's disease mutation in peripheral lymphocytes. Neurobiol.Dis. 27 (1):108-116,
2007.
223. Dalrymple, E. J. Wild, R. Joubert, K. Sathasivam, M. Bjorkqvist, A. Petersen, G. S.
Jackson, J. D. Isaacs, M. Kristiansen, G. P. Bates, B. R. Leavitt, G. Keir, M. Ward, and S. J.
Tabrizi. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory
activation and biomarker candidates. J.Proteome Res. 6 (7):2833-2840, 2007.
224. M. Chen, Y. R. Wu, M. L. Cheng, J. L. Liu, Y. M. Lee, P. W. Lee, B. W. Soong, and D.
T. Chiu. Increased oxidative damage and mitochondrial abnormalities in the peripheral
blood of Huntington's disease patients. Biochem.Biophys.Res.Commun. 359 (2):335-340,
2007.
225. W. J. Powers, R. H. Haas, T. Le, T. O. Videen, T. Hershey, L. Gee-Minnich, and J. S.
Perlmutter. Normal platelet mitochondrial complex I activity in Huntington's disease.
Neurobiol.Dis. 27 (1):99-101, 2007.
226. K. Varani, A. C. Bachoud-Levi, C. Mariotti, A. Tarditi, M. P. Abbracchio, V. Gasperi, P.
A. Borea, G. Dolbeau, C. Gellera, A. Solari, A. Rosser, J. Naji, O. Handley, M.
Maccarrone, M. Peschanski, S. DiDonato, and E. Cattaneo. Biological abnormalities of
peripheral A(2A) receptors in a large representation of polyglutamine disorders and
Huntington's disease stages. Neurobiol.Dis. 27 (1):36-43, 2007.
227. D. R. Langbehn and J. S. Paulsen. Predictors of diagnosis in Huntington disease.
Neurology 68 (20):1710-1717, 2007.
228. C. Beste, C. Saft, C. Konrad, J. Andrich, A. Habbel, I. Schepers, A. Jansen, B. Pfleiderer,
and M. Falkenstein. Levels of error processing in Huntington's disease: a combined study
using event-related potentials and voxel-based morphometry. Hum.Brain Mapp. 29 (2):121130, 2008.
229. Pirogovsky, P. E. Gilbert, M. Jacobson, G. Peavy, S. Wetter, J. Goldstein, J. CoreyBloom, and C. Murphy. Impairments in source memory for olfactory and visual stimuli in
preclinical and clinical stages of Huntington's disease. J.Clin.Exp.Neuropsychol. 29
(4):395-404, 2007.
230. K. F. Hoth, J. S. Paulsen, D. J. Moser, D. Tranel, L. A. Clark, and A. Bechara. Patients
with Huntington's disease have impaired awareness of cognitive, emotional, and functional
abilities. J.Clin.Exp.Neuropsychol. 29 (4):365-376, 2007.
231. Bartzokis, P. H. Lu, T. A. Tishler, S. M. Fong, B. Oluwadara, J. P. Finn, D. Huang, Y.
Bordelon, J. Mintz, and S. Perlman. Myelin breakdown and iron changes in Huntington's
disease: pathogenesis and treatment implications. Neurochem.Res. 32 (10):1655-1664,
2007.
232. K. Duff, J. S. Paulsen, L. J. Beglinger, D. R. Langbehn, and J. C. Stout. Psychiatric
symptoms in Huntington's disease before diagnosis: the predict-HD study. Biol.Psychiatry
62 (12):1341-1346, 2007.
233. M. Farrow, A. Churchyard, P. Chua, J. L. Bradshaw, E. Chiu, and N. GeorgiouKaristianis. Attention, inhibition, and proximity to clinical onset in preclinical mutation
carriers for Huntington's disease. J.Clin.Exp.Neuropsychol. 29 (3):235-246, 2007.
234. C. Hinton, J. S. Paulsen, R. G. Hoffmann, N. C. Reynolds, J. L. Zimbelman, and S. M.
Rao. Motor timing variability increases in preclinical Huntington's disease patients as
estimated onset of motor symptoms approaches. J.Int.Neuropsychol.Soc. 13 (3):539-543,
2007.
235. M. Markianos, M. Panas, N. Kalfakis, and D. Vassilopoulos. Plasma testosterone,
dehydroepiandrosterone sulfate, and cortisol in female patients with Huntington's disease.
Neuro Endocrinol.Lett. 28 (2):199-203, 2007.
236. J. M. Van Raamsdonk, Z. Murphy, D. M. Selva, R. Hamidizadeh, J. Pearson, A. Petersen,
M. Bjorkqvist, C. Muir, I. R. Mackenzie, G. L. Hammond, A. W. Vogl, M. R. Hayden, and
B. R. Leavitt. Testicular degeneration in Huntington disease. Neurobiol.Dis. 26 (3):512520, 2007.
237. Ciammola, J. Sassone, M. Cannella, S. Calza, B. Poletti, L. Frati, F. Squitieri, and V.
Silani. Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington's
disease patients. Am.J.Med.Genet.B Neuropsychiatr.Genet. 144B (4):574-577, 2007.
238. J. D. Davis, J. V. Filoteo, and R. P. Kesner. Is short-term memory for discrete arm
movements impaired in Huntington's disease? Cortex 43 (2):255-263, 2007.
239. Y. F. Tai, N. Pavese, A. Gerhard, S. J. Tabrizi, R. A. Barker, D. J. Brooks, and P. Piccini.
Microglial activation in presymptomatic Huntington's disease gene carriers. Brain 130 (Pt
7):1759-1766, 2007.
240. E. Lazic, A. O. Goodman, H. E. Grote, C. Blakemore, A. J. Morton, A. J. Hannan, Dellen
A. van, and R. A. Barker. Olfactory abnormalities in Huntington's disease: decreased
plasticity in the primary olfactory cortex of R6/1 transgenic mice and reduced olfactory
discrimination in patients. Brain Res. 1151:219-226, 2007.
241. N. Anderson, N. Pavese, P. Edison, Y. F. Tai, A. Hammers, A. Gerhard, D. J. Brooks,
and F. E. Turkheimer. A systematic comparison of kinetic modelling methods generating
parametric maps for [(11)C]-(R)-PK11195. Neuroimage 36 (1):28-37, 2007.
242. M. Muhlau, C. Gaser, A. M. Wohlschlager, A. Weindl, M. Stadtler, M. Valet, C.
Zimmer, J. Kassubek, and A. Peinemann. Striatal gray matter loss in Huntington's disease is
leftward biased. Mov Disord. 22 (8):1169-1173, 2007.
243. Kaptein, M. Scharloo, D. I. Helder, L. Snoei, G. M. van Kempen, J. Weinman, J. C. van
Houwelingen, and R. A. Roos. Quality of life in couples living with Huntington's disease:
the role of patients' and partners' illness perceptions. Qual.Life Res. 16 (5):793-801, 2007.
244. Gomez-Anson, M. Alegret, E. Munoz, A. Sainz, G. C. Monte, and E. Tolosa. Decreased
frontal choline and neuropsychological performance in preclinical Huntington disease.
Neurology 68 (12):906-910, 2007.
245. J. Andrich, C. Saft, N. Ostholt, and T. Muller. Assessment of simple movements and
progression of Huntington's disease. J.Neurol.Neurosurg.Psychiatry 78 (4):405-407, 2007.
246. J. Klempir, O. Klempirova, N. Spackova, J. Zidovska, and J. Roth. Unified Huntington's
disease rating scale: clinical practice and a critical approach. Funct.Neurol. 21 (4):217-221,
2006.
247. J. M. Lafosse, J. R. Corboy, M. A. Leehey, L. C. Seeberger, and C. M. Filley. MS vs.
HD: can white matter and subcortical gray matter pathology be distinguished
neuropsychologically? J.Clin.Exp.Neuropsychol. 29 (2):142-154, 2007.
248. E. J. Wild, A. Petzold, G. Keir, and S. J. Tabrizi. Plasma neurofilament heavy chain
levels in Huntington's disease. Neurosci.Lett. 417 (3):231-233, 2007.
249. R. Nardone, P. Lochner, R. Marth, H. Ausserer, A. Bratti, and F. Tezzon. Abnormal
intracortical facilitation in early-stage Huntington's disease. Clin.Neurophysiol. 118
(5):1149-1154, 2007.
250. J. Andrich, C. Saft, N. Ostholt, and T. Muller. Complex movement behaviour and
progression of Huntington's disease. Neurosci.Lett. 416 (3):272-274, 2007.
251. N. Georgiou-Karistianis, A. Sritharan, M. Farrow, R. Cunnington, J. Stout, J. Bradshaw,
A. Churchyard, T. L. Brawn, P. Chua, E. Chiu, D. Thiruvady, and G. Egan. Increased
cortical recruitment in Huntington's disease using a Simon task. Neuropsychologia 45
(8):1791-1800, 2007.
252. Y. Bombard, E. Penziner, J. Decolongon, M. L. Klimek, S. Creighton, O. Suchowersky,
M. Guttman, J. S. Paulsen, J. L. Bottorff, and M. R. Hayden. Managing genetic
discrimination: strategies used by individuals found to have the Huntington disease
mutation. Clin.Genet. 71 (3):220-231, 2007.
253. C. Solomon, J. C. Stout, S. A. Johnson, D. R. Langbehn, E. H. Aylward, J. Brandt, C. A.
Ross, L. Beglinger, M. R. Hayden, K. Kieburtz, E. Kayson, E. Julian-Baros, K. Duff, M.
Guttman, M. Nance, D. Oakes, I. Shoulson, E. Penziner, and J. S. Paulsen. Verbal episodic
memory declines prior to diagnosis in Huntington's disease. Neuropsychologia 45 (8):17671776, 2007.
254. de Tommaso M., O. Difruscolo, V. Sciruicchio, N. Specchio, and P. Livrea.
Abnormalities of the contingent negative variation in Huntington's disease: correlations
with clinical features. J.Neurol.Sci. 254 (1-2):84-89, 2007.
255. W. J. Powers, T. O. Videen, J. Markham, L. Gee-Minnich, J. V. ntenor-Dorsey, T.
Hershey, and J. S. Perlmutter. Selective defect of in vivo glycolysis in early Huntington's
disease striatum. Proc.Natl.Acad.Sci.U.S.A 104 (8):2945-2949, 2007.
256. Veitch NJ, Ennis M, McAbney JP; US-Venezuela Collaborative Research Project,
Shelbourne PF, Monckton DG. Inherited CAG.CTG allele length is a major modifier of
somatic mutation length variability in Huntington disease. DNA Repair (Amst). 6(6):78996, 2007
257. de Tommaso M., O. Difruscolo, V. Sciruicchio, N. Specchio, and P. Livrea. Two years'
follow-up of rivastigmine treatment in Huntington disease. Clin.Neuropharmacol. 30
(1):43-46, 2007.
258. van der Hiele K., C. K. Jurgens, A. A. Vein, R. H. Reijntjes, M. N. Witjes-Ane, R. A.
Roos, Dijk G. van, and H. A. Middelkoop. Memory activation reveals abnormal EEG in
preclinical Huntington's disease. Mov Disord. 22 (5):690-695, 2007.
259. Barrios, L. Gonzalez, R. Favila, M. E. Alonso, P. M. Salgado, R. Diaz, and J. FernandezRuiz. Olfaction and neurodegeneration in HD. Neuroreport 18 (1):73-76, 2007.
260. M. Decruyenaere, G. Evers-Kiebooms, A. Boogaerts, K. Philippe, K. Demyttenaere, R.
Dom, W. Vandenberghe, and J. P. Fryns. The complexity of reproductive decision-making
in asymptomatic carriers of the Huntington mutation. Eur.J.Hum.Genet. 15 (4):453-462,
2007.
261. J. Marshall, K. White, M. Weaver, Wetherill L. Flury, S. Hui, J. C. Stout, S. A. Johnson,
X. Beristain, J. Gray, J. Wojcieszek, and T. Foroud. Specific psychiatric manifestations
among preclinical Huntington disease mutation carriers. Arch.Neurol. 64 (1):116-121,
2007.
262. Robins Wahlin TB, Lundin A, Dear K. Early cognitive deficits in Swedish gene carriers
of Huntington's disease. Neuropsychology. 21(1):31-44, 2007
263. J. M. Andresen, J. Gayan, L. Djousse, S. Roberts, D. Brocklebank, S. S. Cherny, L. R.
Cardon, J. F. Gusella, M. E. MacDonald, R. H. Myers, D. E. Housman, and N. S. Wexler.
The relationship between CAG repeat length and age of onset differs for Huntington's
disease patients with juvenile onset or adult onset. Ann.Hum.Genet. 71 (Pt 3):295-301,
2007.
264. C. L. Julien, J. C. Thompson, S. Wild, P. Yardumian, J. S. Snowden, G. Turner, and D.
Craufurd.
Psychiatric
disorders
in
preclinical
Huntington's
disease.
J.Neurol.Neurosurg.Psychiatry 78 (9):939-943, 2007.
265. M. Farrow, P. Chua, A. Churchyard, J. L. Bradshaw, E. Chiu, and N. GeorgiouKaristianis. Proximity to clinical onset influences motor and cognitive performance in
presymptomatic Huntington disease gene carriers. Cogn Behav.Neurol. 19 (4):208-216,
2006.
266. Ryu H, Lee J, Hagerty SW, Soh BY, McAlpin SE, Cormier KA, Smith KM, Ferrante RJ.
ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's
disease. Proc Natl Acad Sci U S A. 103(50):19176-81, 2006
267. K. Duff, L. J. Beglinger, S. K. Schultz, D. J. Moser, R. J. McCaffrey, R. F. Haase, H. J.
Westervelt, D. R. Langbehn, and J. S. Paulsen. Practice effects in the prediction of longterm cognitive outcome in three patient samples: a novel prognostic index.
Arch.Clin.Neuropsychol. 22 (1):15-24, 2007.
268. Pechlivanis, J. Andrich, M. Scholz, A. Harders, C. Saft, and K. Schmieder. Chronic
subdural haematoma in patients with Huntington's disease. Br.J.Neurosurg. 20 (5):327-329,
2006.
269. Hayes CJ, Stevenson RJ, Coltheart M. Disgust and Huntington's disease.
Neuropsychologia. 45(6):1135-51, 2007
270. M. Mai, A. D. Akkad, S. Wieczorek, C. Saft, J. Andrich, P. H. Kraus, J. T. Epplen, and L.
Arning. No association between polymorphisms in the BDNF gene and age at onset in
Huntington disease. BMC Med.Genet. 7:79, 2006.
271. C. Kenney, C. Hunter, A. Davidson, and J. Jankovic. Short-term effects of tetrabenazine
on chorea associated with Huntington's disease. Mov Disord. 22 (1):10-13, 2007.
272. L. J. Kristjanson, S. M. Aoun, and L. Oldham. Palliative care and support for people with
neurodegenerative conditions and their carers. Int.J.Palliat.Nurs. 12 (8):368-377, 2006.
273. M. Larsson, A. Lundin, and T. B. Robins Wahlin. Olfactory functions in asymptomatic
carriers of the Huntington disease mutation. J.Clin.Exp.Neuropsychol. 28 (8):1373-1380,
2006.
274. L. J. Tippett, H. J. Waldvogel, S. J. Thomas, V. M. Hogg, W. van Roon-Mom, B. J.
Synek, A. M. Graybiel, and R. L. Faull. Striosomes and mood dysfunction in Huntington's
disease. Brain 130 (Pt 1):206-221, 2007.
275. E. Cubo, K. M. Shannon, D. Tracy, J. A. Jaglin, B. A. Bernard, J. Wuu, and S. E.
Leurgans. Effect of donepezil on motor and cognitive function in Huntington disease.
Neurology 67 (7):1268-1271, 2006.
276. D. R. Thiruvady, N. Georgiou-Karistianis, G. F. Egan, S. Ray, A. Sritharan, M. Farrow,
A. Churchyard, P. Chua, J. L. Bradshaw, T. L. Brawn, and R. Cunnington. Functional
connectivity
of
the
prefrontal
cortex
in
Huntington's
disease.
J.Neurol.Neurosurg.Psychiatry 78 (2):127-133, 2007.
277. M. Muhlau, A. Weindl, A. M. Wohlschlager, C. Gaser, M. Stadtler, M. Valet, C.
Zimmer, J. Kassubek, and A. Peinemann. Voxel-based morphometry indicates relative
preservation of the limbic prefrontal cortex in early Huntington disease. J.Neural Transm.
114 (3):367-372, 2007.
278. Andresen JM, Gayán J, Cherny SS, Brocklebank D, Alkorta-Aranburu G, Addis EA; USVenezuela Collaborative Research Group, Cardon LR, Housman DE, Wexler NS.
Replication of twelve association studies for Huntington's disease residual age of onset in
large Venezuelan kindreds. J Med Genet. 44(1):44-50, 2007
279. Teichmann M, Dupoux E, Kouider S, Bachoud-Lévi AC. The role of the striatum in
processing language rules: evidence from word perception in Huntington's disease. J Cogn
Neurosci. 18(9):1555-69, 2006
280. Fielding J, Georgiou-Karistianis N, Millist L, Fahey M, White O. Saccadic trajectory in
Huntington's disease. J Int Neuropsychol Soc. 12(4):455-64, 2006.
281. Ward, J. M. Sheppard, B. Shpritz, R. L. Margolis, A. Rosenblatt, and J. Brandt. A fouryear prospective study of cognitive functioning in Huntington's disease.
J.Int.Neuropsychol.Soc. 12 (4):445-454, 2006.
282. del Hoyo P, García-Redondo A, de Bustos F, Molina JA, Sayed Y, Alonso-Navarro H,
Caballero L, Arenas J, Jiménez-Jiménez FJ. Oxidative stress in skin fibroblasts cultures of
patients with Huntington's disease. Neurochem Res. 31(9):1103-9, 2006
283. Zesiewicz, K. L. Sullivan, R. A. Hauser, and J. Sanchez-Ramos. Open-label pilot study of
levetiracetam (Keppra) for the treatment of chorea in Huntington's disease. Mov Disord. 21
(11):1998-2001, 2006.
284. S. M. Henley, C. Frost, D. G. MacManus, T. T. Warner, N. C. Fox, and S. J. Tabrizi.
Increased rate of whole-brain atrophy over 6 months in early Huntington disease.
Neurology 67 (4):694-696, 2006.
285. L. Li, M. R. Hayden, S. C. Warby, A. Durr, P. J. Morrison, M. Nance, C. A. Ross, R. L.
Margolis, A. Rosenblatt, F. Squitieri, L. Frati, E. Gomez-Tortosa, C. A. Garcia, O.
Suchowersky, M. L. Klimek, R. J. Trent, E. McCusker, A. Novelletto, M. Frontali, J. S.
Paulsen, R. Jones, T. Ashizawa, A. Lazzarini, V. C. Wheeler, R. Prakash, G. Xu, L.
Djousse, J. S. Mysore, T. Gillis, M. Hakky, L. A. Cupples, M. H. Saint-Hilaire, J. H. Cha,
S. M. Hersch, J. B. Penney, M. B. Harrison, S. L. Perlman, A. Zanko, R. K. Abramson, A.
J. Lechich, A. Duckett, K. Marder, P. M. Conneally, J. F. Gusella, M. E. MacDonald, and
R. H. Myers. Genome-wide significance for a modifier of age at neurological onset in
Huntington's disease at 6q23-24: the HD MAPS study. BMC Med.Genet. 7:71, 2006.
286. H. Ruocco, I. Lopes-Cendes, L. M. Li, M. Santos-Silva, and F. Cendes. Striatal and
extrastriatal atrophy in Huntington's disease and its relationship with length of the CAG
repeat. Braz.J.Med.Biol.Res. 39 (8):1129-1136, 2006.
287. Maria E. Di, A. Marasco, M. Tartari, P. Ciotti, G. Abbruzzese, G. Novelli, E. Bellone, E.
Cattaneo, and P. Mandich. No evidence of association between BDNF gene variants and
age-at-onset of Huntington's disease. Neurobiol.Dis. 24 (2):274-279, 2006.
288. G. Douaud, V. Gaura, M. J. Ribeiro, F. Lethimonnier, R. Maroy, C. Verny, P.
Krystkowiak, P. Damier, A. C. Bachoud-Levi, P. Hantraye, and P. Remy. Distribution of
grey matter atrophy in Huntington's disease patients: a combined ROI-based and voxelbased morphometric study. Neuroimage 32 (4):1562-1575, 2006.
289. Blekher, S. A. Johnson, J. Marshall, K. White, S. Hui, M. Weaver, J. Gray, R. Yee, J. C.
Stout, X. Beristain, J. Wojcieszek, and T. Foroud. Saccades in presymptomatic and early
stages of Huntington disease. Neurology 67 (3):394-399, 2006.
290. S. Metzger, P. Bauer, J. Tomiuk, F. Laccone, S. DiDonato, C. Gellera, C. Mariotti, H. W.
Lange, H. Weirich-Schwaiger, G. K. Wenning, K. Seppi, B. Melegh, V. Havasi, L. Baliko,
S. Wieczorek, J. Zaremba, D. Hoffman-Zacharska, A. Sulek, A. N. Basak, E. Soydan, J.
Zidovska, V. Kebrdlova, M. Pandolfo, P. Ribai, L. Kadasi, M. Kvasnicova, B. H. Weber, F.
Kreuz, M. Dose, M. Stuhrmann, and O. Riess. Genetic analysis of candidate genes
modifying the age-at-onset in Huntington's disease. Hum.Genet. 120 (2):285-292, 2006.
291. J. Beglinger, D. R. Langbehn, K. Duff, L. Stierman, D. W. Black, C. Nehl, K. Anderson,
E. Penziner, and J. S. Paulsen. Probability of obsessive and compulsive symptoms in
Huntington's disease. Biol.Psychiatry 61 (3):415-418, 2007.
292. Anonymous. At risk for Huntington disease: The PHAROS (Prospective Huntington At
Risk Observational Study) cohort enrolled. Arch.Neurol. 63 (7):991-996, 2006.
293. Bjorkqvist, A. Petersen, J. Nielsen, D. Ecker, H. Mulder, M. R. Hayden, B.
Landwehrmeyer, P. Brundin, and B. R. Leavitt. Cerebrospinal fluid levels of orexin-A are
not a clinically useful biomarker for Huntington disease. Clin.Genet. 70 (1):78-79, 2006.
294. C. Lorenzano, L. Dinapoli, F. Gilio, A. Suppa, S. Bagnato, A. Curra, M. Inghilleri, and
A. Berardelli. Motor cortical excitability studied with repetitive transcranial magnetic
stimulation in patients with Huntington's disease. Clin.Neurophysiol. 117 (8):1677-1681,
2006.
295. K. Panegyres, J. Beilby, M. Bulsara, K. Toufexis, and C. Wong. A study of potential
interactive genetic factors in Huntington's disease. Eur.Neurol. 55 (4):189-192, 2006.
296. Pavese, A. Gerhard, Y. F. Tai, A. K. Ho, F. Turkheimer, R. A. Barker, D. J. Brooks, and
P. Piccini. Microglial activation correlates with severity in Huntington disease: a clinical
and PET study. Neurology 66 (11):1638-1643, 2006.
297. S. Paulsen, M. Hayden, J. C. Stout, D. R. Langbehn, E. Aylward, C. A. Ross, M.
Guttman, M. Nance, K. Kieburtz, D. Oakes, I. Shoulson, E. Kayson, S. Johnson, and E.
Penziner. Preparing for preventive clinical trials: the Predict-HD study. Arch.Neurol. 63
(6):883-890, 2006.
298. H. D. Rosas, D. S. Tuch, N. D. Hevelone, A. K. Zaleta, M. Vangel, S. M. Hersch, and D.
H. Salat. Diffusion tensor imaging in presymptomatic and early Huntington's disease:
Selective white matter pathology and its relationship to clinical measures. Mov Disord. 21
(9):1317-1325, 2006.
299. Ciammola A, Sassone J, Alberti L, Meola G, Mancinelli E, Russo MA, Squitieri F, Silani
V. Increased apoptosis, Huntingtin inclusions and altered differentiation in muscle cell
cultures from Huntington's disease subjects. Cell Death Differ. 13(12):2068-78, 2006
300. P. Lefaucheur, I. Menard-Lefaucheur, P. Maison, S. Baudic, P. Cesaro, M. Peschanski,
and A. C. Bachoud-Levi. Electrophysiological deterioration over time in patients with
Huntington's disease. Mov Disord. 21 (9):1350-1354, 2006.
301. C. Saft, J. Andrich, N. M. Meisel, H. Przuntek, and T. Muller. Assessment of simple
movements reflects impairment in Huntington's disease. Mov Disord. 21 (8):1208-1212,
2006.
302. B. Montagne, R. P. Kessels, M. P. Kammers, E. Kingma, E. H. de Haan, R. A. Roos, and
H. A. Middelkoop. Perception of emotional facial expressions at different intensities in
early-symptomatic Huntington's disease. Eur.Neurol. 55 (3):151-154, 2006.
303. C. V. Golding, C. Danchaivijitr, T. L. Hodgson, S. J. Tabrizi, and C. Kennard.
Identification of an oculomotor biomarker of preclinical Huntington disease. Neurology 67
(3):485-487, 2006.
304. Rosenblatt, K. Y. Liang, H. Zhou, M. H. Abbott, L. M. Gourley, R. L. Margolis, J.
Brandt, and C. A. Ross. The association of CAG repeat length with clinical progression in
Huntington disease. Neurology 66 (7):1016-1020, 2006.
305. Christofides, M. Bridel, M. Egerton, G. M. Mackay, C. M. Forrest, N. Stoy, L. G.
Darlington, and T. W. Stone. Blood 5-hydroxytryptamine, 5-hydroxyindoleacetic acid and
melatonin levels in patients with either Huntington's disease or chronic brain injury.
J.Neurochem. 97 (4):1078-1088, 2006.
306. Seppi, M. F. Schocke, K. J. Mair, R. Esterhammer, H. Weirich-Schwaiger, B. Utermann,
K. Egger, C. Brenneis, R. Granata, S. Boesch, W. Poewe, and G. K. Wenning. Diffusionweighted imaging in Huntington's disease. Mov Disord. 21 (7):1043-1047, 2006.
307. C. Bachoud-Levi, V. Gaura, P. Brugieres, J. P. Lefaucheur, M. F. Boisse, P. Maison, S.
Baudic, M. J. Ribeiro, C. Bourdet, P. Remy, P. Cesaro, P. Hantraye, and M. Peschanski.
Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery:
a long-term follow-up study. Lancet Neurol. 5 (4):303-309, 2006.
308. Swainson, D. SenGupta, T. Shetty, L. H. Watkins, B. A. Summers, B. J. Sahakian, C. E.
Polkey, R. A. Barker, and T. W. Robbins. Impaired dimensional selection but intact use of
reward feedback during visual discrimination learning in Parkinson's disease.
Neuropsychologia 44 (8):1290-1304, 2006.
309. Saft, T. Lauter, P. H. Kraus, H. Przuntek, and J. E. Andrich. Dose-dependent
improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease
patients: a case series. BMC Neurol. 6:11, 2006.
310. K. Finke, P. Bublak, M. Dose, H. J. Muller, and W. X. Schneider. Parameter-based
assessment of spatial and non-spatial attentional deficits in Huntington's disease. Brain 129
(Pt 5):1137-1151, 2006.
311. Baudic, P. Maison, G. Dolbeau, M. F. Boisse, P. Bartolomeo, Barba G. Dalla, L.
Traykov, and A. C. Bachoud-Levi. Cognitive impairment related to apathy in early
Huntington's disease. Dement.Geriatr.Cogn Disord. 21 (5-6):316-321, 2006.
312. Anonymous. Tetrabenazine as antichorea therapy in Huntington disease: a randomized
controlled trial. Neurology 66 (3):366-372, 2006.
313. R. Underwood, D. Broadhurst, W. B. Dunn, D. I. Ellis, A. W. Michell, C. Vacher, D. E.
Mosedale, D. B. Kell, R. A. Barker, D. J. Grainger, and D. C. Rubinsztein. Huntington
disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles.
Brain 129 (Pt 4):877-886, 2006.
314. Ciarmiello, M. Cannella, S. Lastoria, M. Simonelli, L. Frati, D. C. Rubinsztein, and F.
Squitieri. Brain white-matter volume loss and glucose hypometabolism precede the clinical
symptoms of Huntington's disease. J.Nucl.Med. 47 (2):215-222, 2006.
315. M. Hersch, S. Gevorkian, K. Marder, C. Moskowitz, A. Feigin, M. Cox, P. Como, C.
Zimmerman, M. Lin, L. Zhang, A. M. Ulug, M. F. Beal, W. Matson, M. Bogdanov, E.
Ebbel, A. Zaleta, Y. Kaneko, B. Jenkins, N. Hevelone, H. Zhang, H. Yu, D. Schoenfeld, R.
Ferrante, and H. D. Rosas. Creatine in Huntington disease is safe, tolerable, bioavailable in
brain and reduces serum 8OH2'dG. Neurology 66 (2):250-252, 2006.
316. J. S. Paulsen, C. Nehl, K. F. Hoth, J. E. Kanz, M. Benjamin, R. Conybeare, B.
McDowell, and B. Turner. Depression and stages of Huntington's disease.
J.Neuropsychiatry Clin.Neurosci. 17 (4):496-502, 2005.
317. K. Festa, R. Z. Insler, D. P. Salmon, J. Paxton, J. M. Hamilton, and W. C. Heindel.
Neocortical disconnectivity disrupts sensory integration in Alzheimer's disease.
Neuropsychology 19 (6):728-738, 2005.
318. S. Zizak, J. V. Filoteo, K. L. Possin, J. A. Lucas, L. M. Rilling, J. D. Davis, G. Peavy, A.
Wong, and D. P. Salmon. The ubiquity of memory retrieval deficits in patients with frontalstriatal dysfunction. Cogn Behav.Neurol. 18 (4):198-205, 2005.
319. Tommaso M. de, Fruscolo O. Di, V. Sciruicchio, N. Specchio, C. Cormio, M. F. De Caro,
and P. Livrea. Efficacy of levetiracetam in Huntington disease. Clin.Neuropharmacol. 28
(6):280-284, 2005.
320. J. Roth, J. Klempii, R. Jech, J. Zidovska, T. Uhrova, P. Doubek, O. Ulmanova, H.
Brozova, M. Volfova, T. Serranova, and E. Ruzicka. Caudate nucleus atrophy in
Huntington's disease and its relationship with clinical and genetic parameters.
Funct.Neurol. 20 (3):127-130, 2005.
321. R. Ali, A. W. Michell, R. A. Barker, and R. H. Carpenter. The use of quantitative
oculometry in the assessment of Huntington's disease. Exp.Brain Res. 169 (2):237-245,
2006.
322. Meier, B. Mollenhauer, S. Cohrs, A. Rodenbeck, W. Jordan, J. Meller, and M. Otto.
Normal hypocretin-1 (orexin-A) levels in the cerebrospinal fluid of patients with
Huntington's disease. Brain Res. 1063 (2):201-203, 2005.
323. Feigin, M. F. Ghilardi, C. Huang, Y. Ma, M. Carbon, M. Guttman, J. S. Paulsen, C. P.
Ghez, and D. Eidelberg. Preclinical Huntington's disease: compensatory brain responses
during learning. Ann.Neurol. 59 (1):53-59, 2006.
324. R. Dubinsky and C. Gray. CYTE-I-HD: phase I dose finding and tolerability study of
cysteamine (Cystagon) in Huntington's disease. Mov Disord. 21 (4):530-533, 2006.
325. D. C. Delis, S. R. Wetter, M. W. Jacobson, G. Peavy, J. Hamilton, A. Gongvatana, J. H.
Kramer, M. W. Bondi, J. Corey-Bloom, and D. P. Salmon. Recall discriminability: utility of
a new CVLT-II measure in the differential diagnosis of dementia. J.Int.Neuropsychol.Soc.
11 (6):708-715, 2005.
326. J. Brandt, B. Shpritz, C. A. Munro, L. Marsh, and A. Rosenblatt. Differential impairment
of spatial location memory in Huntington's disease. J.Neurol.Neurosurg.Psychiatry 76
(11):1516-1519, 2005.
327. Maglione, M. Cannella, T. Martino, Blasi A. De, L. Frati, and F. Squitieri. The platelet
maximum number of A2A-receptor binding sites (Bmax) linearly correlates with age at
onset and CAG repeat expansion in Huntington's disease patients with predominant chorea.
Neurosci.Lett. 393 (1):27-30, 2006.
328. K. Ho, A. O. Robbins, and R. A. Barker. Huntington's disease patients have selective
problems with insight. Mov Disord. 21 (3):385-389, 2006.
329. K. L. Possin, J. V. Filoteo, S. C. Roesch, V. Zizak, L. M. Rilling, and J. D. Davis. Is a
perseveration a perseveration? An evaluation of cognitive error types in patients with
subcortical pathology. J.Clin.Exp.Neuropsychol. 27 (8):953-966, 2005.
330. S. A. Reading, M. A. Yassa, A. Bakker, A. C. Dziorny, L. M. Gourley, V. Yallapragada,
A. Rosenblatt, R. L. Margolis, E. H. Aylward, J. Brandt, S. Mori, Zijl P. van, S. S. Bassett,
and C. A. Ross. Regional white matter change in pre-symptomatic Huntington's disease: a
diffusion tensor imaging study. Psychiatry Res. 140 (1):55-62, 2005.
331. J. Alberch, M. Lopez, C. Badenas, J. L. Carrasco, M. Mila, E. Munoz, and J. M. Canals.
Association between BDNF Val66Met polymorphism and age at onset in Huntington
disease. Neurology 65 (6):964-965, 2005.
332. J. C. van Oostrom, R. P. Maguire, C. C. Verschuuren-Bemelmans, Duin L. Veenma-van
der, J. Pruim, R. A. Roos, and K. L. Leenders. Striatal dopamine D2 receptors, metabolism,
and volume in preclinical Huntington disease. Neurology 65 (6):941-943, 2005.
333. Peinemann, S. Schuller, C. Pohl, T. Jahn, A. Weindl, and J. Kassubek. Executive
dysfunction in early stages of Huntington's disease is associated with striatal and insular
atrophy: a neuropsychological and voxel-based morphometric study. J.Neurol.Sci. 239
(1):11-19, 2005.
334. Maglione, P. Giallonardo, M. Cannella, T. Martino, L. Frati, and F. Squitieri. Adenosine
A2A receptor dysfunction correlates with age at onset anticipation in blood platelets of
subjects with Huntington's disease. Am.J.Med.Genet.B Neuropsychiatr.Genet. 139B
(1):101-105, 2005.
335. Chatterjee, K. E. Anderson, C. B. Moskowitz, W. A. Hauser, and K. S. Marder. A
comparison of self-report and caregiver assessment of depression, apathy, and irritability in
Huntington's disease. J.Neuropsychiatry Clin.Neurosci. 17 (3):378-383, 2005.
336. D. Rosas, N. D. Hevelone, A. K. Zaleta, D. N. Greve, D. H. Salat, and B. Fischl.
Regional cortical thinning in preclinical Huntington disease and its relationship to
cognition. Neurology 65 (5):745-747, 2005.
337. M. Jensen, H. J. Chenery, and D. A. Copland. A comparison of picture description
abilities in individuals with vascular subcortical lesions and Huntington's Disease.
J.Commun.Disord. 39 (1):62-77, 2006.
338. Fielding, N. Georgiou-Karistianis, J. Bradshaw, L. Millist, A. Churchyard, and O. White.
Accelerated time-course of inhibition of return in Huntington's disease. Behav.Brain Res.
166 (2):211-219, 2006.
339. C. rango-Lasprilla, H. Rogers, J. Lengenfelder, J. Deluca, S. Moreno, and F. Lopera.
Cortical and subcortical diseases: do true neuropsychological differences exist?
Arch.Clin.Neuropsychol. 21 (1):29-40, 2006.
340. S. Paulsen, V. A. Magnotta, A. E. Mikos, H. L. Paulson, E. Penziner, N. C. Andreasen,
and P. C. Nopoulos. Brain structure in preclinical Huntington's disease. Biol.Psychiatry 59
(1):57-63, 2006.
341. R. Sprengelmeyer, U. Schroeder, A. W. Young, and J. T. Epplen. Disgust in pre-clinical
Huntington's disease: a longitudinal study. Neuropsychologia 44 (4):518-533, 2006.
342. Delval, P. Krystkowiak, J. L. Blatt, E. Labyt, K. Dujardin, A. Destee, P. Derambure, and
L. Defebvre. Role of hypokinesia and bradykinesia in gait disturbances in Huntington's
disease: a biomechanical study. J.Neurol. 253 (1):73-80, 2006.
343. Trejo, M. C. Boll, M. E. Alonso, A. Ochoa, and L. Velasquez. Use of oral nutritional
supplements in patients with Huntington's disease. Nutrition 21 (9):889-894, 2005.
344. J. K. Tang, E. Moro, A. M. Lozano, A. E. Lang, W. D. Hutchison, N. Mahant, and J. O.
Dostrovsky. Firing rates of pallidal neurons are similar in Huntington's and Parkinson's
disease patients. Exp.Brain Res. 166 (2):230-236, 2005.
345. S. Wetter, G. Peavy, M. Jacobson, J. Hamilton, D. Salmon, and C. Murphy. Olfactory
and auditory event-related potentials in Huntington's disease. Neuropsychology 19 (4):428436, 2005.
346. S. Furtado, V. Sossi, R. A. Hauser, A. Samii, M. Schulzer, C. B. Murphy, T. B. Freeman,
and A. J. Stoessl. Positron emission tomography after fetal transplantation in Huntington's
disease. Ann.Neurol. 58 (2):331-337, 2005.
347. Yaguez, H. W. Lange, and V. Homberg. Differential effect of Huntington's and
Parkinson's diseases in programming motor sequences of varied lengths. J.Neurol. 253
(2):186-193, 2006.
348. K. Puri, B. R. Leavitt, M. R. Hayden, C. A. Ross, A. Rosenblatt, J. T. Greenamyre, S.
Hersch, K. S. Vaddadi, A. Sword, D. F. Horrobin, M. Manku, and H. Murck. Ethyl-EPA in
Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology 65
(2):286-292, 2005.
349. R. Bellotti, Carlo F. De, R. Massafra, Tommaso M. de, and V. Sciruicchio. Topographic
classification of EEG patterns in Huntington's disease. Neurol.Clin.Neurophysiol. 2004:37,
2004.
350. Decruyenaere, G. Evers-Kiebooms, A. Boogaerts, K. Demyttenaere, R. Dom, and J. P.
Fryns. Partners of mutation-carriers for Huntington's disease: forgotten persons?
Eur.J.Hum.Genet. 13 (9):1077-1085, 2005.
351. L. J. Beglinger, P. C. Nopoulos, R. E. Jorge, D. R. Langbehn, A. E. Mikos, D. J. Moser,
K. Duff, R. G. Robinson, and J. S. Paulsen. White matter volume and cognitive dysfunction
in early Huntington's disease. Cogn Behav.Neurol. 18 (2):102-107, 2005.
352. M. Gaba, K. Zhang, K. Marder, C. B. Moskowitz, P. Werner, and C. N. Boozer. Energy
balance in early-stage Huntington disease. Am.J.Clin.Nutr. 81 (6):1335-1341, 2005.
353. K. I. Taylor, D. P. Salmon, A. U. Monsch, and P. Brugger. Semantic and phonemic
sequence effects in random word generation: a dissociation between Alzheimer's and
Huntington's disease patients. J.Int.Neuropsychol.Soc. 11 (3):303-310, 2005.
354. S. J. Tabrizi, A. M. Blamire, D. N. Manners, B. Rajagopalan, P. Styles, A. H. Schapira,
and T. T. Warner. High-dose creatine therapy for Huntington disease: a 2-year clinical and
MRS study. Neurology 64 (9):1655-1656, 2005.
355. Lemay, E. Fimbel, A. Beuter, S. Chouinard, and F. Richer. Sensorimotor mapping affects
movement correction deficits in early Huntington's disease. Exp.Brain Res. 165 (4):454460, 2005.
356. K. Rao, L. Quinn, and K. S. Marder. Reliability of spatiotemporal gait outcome measures
in Huntington's disease. Mov Disord. 20 (8):1033-1037, 2005.
357. Stoy N, Mackay GM, Forrest CM, Christofides J, Egerton M, Stone TW, Darlington LG.
Tryptophan metabolism and oxidative stress in patients with Huntington's disease. J
Neurochem. 93(3):611-23, 2005
358. M. Kipps, A. J. Duggins, N. Mahant, L. Gomes, J. Ashburner, and E. A. McCusker.
Progression of structural neuropathology in preclinical Huntington's disease: a tensor based
morphometry study. J.Neurol.Neurosurg.Psychiatry 76 (5):650-655, 2005.
359. Byth K, Cox DR. On the relation between initial value and slope. Biostatistics. 6(3):395403, 2005
360. J. S. Paulsen, K. F. Hoth, C. Nehl, and L. Stierman. Critical periods of suicide risk in
Huntington's disease. Am.J.Psychiatry 162 (4):725-731, 2005.
361. Teichmann, E. Dupoux, S. Kouider, P. Brugieres, M. F. Boisse, S. Baudic, P. Cesaro, M.
Peschanski, and A. C. Bachoud-Levi. The role of the striatum in rule application: the model
of Huntington's disease at early stage. Brain 128 (Pt 5):1155-1167, 2005.
362. Markianos, M. Panas, N. Kalfakis, and D. Vassilopoulos. Plasma testosterone in male
patients with Huntington's disease: relations to severity of illness and dementia.
Ann.Neurol. 57 (4):520-525, 2005.
363. Boulet, M. Lemay, M. A. Bedard, M. J. Chouinard, S. Chouinard, and F. Richer. Early
Huntington's disease affects movements in transformed sensorimotor mappings. Brain
Cogn 57 (3):236-243, 2005.
364. J. Mitchell, H. Heims, E. A. Neville, and H. Rickards. Huntington's disease patients show
impaired perception of disgust in the gustatory and olfactory modalities. J.Neuropsychiatry
Clin.Neurosci. 17 (1):119-121, 2005.
365. Arning L, Kraus PH, Valentin S, Saft C, Andrich J, Epplen JT. NR2A and NR2B
receptor gene variations modify age at onset in Huntington disease. Neurogenetics. 6(1):258, 2005
366. Hurelbrink CB, Lewis SJ, Barker RA. The use of the Actiwatch-Neurologica system to
objectively assess the involuntary movements and sleep-wake activity in patients with mildmoderate Huntington's disease. J Neurol. 252(6):642-7, 2005
367. Saft C, Zange J, Andrich J, Müller K, Lindenberg K, Landwehrmeyer B, Vorgerd M,
Kraus PH, Przuntek H, Schöls L. Mitochondrial impairment in patients and asymptomatic
mutation carriers of Huntington's disease. Mov Disord. 20(6):674-9, 2005.
368. T. T. Lineweaver, D. P. Salmon, M. W. Bondi, and J. Corey-Bloom. Differential effects
of Alzheimer's disease and Huntington's disease on the performance of mental rotation.
J.Int.Neuropsychol.Soc. 11 (1):30-39, 2005.
369. Bender, D. P. Auer, T. Merl, R. Reilmann, P. Saemann, A. Yassouridis, J. Bender, A.
Weindl, M. Dose, T. Gasser, and T. Klopstock. Creatine supplementation lowers brain
glutamate levels in Huntington's disease. J.Neurol. 252 (1):36-41, 2005.
370. Kobal, B. Meglic, A. Mesec, and B. Peterlin. Early sympathetic hyperactivity in
Huntington's disease. Eur.J.Neurol. 11 (12):842-848, 2004.
371. Longworth CE, Keenan SE, Barker RA, Marslen-Wilson WD, Tyler LK. The basal
ganglia and rule-governed language use: evidence from vascular and degenerative
conditions. Brain. 128(Pt 3):584-96, 2005
372. Chattopadhyay, K. Baksi, S. Mukhopadhyay, and N. P. Bhattacharyya. Modulation of
age at onset of Huntington disease patients by variations in TP53 and human caspase
activated DNase (hCAD) genes. Neurosci.Lett. 374 (2):81-86, 2005.
373. J. Morton, N. I. Wood, M. H. Hastings, C. Hurelbrink, R. A. Barker, and E. S. Maywood.
Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease.
J.Neurosci. 25 (1):157-163, 2005.
374. Allain P, Verny C, Aubin G, Pinon K, Bonneau D, Dubas F, Le Gall D. Arithmetic wordproblem-solving in Huntington's disease. Brain Cogn. 57(1):1-3, 2005
375. M. A. Smith and R. Shadmehr. Intact ability to learn internal models of arm dynamics in
Huntington's disease but not cerebellar degeneration. J.Neurophysiol. 93 (5):2809-2821,
2005.
376. K. Ho, B. J. Sahakian, T. W. Robbins, and R. A. Barker. Random number generation in
patients with symptomatic and presymptomatic Huntington's disease. Cogn Behav.Neurol.
17 (4):208-212, 2004.
377. C. Reynolds, Jr., R. W. Prost, and L. P. Mark. Heterogeneity in 1H-MRS profiles of
presymptomatic and early manifest Huntington's disease. Brain Res. 1031 (1):82-89, 2005.
378. Tumas, S. T. Camargos, P. S. Jalali, Ade P. Galesso, and Jr W. Marques. Internal
consistency of a Brazilian version of the unified Huntington's disease rating scale. Arq
Neuropsiquiatr. 62 (4):977-982, 2004.
379. Bloch, A. C. Bachoud-Levi, N. Deglon, J. P. Lefaucheur, L. Winkel, S. Palfi, J. P.
Nguyen, C. Bourdet, V. Gaura, P. Remy, P. Brugieres, M. F. Boisse, S. Baudic, P. Cesaro,
P. Hantraye, P. Aebischer, and M. Peschanski. Neuroprotective gene therapy for
Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary
neurotrophic factor: results of a phase I study. Hum.Gene Ther. 15 (10):968-975, 2004.
380. Guidetti P, Luthi-Carter RE, Augood SJ, Schwarcz R. Neostriatal and cortical quinolinate
levels are increased in early grade Huntington's disease. Neurobiol Dis. 17(3):455-61, 2004
381. J. S. Paulsen, J. L. Zimbelman, S. C. Hinton, D. R. Langbehn, C. L. Leveroni, M. L.
Benjamin, N. C. Reynolds, and S. M. Rao. fMRI biomarker of early neuronal dysfunction
in presymptomatic Huntington's Disease. AJNR Am.J.Neuroradiol. 25 (10):1715-1721,
2004.
382. Saft, J. E. Andrich, N. Brune, M. Gencik, P. H. Kraus, H. Przuntek, and J. T. Epplen.
Apolipoprotein E genotypes do not influence the age of onset in Huntington's disease.
J.Neurol.Neurosurg.Psychiatry 75 (12):1692-1696, 2004.
383. J. R. Sadek, S. A. Johnson, D. A. White, D. P. Salmon, K. I. Taylor, J. H. Delapena, J. S.
Paulsen, R. K. Heaton, and I. Grant. Retrograde amnesia in dementia: comparison of HIVassociated dementia, Alzheimer's disease, and Huntington's disease. Neuropsychology 18
(4):692-699, 2004.
384. R. M. Bonelli, A. K. Hodl, P. Hofmann, and H. P. Kapfhammer. Neuroprotection in
Huntington's disease: a 2-year study on minocycline. Int.Clin.Psychopharmacol. 19
(6):337-342, 2004.
385. V. Popovic, M. Svetel, M. Djurovic, S. Petrovic, M. Doknic, S. Pekic, D. Miljic, N.
Milic, J. Glodic, C. Dieguez, F. F. Casanueva, and V. Kostic. Circulating and cerebrospinal
fluid ghrelin and leptin: potential role in altered body weight in Huntington's disease.
Eur.J.Endocrinol. 151 (4):451-455, 2004.
386. Margolis RL, Holmes SE, Rosenblatt A, Gourley L, O'Hearn E, Ross CA, Seltzer WK,
Walker RH, Ashizawa T, Rasmussen A, Hayden M, Almqvist EW, Harris J, Fahn S,
MacDonald ME, Mysore J, Shimohata T, Tsuji S, Potter N, Nakaso K, Adachi Y,
Nakashima K, Bird T, Krause A, Greenstein P. Huntington's Disease-like 2 (HDL2) in
North America and Japan. Ann Neurol. 56(5):670-4, 2004
387. J. Kassubek, F. D. Juengling, D. Ecker, and G. B. Landwehrmeyer. Thalamic atrophy in
Huntington's disease co-varies with cognitive performance: a morphometric MRI analysis.
Cereb.Cortex 15 (6):846-853, 2005.
388. Fennema-Notestine C, Archibald SL, Jacobson MW, Corey-Bloom J, Paulsen JS, Peavy
GM, Gamst AC, Hamilton JM, Salmon DP, Jernigan TL. In vivo evidence of cerebellar
atrophy and cerebral white matter loss in Huntington disease. Neurology. 63(6):989-95,
2004
389. Bilney, M. E. Morris, A. Churchyard, E. Chiu, and N. Georgiou-Karistianis. Evidence for
a disorder of locomotor timing in Huntington's disease. Mov Disord. 20 (1):51-57, 2005.
390. Tommaso M. de, N. Specchio, V. Sciruicchio, O. Difruscolo, and L. M. Specchio. Effects
of rivastigmine on motor and cognitive impairment in Huntington's disease. Mov Disord. 19
(12):1516-1518, 2004.
391. K. Ho, A. O. Robbins, S. J. Walters, S. Kaptoge, B. J. Sahakian, and R. A. Barker.
Health-related quality of life in Huntington's disease: a comparison of two generic
instruments, SF-36 and SIP. Mov Disord. 19 (11):1341-1348, 2004.
392. T. M. Blekher, R. D. Yee, S. C. Kirkwood, A. M. Hake, J. C. Stout, M. R. Weaver, and
T. M. Foroud. Oculomotor control in asymptomatic and recently diagnosed individuals with
the genetic marker for Huntington's disease. Vision Res. 44 (23):2729-2736, 2004.
393. Beister, P. Kraus, W. Kuhn, M. Dose, A. Weindl, and M. Gerlach. The N-methyl-Daspartate antagonist memantine retards progression of Huntington's disease. J.Neural
Transm.Suppl (68):117-122, 2004.
394. J. Andrich, C. Saft, M. Gerlach, B. Schneider, A. Arz, W. Kuhn, and T. Muller.
Coenzyme Q10 serum levels in Huntington's disease. J.Neural Transm.Suppl (68):111-116,
2004.
395. Brune, J. Andrich, M. Gencik, C. Saft, T. Muller, S. Valentin, H. Przuntek, and J. T.
Epplen. Methyltetrahydrofolate reductase polymorphism influences onset of Huntington's
disease. J.Neural Transm.Suppl (68):105-110, 2004.
396. Saft, J. Andrich, N. M. Meisel, H. Przuntek, and T. Muller. Congruent deterioration of
complex and simple movements in patients with Huntington's disease. J.Neural
Transm.Suppl (68):97-104, 2004.
397. M. Codori, P. R. Slavney, A. Rosenblatt, and J. Brandt. Prevalence of major depression
one year after predictive testing for Huntington's disease. Genet.Test. 8 (2):114-119, 2004.
398. J. Lemiere, M. Decruyenaere, G. Evers-Kiebooms, E. Vandenbussche, and R. Dom.
Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of
the HD mutation--a longitudinal follow-up study. J.Neurol. 251 (8):935-942, 2004.
399. Baliko, B. Csala, and J. Czopf. Suicide in Hungarian Huntington's disease patients.
Neuroepidemiology 23 (5):258-260, 2004.
400. J. M. Heckmann, P. Legg, D. Sklar, J. Fine, A. Bryer, and B. Kies. IV amantadine
improves chorea in Huntington's disease: an acute randomized, controlled study. Neurology
63 (3):597-598, 2004.
401. Anonymous. Minocycline safety and tolerability in Huntington disease. Neurology 63
(3):547-549, 2004.
402. C. Voermans, K. M. Petersson, L. Daudey, B. Weber, K. P. Van Spaendonck, H. P.
Kremer, and G. Fernandez. Interaction between the human hippocampus and the caudate
nucleus during route recognition. Neuron 43 (3):427-435, 2004.
403. K. Wang, Y. R. Wu, W. L. Hwu, C. M. Chen, L. S. Ro, S. T. Chen, K. Gwinn-Hardy, C.
C. Yang, R. M. Wu, T. F. Chen, H. C. Wang, M. C. Chao, M. J. Chiu, C. J. Lu, and G. J.
Lee-Chen. DNA haplotype analysis of CAG repeat in Taiwanese Huntington's disease
patients. Eur.Neurol. 52 (2):96-100, 2004.
404. J. Brandt, I. Leroi, E. O'Hearn, A. Rosenblatt, and R. L. Margolis. Cognitive impairments
in cerebellar degeneration: a comparison with Huntington's disease. J.Neuropsychiatry
Clin.Neurosci. 16 (2):176-184, 2004.
405. H. Aylward, B. F. Sparks, K. M. Field, V. Yallapragada, B. D. Shpritz, A. Rosenblatt, J.
Brandt, L. M. Gourley, K. Liang, H. Zhou, R. L. Margolis, and C. A. Ross. Onset and rate
of striatal atrophy in preclinical Huntington disease. Neurology 63 (1):66-72, 2004.
406. J. S. Kim, S. A. Reading, T. Brashers-Krug, V. D. Calhoun, C. A. Ross, and G. D.
Pearlson. Functional MRI study of a serial reaction time task in Huntington's disease.
Psychiatry Res. 131 (1):23-30, 2004.
407. Mascalchi, F. Lolli, Nave R. Della, C. Tessa, R. Petralli, C. Gavazzi, L. S. Politi, M.
Macucci, M. Filippi, and S. Piacentini. Huntington disease: volumetric, diffusion-weighted,
and magnetization transfer MR imaging of brain. Radiology 232 (3):867-873, 2004.
408. J. Valls-Sole, J. E. Munoz, and F. Valldeoriola. Abnormalities of prepulse inhibition do
not depend on blink reflex excitability: a study in Parkinson's disease and Huntington's
disease. Clin.Neurophysiol. 115 (7):1527-1536, 2004.
409. M. Thomas, T. Ashizawa, and J. Jankovic. Minocycline in Huntington's disease: a pilot
study. Mov Disord. 19 (6):692-695, 2004.
410. S. A. Reading, A. C. Dziorny, L. A. Peroutka, M. Schreiber, L. M. Gourley, V.
Yallapragada, A. Rosenblatt, R. L. Margolis, J. J. Pekar, G. D. Pearlson, E. Aylward, J.
Brandt, S. S. Bassett, and C. A. Ross. Functional brain changes in presymptomatic
Huntington's disease. Ann.Neurol. 55 (6):879-883, 2004.
411. Georgiou-Karistianis, K. E. Hoy, J. L. Bradshaw, M. Farrow, E. Chiu, A. Churchyard, P.
B. Fitzgerald, and C. A. Armatas. Motor overflow in Huntington's disease.
J.Neurol.Neurosurg.Psychiatry 75 (6):904-906, 2004.
412. Peran, J. F. Demonet, C. Pernet, and D. Cardebat. Verb and noun generation tasks in
Huntington's disease. Mov Disord. 19 (5):565-571, 2004.
413. Glatting, F. M. Mottaghy, J. Karitzky, A. Baune, F. T. Sommer, G. B. Landwehrmeyer,
and S. N. Reske. Improving binding potential analysis in [11C]raclopride PET studies using
cluster analysis. Med.Phys. 31 (4):902-906, 2004.
414. Allain P, Verny C, Aubin G, Bonneau D, Dubas F, Le Gall D. Processing of "scripts" and
frontal lobe function in Huntington's disease. Rev Neurol (Paris). 160(4 Pt 1):434-40, 2004
415. Beal MF, Ferrante RJ. Experimental therapeutics in transgenic mouse models of
Huntington's disease. Nat Rev Neurosci. 5(5):373-84, 2004
416. Hennenlotter, U. Schroeder, P. Erhard, B. Haslinger, R. Stahl, A. Weindl, H. G. von
Einsiedel, K. W. Lange, and A. O. Ceballos-Baumann. Neural correlates associated with
impaired disgust processing in pre-symptomatic Huntington's disease. Brain 127 (Pt
6):1446-1453, 2004.
417. J. Kassubek, Landwehrmeyer G. Bernhard, D. Ecker, F. D. Juengling, R. Muche, S.
Schuller, A. Weindl, and A. Peinemann. Global cerebral atrophy in early stages of
Huntington's disease: quantitative MRI study. Neuroreport 15 (2):363-365, 2004.
418. K. Ho, P. J. Nestor, G. B. Williams, J. L. Bradshaw, B. J. Sahakian, T. W. Robbins, and
R. A. Barker. Pseudo-neglect in Huntington's disease correlates with decreased angular
gyrus density. Neuroreport 15 (6):1061-1064, 2004.
419. M. Markianos, M. Panas, N. Kalfakis, and D. Vassilopoulos. Platelet monoamine oxidase
activity in subjects tested for Huntington's disease gene mutation. J.Neural Transm. 111
(4):475-483, 2004.
420. L. Arning, P. Jagiello, S. Wieczorek, C. Saft, J. Andrich, and J. T. Epplen. Glutathione STransferase Omega 1 variation does not influence age at onset of Huntington's disease.
BMC Med.Genet. 5:7, 2004.
421. L. Djousse, B. Knowlton, M. R. Hayden, E. W. Almqvist, R. R. Brinkman, C. A. Ross,
R. L. Margolis, A. Rosenblatt, A. Durr, C. Dode, P. J. Morrison, A. Novelletto, M. Frontali,
R. J. Trent, E. McCusker, E. Gomez-Tortosa, Cabrero D. Mayo, R. Jones, A. Zanko, M.
Nance, R. K. Abramson, O. Suchowersky, J. S. Paulsen, M. B. Harrison, Q. Yang, L. A.
Cupples, J. Mysore, J. F. Gusella, M. E. MacDonald, and R. H. Myers. Evidence for a
modifier of onset age in Huntington disease linked to the HD gene in 4p16. Neurogenetics.
5 (2):109-114, 2004.
422. J. P. van Vugt, K. K. Piet, L. J. Vink, S. Siesling, A. H. Zwinderman, H. A. Middelkoop,
and R. A. Roos. Objective assessment of motor slowness in Huntington's disease: clinical
correlates and 2-year follow-up. Mov Disord. 19 (3):285-297, 2004.
423. Campbell MC, Stout JC, Finn PR. Reduced autonomic responsiveness to gambling task
losses in Huntington's disease. J Int Neuropsychol Soc. 10(2):239-45, 2004
424. Tommaso M. de, V. Sciruicchio, N. Specchio, O. Difruscolo, C. Vitale, L. M. Specchio,
and F. Puca. Early modifications of auditory event-related potentials in carriers of the
Huntington's disease gene. Acta Neurol.Belg. 103 (4):192-198, 2003.
425. S. Wexler, J. Lorimer, J. Porter, F. Gomez, C. Moskowitz, E. Shackell, K. Marder, G.
Penchaszadeh, S. A. Roberts, J. Gayan, D. Brocklebank, S. S. Cherny, L. R. Cardon, J.
Gray, S. R. Dlouhy, S. Wiktorski, M. E. Hodes, P. M. Conneally, J. B. Penney, J. Gusella,
J. H. Cha, M. Irizarry, D. Rosas, S. Hersch, Z. Hollingsworth, M. MacDonald, A. B.
Young, J. M. Andresen, D. E. Housman, M. M. De Young, E. Bonilla, T. Stillings, A.
Negrette, S. R. Snodgrass, M. D. Martinez-Jaurrieta, M. A. Ramos-Arroyo, J. Bickham, J.
S. Ramos, F. Marshall, I. Shoulson, G. J. Rey, A. Feigin, N. Arnheim, A. cevedo-Cruz, L.
Acosta, J. Alvir, K. Fischbeck, L. M. Thompson, A. Young, L. Dure, C. J. O'Brien, J.
Paulsen, A. Brickman, D. Krch, S. Peery, P. Hogarth, D. S. Higgins, Jr., and B.
Landwehrmeyer. Venezuelan kindreds reveal that genetic and environmental factors
modulate Huntington's disease age of onset. Proc.Natl.Acad.Sci.U.S.A 101 (10):3498-3503,
2004.
426. J. Andrich, C. Saft, A. Arz, B. Schneider, M. W. Agelink, P. H. Kraus, W. Kuhn, and T.
Muller. Hyperhomocysteinaemia in treated patients with Huntington's disease
homocysteine in HD. Mov Disord. 19 (2):226-228, 2004.
427. Trejo, R. M. Tarrats, M. E. Alonso, M. C. Boll, A. Ochoa, and L. Velasquez. Assessment
of the nutrition status of patients with Huntington's disease. Nutrition 20 (2):192-196, 2004.
428. Cannella M, Gellera C, Maglione V, Giallonardo P, Cislaghi G, Muglia M, Quattrone A,
Pierelli F, Di Donato S, Squitieri F. The gender effect in juvenile Huntington disease
patients of Italian origin. Am J Med Genet B Neuropsychiatr Genet. 125B(1):92-8, 2004
429. J. Fielding, N. Georgiou-Karistianis, J. Bradshaw, L. Millist, A. Churchyard, E. Chiu, and
O. White. Impaired modulation of the vestibulo-ocular reflex in Huntington's disease. Mov
Disord. 19 (1):68-75, 2004.
430. J. Kassubek, F. D. Juengling, T. Kioschies, K. Henkel, J. Karitzky, B. Kramer, D. Ecker,
J. Andrich, C. Saft, P. Kraus, A. J. Aschoff, A. C. Ludolph, and G. B. Landwehrmeyer.
Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric
MRI study. J.Neurol.Neurosurg.Psychiatry 75 (2):213-220, 2004.
431. J. M. Hamilton, T. Wolfson, G. M. Peavy, M. W. Jacobson, and J. Corey-Bloom. Rate
and correlates of weight change in Huntington's disease. J.Neurol.Neurosurg.Psychiatry 75
(2):209-212, 2004.
432. Nehl and J. S. Paulsen. Cognitive and psychiatric aspects of Huntington disease
contribute to functional capacity. J.Nerv.Ment.Dis. 192 (1):72-74, 2004.
433. K. O. Bushara, M. Nance, and C. M. Gomez. Antigliadin antibodies in Huntington's
disease. Neurology 62 (1):132-133, 2004.
434. K. Ho, B. J. Sahakian, R. G. Brown, R. A. Barker, J. R. Hodges, M. N. Ane, J. Snowden,
J. Thompson, T. Esmonde, R. Gentry, J. W. Moore, and T. Bodner. Profile of cognitive
progression in early Huntington's disease. Neurology 61 (12):1702-1706, 2003.
435. Saft, J. Andrich, N. M. Meisel, H. Przuntek, and T. Muller. Assessment of complex
movements reflects dysfunction in Huntington's disease. J.Neurol. 250 (12):1469-1474,
2003.
436. Anonymous. Dosage effects of riluzole in Huntington's disease: a multicenter placebocontrolled study. Neurology 61 (11):1551-1556, 2003.
437. L. Hyer, S. Sohnle, M. H. Miller, and R. Hamer. Cognitive Testing Battery: differences
among groups with dementia, Huntington's disease, and controls. Psychol.Rep. 93 (2):497504, 2003.
438. H. Aylward, A. Rosenblatt, K. Field, V. Yallapragada, K. Kieburtz, M. McDermott, L. A.
Raymond, E. W. Almqvist, M. Hayden, and C. A. Ross. Caudate volume as an outcome
measure in clinical trials for Huntington's disease: a pilot study. Brain Res.Bull. 62 (2):137141, 2003.
439. C. Delis, M. Jacobson, M. W. Bondi, J. M. Hamilton, and D. P. Salmon. The myth of
testing construct validity using factor analysis or correlations with normal or mixed clinical
populations: lessons from memory assessment. J.Int.Neuropsychol.Soc. 9 (6):936-946,
2003.
440. V. Gaura, A. C. Bachoud-Levi, M. J. Ribeiro, J. P. Nguyen, V. Frouin, S. Baudic, P.
Brugieres, J. F. Mangin, M. F. Boisse, S. Palfi, P. Cesaro, Y. Samson, P. Hantraye, M.
Peschanski, and P. Remy. Striatal neural grafting improves cortical metabolism in
Huntington's disease patients. Brain 127 (Pt 1):65-72, 2004.
441. N. Mahant, E. A. McCusker, K. Byth, and S. Graham. Huntington's disease: clinical
correlates of disability and progression. Neurology 61 (8):1085-1092, 2003.
442. Mdo C. Costa, P. Magalhaes, F. Ferreirinha, L. Guimaraes, C. Januario, I. Gaspar, L.
Loureiro, J. Vale, C. Garrett, F. Regateiro, M. Magalhaes, A. Sousa, P. Maciel, and J.
Sequeiros. Molecular diagnosis of Huntington disease in Portugal: implications for genetic
counselling and clinical practice. Eur.J.Hum.Genet. 11 (11):872-878, 2003.
443. Verbessem, J. Lemiere, B. O. Eijnde, S. Swinnen, L. Vanhees, Leemputte M. Van, P.
Hespel, and R. Dom. Creatine supplementation in Huntington's disease: a placebocontrolled pilot trial. Neurology 61 (7):925-930, 2003.
444. Rosenblatt, M. H. Abbott, L. M. Gourley, J. C. Troncoso, R. L. Margolis, J. Brandt, and
C. A. Ross. Predictors of neuropathological severity in 100 patients with Huntington's
disease. Ann.Neurol. 54 (4):488-493, 2003.
445. Gagnon DR, Glickman ME, Myers RH, Cupples LA. The analysis of survival data with a
non-susceptible fraction and dual censoring mechanisms. Stat Med. 22(20):3249-62, 2003
446. Antal, S. Beniczky, T. Z. Kincses, K. Jakab, G. Benedek, and L. Vecsei. Perceptual
categorization is impaired in Huntington's disease: an electrophysiological study.
Dement.Geriatr.Cogn Disord. 16 (4):187-192, 2003.
447. F. O'Donnell, M. A. Wilt, A. M. Hake, J. C. Stout, S. C. Kirkwood, and T. Foroud.
Visual function in Huntington's disease patients and presymptomatic gene carriers. Mov
Disord. 18 (9):1027-1034, 2003.
448. R. Aron, L. Watkins, B. J. Sahakian, S. Monsell, R. A. Barker, and T. W. Robbins. Taskset switching deficits in early-stage Huntington's disease: implications for basal ganglia
function. J.Cogn Neurosci. 15 (5):629-642, 2003.
449. K. Varani, M. P. Abbracchio, M. Cannella, G. Cislaghi, P. Giallonardo, C. Mariotti, E.
Cattabriga, F. Cattabeni, P. A. Borea, F. Squitieri, and E. Cattaneo. Aberrant A2A receptor
function in peripheral blood cells in Huntington's disease. FASEB J. 17 (14):2148-2150,
2003.
450. J. Fernandez-Ruiz, R. Diaz, C. Hall-Haro, P. Vergara, J. Mischner, L. Nunez, R. DruckerColin, A. Ochoa, and M. E. Alonso. Normal prism adaptation but reduced after-effect in
basal ganglia disorders using a throwing task. Eur.J.Neurosci. 18 (3):689-694, 2003.
451. T. Winograd-Gurvich, N. Georgiou-Karistianis, A. Evans, L. Millist, J. L. Bradshaw, A.
Churchyard, E. Chiu, and O. B. White. Hypometric primary saccades and increased
variability in visually-guided saccades in Huntington's disease. Neuropsychologia 41
(12):1683-1692, 2003.
452. O'Suilleabhain and R. B. Dewey, Jr. A randomized trial of amantadine in Huntington
disease. Arch.Neurol. 60 (7):996-998, 2003.
453. M. Milders, J. R. Crawford, A. Lamb, and S. A. Simpson. Differential deficits in
expression recognition in gene-carriers and patients with Huntington's disease.
Neuropsychologia 41 (11):1484-1492, 2003.
454. J. Tabrizi, A. M. Blamire, D. N. Manners, B. Rajagopalan, P. Styles, A. H. Schapira, and
T. T. Warner. Creatine therapy for Huntington's disease: clinical and MRS findings in a 1year pilot study. Neurology 61 (1):141-142, 2003.
455. Munoz, A. Cervera, and J. Valls-Sole. Neurophysiological study of facial chorea in
patients with Huntington's disease. Clin.Neurophysiol. 114 (7):1246-1252, 2003.
456. Tommaso M. de, Carlo F. De, O. Difruscolo, R. Massafra, V. Sciruicchio, and R. Bellotti.
Detection of subclinical brain electrical activity changes in Huntington's disease using
artificial neural networks. Clin.Neurophysiol. 114 (7):1237-1245, 2003.
457. Lucetti, Dotto P. Del, G. Gambaccini, Agnello G. Dell', S. Bernardini, G. Rossi, L. Murri,
and U. Bonuccelli. IV amantadine improves chorea in Huntington's disease: an acute
randomized, controlled study. Neurology 60 (12):1995-1997, 2003.
458. Chattopadhyay, S. Ghosh, P. K. Gangopadhyay, S. K. Das, T. Roy, K. K. Sinha, D. K.
Jha, S. C. Mukherjee, A. Chakraborty, B. S. Singhal, A. K. Bhattacharya, and N. P.
Bhattacharyya. Modulation of age at onset in Huntington's disease and spinocerebellar
ataxia type 2 patients originated from eastern India. Neurosci.Lett. 345 (2):93-96, 2003.
459. Y. Uc, R. D. Skinner, R. L. Rodnitzky, and E. Garcia-Rill. The midlatency auditory
evoked potential P50 is abnormal in Huntington's disease. J.Neurol.Sci. 212 (1-2):1-5,
2003.
460. J. D. Davis, J. V. Filoteo, R. P. Kesner, and J. W. Roberts. Recognition memory for hand
positions and spatial locations in patients with Huntington's disease: differential
visuospatial memory impairment? Cortex 39 (2):239-253, 2003.
461. L. Djousse, B. Knowlton, M. Hayden, E. W. Almqvist, R. Brinkman, C. Ross, R.
Margolis, A. Rosenblatt, A. Durr, C. Dode, P. J. Morrison, A. Novelletto, M. Frontali, R. J.
Trent, E. McCusker, E. Gomez-Tortosa, D. Mayo, R. Jones, A. Zanko, M. Nance, R.
Abramson, O. Suchowersky, J. Paulsen, M. Harrison, Q. Yang, L. A. Cupples, J. F.
Gusella, M. E. MacDonald, and R. H. Myers. Interaction of normal and expanded CAG
repeat sizes influences age at onset of Huntington disease. Am.J.Med.Genet.A 119A
(3):279-282, 2003.
462. Brannan. The hung-up knee jerk in Huntington's Disease. Parkinsonism Relat Disord. 9
(5):257-259, 2003.
463. D. Rosas, W. J. Koroshetz, Y. I. Chen, C. Skeuse, M. Vangel, M. E. Cudkowicz, K.
Caplan, K. Marek, L. J. Seidman, N. Makris, B. G. Jenkins, and J. M. Goldstein. Evidence
for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis.
Neurology 60 (10):1615-1620, 2003.
464. R. Aron, B. J. Sahakian, and T. W. Robbins. Distractibility during selection-for-action:
differential deficits in Huntington's disease and following frontal lobe damage.
Neuropsychologia 41 (9):1137-1147, 2003.
465. K. Kurup and P. A. Kurup. Cerebral chemical dominance and neural regulation of cell
division, cell proliferation, neoplastic transformation, and genomic function. Int.J.Neurosci.
113 (5):703-720, 2003.
466. Piccolo I, Defanti CA, Soliveri P, Volontè MA, Cislaghi G, Girotti F. Cause and course
in a series of patients with sporadic chorea. J Neurol. 250(4):429-35, 2003
467. N. Pavese, T. C. Andrews, D. J. Brooks, A. K. Ho, A. E. Rosser, R. A. Barker, T. W.
Robbins, B. J. Sahakian, S. B. Dunnett, and P. Piccini. Progressive striatal and cortical
dopamine receptor dysfunction in Huntington's disease: a PET study. Brain 126 (Pt
5):1127-1135, 2003.
468. M. Bonelli, C. Heuberger, and F. Reisecker. Minocycline for Huntington's disease: an
open label study. Neurology 60 (5):883-884, 2003.
469. Carella F, Bressanelli M, Piacentini S, Soliveri P, Geminiani G, Monza D, Albanese A,
Girotti F. A study of arm movements in Huntington's disease under visually controlled and
blindfolded conditions. Neurol Sci. 23(6):287-93, 2003
470. R. Leng, M. J. Woodward, M. J. Stokes, A. V. Swan, L. A. Wareing, and R. Baker.
Effects of multisensory stimulation in people with Huntington's disease: a randomized
controlled pilot study. Clin.Rehabil. 17 (1):30-41, 2003.
471. Squitieri, C. Gellera, M. Cannella, C. Mariotti, G. Cislaghi, D. C. Rubinsztein, E. W.
Almqvist, D. Turner, A. C. Bachoud-Levi, S. A. Simpson, M. Delatycki, V. Maglione, M.
R. Hayden, and S. D. Donato. Homozygosity for CAG mutation in Huntington disease is
associated with a more severe clinical course. Brain 126 (Pt 4):946-955, 2003.
472. Amann B, Sterr A, Thoma H, Messer T, Kapfhammer HP, Grunze H. Psychopathological
changes preceding motor symptoms in Huntington's disease: a report on four cases. World J
Biol Psychiatry. 1(1):55-8, 2000
473. J. S. Snowden, Z. C. Gibbons, A. Blackshaw, E. Doubleday, J. Thompson, D. Craufurd,
J. Foster, F. Happe, and D. Neary. Social cognition in frontotemporal dementia and
Huntington's disease. Neuropsychologia 41 (6):688-701, 2003.
474. R. Aron, F. Schlaghecken, P. C. Fletcher, E. T. Bullmore, M. Eimer, R. Barker, B. J.
Sahakian, and T. W. Robbins. Inhibition of subliminally primed responses is mediated by
the caudate and thalamus: evidence from functional MRI and Huntington's disease. Brain
126 (Pt 3):713-723, 2003.
475. J. P. van Vugt, M. Stijl, R. A. Roos, and J. G. van Dijk. Impaired antagonist inhibition
may contribute to akinesia and bradykinesia in Huntington's disease. Clin.Neurophysiol.
114 (2):295-305, 2003.
476. J. M. Hamilton, K. Y. Haaland, J. C. Adair, and J. Brandt. Ideomotor limb apraxia in
Huntington's disease: implications for corticostriate involvement. Neuropsychologia 41
(5):614-621, 2003.
477. Wang K, Hoosain R, Yang RM, Meng Y, Wang CQ. Impairment of recognition of
disgust in Chinese with Huntington's or Wilson's disease. Neuropsychologia. 41(5):527-37,
2003
478. M. N. Witjes-Ane, der Vegter-van, V, J. P. van Vugt, J. B. Lanser, J. Hermans, A. H.
Zwinderman, G. J. van Ommen, and R. A. Roos. Cognitive and motor functioning in gene
carriers for Huntington's disease: a baseline study. J.Neuropsychiatry Clin.Neurosci. 15
(1):7-16, 2003.
479. Squitieri, M. Cannella, and M. Simonelli. CAG mutation effect on rate of progression in
Huntington's disease. Neurol.Sci. 23 Suppl 2:S107-S108, 2002.
480. Soliveri, D. Monza, S. Piacentini, D. Paridi, C. Nespolo, C. Gellera, C. Mariotti, A.
Albanese, and F. Girotti. Cognitive and psychiatric characterization of patients with
Huntington's disease and their at-risk relatives. Neurol.Sci. 23 Suppl 2:S105-S106, 2002.
481. Lucetti, G. Gambaccini, S. Bernardini, G. Dell'Agnello, L. Petrozzi, G. Rossi, and U.
Bonuccelli. Amantadine in Huntington's disease: open-label video-blinded study.
Neurol.Sci. 23 Suppl 2:S83-S84, 2002.
482. Seiss E, Praamstra P, Hesse CW, Rickards H. Proprioceptive sensory function in
Parkinson's disease and Huntington's disease: evidence from proprioception-related EEG
potentials. Exp Brain Res. 148(3):308-19, 2003
483. M. van Roon-Mom, S. J. Reid, A. L. Jones, M. E. MacDonald, R. L. Faull, and R. G.
Snell. Insoluble TATA-binding protein accumulation in Huntington's disease cortex. Brain
Res.Mol.Brain Res. 109 (1-2):1-10, 2002.
484. M. Decruyenaere, G. Evers-Kiebooms, T. Cloostermans, A. Boogaerts, K. Demyttenaere,
R. Dom, and J. P. Fryns. Psychological distress in the 5-year period after predictive testing
for Huntington's disease. Eur.J.Hum.Genet. 11 (1):30-38, 2003.
485. Beniczky, S. Keri, A. Antal, K. Jakab, H. Nagy, G. Benedek, Z. Janka, and L. Vecsei.
Somatosensory evoked potentials correlate with genetics in Huntington's disease.
Neuroreport 13 (17):2295-2298, 2002.
486. J. M. Hamilton, D. P. Salmon, J. Corey-Bloom, A. Gamst, J. S. Paulsen, S. Jerkins, M.
W. Jacobson, and G. Peavy. Behavioural abnormalities contribute to functional decline in
Huntington's disease. J.Neurol.Neurosurg.Psychiatry 74 (1):120-122, 2003.
487. W. G. Ondo, R. Tintner, M. Thomas, and J. Jankovic. Tetrabenazine treatment for
Huntington's disease-associated chorea. Clin.Neuropharmacol. 25 (6):300-302, 2002.
488. J. P. Lefaucheur, A. C. Bachoud-Levi, C. Bourdet, T. Grandmougin, P. Hantraye, P.
Cesaro, J. D. Degos, M. Peschanski, and F. Lisovoski. Clinical relevance of
electrophysiological tests in the assessment of patients with Huntington's disease. Mov
Disord. 17 (6):1294-1301, 2002.
489. N. Georgiou-Karistianis, A. Churchyard, E. Chiu, and J. L. Bradshaw. Reorientation of
attention in Huntington disease. Neuropsychiatry Neuropsychol.Behav.Neurol. 15 (4):225231, 2002.
490. K. Schmidtke, H. Manner, R. Kaufmann, and H. Schmolck. Cognitive procedural
learning in patients with fronto-striatal lesions. Learn.Mem. 9 (6):419-429, 2002.
491. K. Marder, S. Sandler, A. Lechich, J. Klager, and S. M. Albert. Relationship between
CAG repeat length and late-stage outcomes in Huntington's disease. Neurology 59
(10):1622-1624, 2002.
492. Verbessem, Eijnde B. Op't, S. P. Swinnen, S. Vangheluwe, P. Hespel, and R. Dom.
Unimanual and bimanual voluntary movement in Huntington's disease. Exp.Brain Res. 147
(4):529-537, 2002.
493. Goizet C, Lesca G, Dürr A; French Group for Presymptomatic Testing in Neurogenetic
Disorders. Presymptomatic testing in Huntington's disease and autosomal dominant
cerebellar ataxias. Neurology. 59(9):1330-6, 2002
494. Djoussé L, Knowlton B, Cupples LA, Marder K, Shoulson I, Myers RH. Weight loss in
early stage of Huntington's disease. Neurology. 59(9):1325-30, 2002
495. M. N. Witjes-Ane, A. H. Zwinderman, A. Tibben, G. J. van Ommen, and R. A. Roos.
Behavioural complaints in participants who underwent predictive testing for Huntington's
disease. J.Med.Genet. 39 (11):857-862, 2002.
496. M. Bonelli, F. A. Mahnert, and G. Niederwieser. Olanzapine for Huntington's disease: an
open label study. Clin.Neuropharmacol. 25 (5):263-265, 2002.
497. J. Brandt, B. Shpritz, A. M. Codori, R. Margolis, and A. Rosenblatt. Neuropsychological
manifestations of the genetic mutation for Huntington's disease in presymptomatic
individuals. J.Int.Neuropsychol.Soc. 8 (7):918-924, 2002.
498. J. Chenery, D. A. Copland, and B. E. Murdoch. Complex language functions and
subcortical mechanisms: evidence from Huntington's disease and patients with nonthalamic subcortical lesions. Int.J.Lang Commun.Disord. 37 (4):459-474, 2002.
499. Kirkwood S. Close, E. Siemers, R. J. Viken, M. E. Hodes, P. M. Conneally, J. C.
Christian, and T. Foroud. Evaluation of psychological symptoms among presymptomatic
HD gene carriers as measured by selected MMPI scales. J.Psychiatr.Res. 36 (6):377-382,
2002.
500. Johnson KA, Cunnington R, Bradshaw JL, Chiu E, Iansek R. Effect of an attentional
strategy on movement-related potentials recorded from subjects with Huntington's disease.
Mov Disord. 17(5):998-1003, 2002
501. Metman L. Verhagen, M. J. Morris, C. Farmer, M. Gillespie, K. Mosby, J. Wuu, and T.
N. Chase. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist
amantadine. Neurology 59 (5):694-699, 2002.
502. K. Panegyres and K. Zafiris-Toufexis. Polymorphisms in the tau gene in sporadic
frontotemporal dementia and other neurodegenerative disorders. Eur.J.Neurol. 9 (5):485489, 2002.
503. C. Kirkwood, E. Siemers, R. Viken, M. E. Hodes, P. M. Conneally, J. C. Christian, and
T. Foroud. Longitudinal personality changes among presymptomatic Huntington disease
gene carriers. Neuropsychiatry Neuropsychol.Behav.Neurol. 15 (3):192-197, 2002.
504. V. Muller, A. Jung, J. Preinfalk, H. Kolbe, M. Ridao-Alonso, R. Dengler, and T. F.
Munte.
Disturbance
of
"extrinsic
alertness"
in
Huntington's
disease.
J.Clin.Exp.Neuropsychol. 24 (4):517-526, 2002.
505. J. Lemiere, M. Decruyenaere, G. Evers-Kiebooms, E. Vandenbussche, and R. Dom.
Longitudinal study evaluating neuropsychological changes in so-called asymptomatic
carriers of the Huntington's disease mutation after 1 year. Acta Neurol.Scand. 106 (3):131141, 2002.
506. Maat-Kievit, M. Losekoot, K. Zwinderman, der Vegter-van, V, R. Belfroid, F. Lopez, G.
J. van Ommen, M. Breuning, and R. Roos. Predictability of age at onset in Huntington
disease in the Dutch population. Medicine (Baltimore) 81 (4):251-259, 2002.
507. Leroi, E. O'Hearn, L. Marsh, C. G. Lyketsos, A. Rosenblatt, C. A. Ross, J. Brandt, and R.
L. Margolis. Psychopathology in patients with degenerative cerebellar diseases: a
comparison to Huntington's disease. Am.J.Psychiatry 159 (8):1306-1314, 2002.
508. M. J. Thieben, A. J. Duggins, C. D. Good, L. Gomes, N. Mahant, F. Richards, E.
McCusker, and R. S. Frackowiak. The distribution of structural neuropathology in preclinical Huntington's disease. Brain 125 (Pt 8):1815-1828, 2002.
509. Paleacu, M. Anca, and N. Giladi. Olanzapine in Huntington's disease. Acta Neurol.Scand.
105 (6):441-444, 2002.
510. Andrich, T. Schmitz, C. Saft, T. Postert, P. Kraus, J. T. Epplen, H. Przuntek, and M. W.
Agelink.
Autonomic
nervous
system
function
in
Huntington's
disease.
J.Neurol.Neurosurg.Psychiatry 72 (6):726-731, 2002.
511. Lafargue and A. Sirigu. Sensation of effort is altered in Huntington's disease.
Neuropsychologia 40 (10):1654-1661, 2002.
512. S. Snowden, D. Craufurd, J. Thompson, and D. Neary. Psychomotor, executive, and
memory function in preclinical Huntington's disease. J.Clin.Exp.Neuropsychol. 24 (2):133145, 2002.
513. Evers-Kiebooms G, Nys K, Harper P, Zoeteweij M, Dürr A, Jacopini G, Yapijakis C,
Simpson S. Predictive DNA-testing for Huntington's disease and reproductive decision
making: a European collaborative study. Eur J Hum Genet. 10(3):167-76. 2002
514. Clark VP, Lai S, Deckel AW. Altered functional MRI responses in Huntington's disease.
Neuroreport. 13(5):703-6, 2002
515. J. Garcia Ruiz, J. Hernandez, S. Cantarero, M. Bartolome, Bernardos Sanchez, V, and
Yebenez J. Garcia de. Bradykinesia in Huntington's disease. A prospective, follow-up
study. J.Neurol. 249 (4):437-440, 2002.
516. E. Berrios, A. C. Wagle, I. S. Markova, S. A. Wagle, A. Rosser, and J. R. Hodges.
Psychiatric symptoms in neurologically asymptomatic Huntington's disease gene carriers: a
comparison with gene negative at risk subjects. Acta Psychiatr.Scand. 105 (3):224-230,
2002.
517. K. Ho, B. J. Sahakian, T. W. Robbins, R. A. Barker, A. E. Rosser, and J. R. Hodges.
Verbal fluency in Huntington's disease: a longitudinal analysis of phonemic and semantic
clustering and switching. Neuropsychologia 40 (8):1277-1284, 2002.
518. S. Vaddadi, E. Soosai, E. Chiu, and P. Dingjan. A randomised, placebo-controlled,
double blind study of treatment of Huntington's disease with unsaturated fatty acids.
Neuroreport 13 (1):29-33, 2002.
519. K. Puri, G. M. Bydder, S. J. Counsell, B. J. Corridan, A. J. Richardson, J. V. Hajnal, C.
Appel, H. M. Mckee, K. S. Vaddadi, and D. F. Horrobin. MRI and neuropsychological
improvement in Huntington disease following ethyl-EPA treatment. Neuroreport 13
(1):123-126, 2002.
520. J. Serrien, J. M. Burgunder, and M. Wiesendanger. Control of manipulative forces during
unimanual and bimanual tasks in patients with Huntington's disease. Exp.Brain Res. 143
(3):328-334, 2002.
521. D. Rosas, A. K. Liu, S. Hersch, M. Glessner, R. J. Ferrante, D. H. Salat, Kouwe A. van
der, B. G. Jenkins, A. M. Dale, and B. Fischl. Regional and progressive thinning of the
cortical ribbon in Huntington's disease. Neurology 58 (5):695-701, 2002.
522. Hauser, S. Furtado, C. R. Cimino, H. Delgado, S. Eichler, S. Schwartz, D. Scott, G. M.
Nauert, E. Soety, V. Sossi, D. A. Holt, P. R. Sanberg, A. J. Stoessl, and T. B. Freeman.
Bilateral human fetal striatal transplantation in Huntington's disease. Neurology 58 (5):687695, 2002.
523. Thompson, J. S. Snowden, D. Craufurd, and D. Neary. Behavior in Huntington's disease:
dissociating cognition-based and mood-based changes. J.Neuropsychiatry Clin.Neurosci.
14 (1):37-43, 2002.
524. Kulisevsky J, Litvan I, Berthier ML, Pascual-Sedano B, Paulsen JS, Cummings JL.
Neuropsychiatric assessment of Gilles de la Tourette patients: comparative study with other
hyperkinetic and hypokinetic movement disorders. Mov Disord. 16(6):1098-104, 2001
525. Reynolds NC Jr, Hellman RS, Tikofsky RS, Prost RW, Mark LP, Elejalde BR, Lebel R,
Hamsher KS, Swanson S, Benezra EE. Single photon emission computerized tomography
(SPECT) in detecting neurodegeneration in Huntington's disease. Nucl Med Commun.
23(1):13-8, 2002
526. García Ruiz PJ, Cenjor C, Ulmer E, Hernández J, Cantarero S, Fanjul S, García de
Yébenes Speed of ocular saccades in Huntington disease. Prospective study J.Neurologia.
16(2):70-3, 2001
527. Bartzokis G, Tishler TA. MRI evaluation of basal ganglia ferritin iron and neurotoxicity
in Alzheimer's and Huntingon's disease. Cell Mol Biol (Noisy-le-grand). 46(4):821-33,
2000
528. M. Gordon, L. Quinn, R. Reilmann, and K. Marder. Coordination of prehensile forces
during precision grip in Huntington's disease. Exp.Neurol. 163 (1):136-148, 2000.
529. Bachoud-Levi, C. Bourdet, P. Brugieres, J. P. Nguyen, T. Grandmougin, B. Haddad, R.
Jeny, P. Bartolomeo, M. F. Boisse, G. D. Barba, J. D. Degos, A. M. Ergis, J. P. Lefaucheur,
F. Lisovoski, E. Pailhous, P. Remy, S. Palfi, G. L. Defer, P. Cesaro, P. Hantraye, and M.
Peschanski. Safety and tolerability assessment of intrastriatal neural allografts in five
patients with Huntington's disease. Exp.Neurol. 161 (1):194-202, 2000.
530. Garcia Ruiz, Tortosa E. Gomez, Bernados Sanchez, V, A. Rojo, A. Fontan, and Yebenes
J. Garcia de. Bradykinesia in Huntington's disease. Clin.Neuropharmacol. 23 (1):50-52,
2000.
531. M. A. Smith, J. Brandt, and R. Shadmehr. Motor disorder in Huntington's disease begins
as a dysfunction in error feedback control. Nature 403 (6769):544-549, 2000.
532. Marder, H. Zhao, R. H. Myers, M. Cudkowicz, E. Kayson, K. Kieburtz, C. Orme, J.
Paulsen, J. B. Penney, Jr., E. Siemers, and I. Shoulson. Rate of functional decline in
Huntington's disease. Huntington Study Group. Neurology 54 (2):452-458, 2000.
533. M. de Boo, A. A. Tibben, J. A. Hermans, A. Jennekens-Schinkel, A. Maat-Kievit, and R.
A. Roos. Memory and learning are not impaired in presymptomatic individuals with an
increased risk of Huntington's disease. J.Clin.Exp.Neuropsychol. 21 (6):831-836, 1999.
534. M. Hamilton, C. Murphy, and J. S. Paulsen. Odor detection, learning, and memory in
Huntington's disease. J.Int.Neuropsychol.Soc. 5 (7):609-615, 1999.
535. Sanchez-Pernaute, G. Kunig, Alba A. del Barrio, J. G. de Yebenes, P. Vontobel, and K.
L. Leenders. Bradykinesia in early Huntington's disease. Neurology 54 (1):119-125, 2000.
536. H. Fernandez, J. H. Friedman, J. Grace, and S. Beason-Hazen. Donepezil for
Huntington's disease. Mov Disord. 15 (1):173-176, 2000.
537. E. Pratley, A. D. Salbe, E. Ravussin, and J. N. Caviness. Higher sedentary energy
expenditure in patients with Huntington's disease. Ann.Neurol. 47 (1):64-70, 2000.
538. Culjkovic, O. Stojkovic, N. Vojvodic, M. Svetel, L. Rakic, S. Romac, and V. Kostic.
Correlation between triplet repeat expansion and computed tomography measures of
caudate nuclei atrophy in Huntington's disease. J.Neurol. 246 (11):1090-1093, 1999.
539. Andrews TC, Weeks RA, Turjanski N, Gunn RN, Watkins LH, Sahakian B, Hodges JR,
Rosser AE, Wood NW, Brooks DJ. Huntington's disease progression. PET and clinical
observations. Brain. 122 ( Pt 12):2353-63, 1999
540. Lang CJ, Reischies FM, Majer M, Daum RF. Visually guided exploration in Huntington
disease. Cortex. 35(4):583-90, 1999
541. Hille ET, Siesling S, Vegter-van der Vlis M, Vandenbroucke JP, Roos RA, Rosendaal
FR. Two centuries of mortality in ten large families with Huntington disease: a rising
impact of gene carriership. Epidemiology. 10(6):706-10, 1999
542. D. Leslie, C. R. Greenberg, D. N. Abrams, and D. Hobson. Clinical deficits in
Huntington disease correlate with reduced striatal uptake on iodine-123 epidepride singlephoton emission tomography. Eur.J.Nucl.Med. 26 (11):1458-1464, 1999.
543. B. Rich, A. K. Troyer, F. W. Bylsma, and J. Brandt. Longitudinal analysis of phonemic
clustering and switching during word-list generation in Huntington's disease.
Neuropsychology 13 (4):525-531, 1999.
544. E. MacDonald, J. P. Vonsattel, J. Shrinidhi, N. N. Couropmitree, L. A. Cupples, E. D.
Bird, J. F. Gusella, and R. H. Myers. Evidence for the GluR6 gene associated with younger
onset age of Huntington's disease. Neurology 53 (6):1330-1332, 1999.
545. R. Sharma, J. G. Romano, D. R. Ayyar, F. T. Rotta, A. Facca, and J. Sanchez-Ramos.
Sympathetic skin response and heart rate variability in patients with Huntington disease.
Arch.Neurol. 56 (10):1248-1252, 1999.
546. Kremer, C. M. Clark, E. W. Almqvist, L. A. Raymond, P. Graf, C. Jacova, M. Mezei, M.
A. Hardy, B. Snow, W. Martin, and M. R. Hayden. Influence of lamotrigine on progression
of early Huntington disease: a randomized clinical trial. Neurology 53 (5):1000-1011, 1999.
547. H. Thaut, R. Miltner, H. W. Lange, C. P. Hurt, and V. Hoemberg. Velocity modulation
and rhythmic synchronization of gait in Huntington's disease. Mov Disord. 14 (5):808-819,
1999.
548. Sanchez-Pernaute, J. M. Garcia-Segura, Alba A. del Barrio, J. Viano, and J. G. de
Yebenes. Clinical correlation of striatal 1H MRS changes in Huntington's disease.
Neurology 53 (4):806-812, 1999.
549. Postert, B. Lack, W. Kuhn, M. Jergas, J. Andrich, B. Braun, H. Przuntek, R.
Sprengelmeyer, M. Agelink, and T. Buttner. Basal ganglia alterations and brain atrophy in
Huntington's
disease
depicted
by
transcranial
real
time
sonography.
J.Neurol.Neurosurg.Psychiatry 67 (4):457-462, 1999.
550. Roman, D. C. Delis, J. V. Filoteo, T. L. Demadura, J. Paulsen, N. R. Swerdlow, M. R.
Swenson, D. Salmon, N. Butters, and C. Shults. Is there a "subcortical" profile of
attentional dysfunction? A comparison of patients with Huntington's and Parkinson's
diseases on a global-local focused attention task. J.Clin.Exp.Neuropsychol. 20 (6):873-884,
1998.
551. F. B. Atac, B. Elibol, and F. Schaefer. The genetic analysis of Turkish patients with
Huntington's disease. Acta Neurol.Scand. 100 (3):195-198, 1999.
552. Bacon Moore,A.S., Paulsen,J.S., and Murphy,C., 1999. A test of odor fluency in patients
with Alzheimer's and Huntington's disease. J.Clin.Exp.Neuropsychol. 21, 341-351.
553. Harris,G.J., Codori,A.M., Lewis,R.F., Schmidt,E., Bedi,A., and Brandt,J., 1999. Reduced
basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for
Huntington's disease. Brain 122 ( Pt 9), 1667-1678.
554. Boecker,H.,
Ceballos-Baumann,A.,
Bartenstein,P.,
Weindl,A.,
Siebner,H.R.,
Fassbender,T., Munz,F., Schwaiger,M., and Conrad,B., 1999. Sensory processing in
Parkinson's and Huntington's disease: investigations with 3D H(2)(15)O-PET. Brain 122 (
Pt 9), 1651-1665.
555. Panas,M., Avramopoulos,D., Karadima,G., Petersen,M.B., and Vassilopoulos,D., 1999.
Apolipoprotein E and presenilin-1 genotypes in Huntington's disease. J.Neurol. 246, 574577.
556. Rohrer,D., Salmon,D.P., Wixted,J.T., and Paulsen,J.S., 1999. The disparate effects of
Alzheimer's disease and Huntington's disease on semantic memory. Neuropsychology 13,
381-388.
557. Ross,B.D., Hoang,T.Q., Bluml,S., Dubowitz,D., Kopyov,O.V., Jacques,D.B., Lin,A.,
Seymour,K., and Tan,J., 1999. In vivo magnetic resonance spectroscopy of human fetal
neural transplants. NMR Biomed. 12, 221-236.
558. Yaguez,L., Canavan,A.G., Lange,H.W., and Homberg,V., 1999. Motor learning by
imagery is differentially affected in Parkinson's and Huntington's diseases. Behav.Brain
Res. 102, 115-127.
559. Bartzokis,G., Cummings,J., Perlman,S., Hance,D.B., and Mintz,J., 1999. Increased basal
ganglia iron levels in Huntington disease. Arch.Neurol. 56, 569-574.
560. Kirkwood,S.C., Siemers,E., Stout,J.C., Hodes,M.E., Conneally,P.M., Christian,J.C., and
Foroud,T., 1999. Longitudinal cognitive and motor changes among presymptomatic
Huntington disease gene carriers. Arch.Neurol. 56, 563-568.
561. Almqvist,E.W., Bloch,M., Brinkman,R., Craufurd,D., and Hayden,M.R., 1999. A
worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric
hospitalization after predictive testing for Huntington disease. Am.J.Hum.Genet. 64, 12931304.
562. Montine,T.J., Beal,M.F., Robertson,D., Cudkowicz,M.E., Biaggioni,I., O'Donnell,H.,
Zackert,W.E., Roberts,L.J., and Morrow,J.D., 1999. Cerebrospinal fluid F2-isoprostanes are
elevated in Huntington's disease. Neurology 52, 1104-1105.
563. Rosas,H.D., Koroshetz,W.J., Jenkins,B.G., Chen,Y.I., Hayden,D.L., Beal,M.F., and
Cudkowicz,M.E., 1999. Riluzole therapy in Huntington's disease (HD). Mov Disord. 14,
326-330.
564. Dallocchio,C., Buffa,C., Tinelli,C., and Mazzarello,P., 1999. Effectiveness of risperidone
in Huntington chorea patients. J.Clin.Psychopharmacol. 19, 101-103.
565. Reynolds,N.C., Jr., Myklebust,J.B., Prieto,T.E., and Myklebust,B.M., 1999. Analysis of
gait abnormalities in Huntington disease. Arch.Phys.Med.Rehabil. 80, 59-65.
566. Foroud,T., Gray,J., Ivashina,J., and Conneally,P.M., 1999. Differences in duration of
Huntington's disease based on age at onset. J.Neurol.Neurosurg.Psychiatry 66, 52-56.
567. Halliday,G.M., McRitchie,D.A., Macdonald,V., Double,K.L., Trent,R.J., and
McCusker,E., 1998. Regional specificity of brain atrophy in Huntington's disease.
Exp.Neurol. 154, 663-672.
568. Deckel,A.W., Cohen,D., and Duckrow,R., 1998. Cerebral blood flow velocity decreases
during cognitive stimulation in Huntington's disease. Neurology 51, 1576-1583.
569. Leblhuber,F., Walli,J., Jellinger,K., Tilz,G.P., Widner,B., Laccone,F., and Fuchs,D.,
1998. Activated immune system in patients with Huntington's disease. Clin.Chem.Lab Med.
36, 747-750.
570. Randolph,C., Tierney,M.C., Mohr,E., and Chase,T.N., 1998. The Repeatable Battery for
the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity.
J.Clin.Exp.Neuropsychol. 20, 310-319.
571. Bonfiglioli,C., De,B.G., Nichelli,P., Nicoletti,R., and Castiello,U., 1998. Kinematic
analysis of the reach to grasp movement in Parkinson's and Huntington's disease subjects.
Neuropsychologia 36, 1203-1208.
572. Warren,J.D., Firgaira,F., Thompson,E.M., Kneebone,C.S., Blumbergs,P.C., and
Thompson,P.D., 1998. The causes of sporadic and 'senile' chorea. Aust.N.Z.J.Med. 28, 429431.
573. Dudok deWit,A.C., Duivenvoorden,H.J., Passchier,J., Niermeijer,M.F., and Tibben,A.,
1998. Course of distress experienced by persons at risk for an autosomal dominant
inheritable disorder participating in a predictive testing program: an explorative study.
Rotterdam/Leiden Genetics Workgroup. Psychosom.Med. 60, 543-549.
574. Jensen,P., Fenger,K., Bolwig,T.G., and Sorensen,S.A., 1998. Crime in Huntington's
disease: a study of registered offences among patients, relatives, and controls.
J.Neurol.Neurosurg.Psychiatry 65, 467-471.
575. Campodonico,J.R., Aylward,E., Codori,A.M., Young,C., Krafft,L., Magdalinski,M.,
Ranen,N., Slavney,P.R., and Brandt,J., 1998. When does Huntington's disease begin?
J.Int.Neuropsychol.Soc. 4, 467-473.
576. Levy,M.L., Cummings,J.L., Fairbanks,L.A., Masterman,D., Miller,B.L., Craig,A.H.,
Paulsen,J.S., and Litvan,I., 1998. Apathy is not depression. J.Neuropsychiatry
Clin.Neurosci. 10, 314-319.
577. Lawrence,A.D., Weeks,R.A., Brooks,D.J., Andrews,T.C., Watkins,L.H., Harding,A.E.,
Robbins,T.W., and Sahakian,B.J., 1998. The relationship between striatal dopamine
receptor binding and cognitive performance in Huntington's disease. Brain 121 ( Pt 7),
1343-1355.
578. Lawrence,A.D., Hodges,J.R., Rosser,A.E., Kershaw,A.,
Ffrench-Constant,C.,
Rubinsztein,D.C., Robbins,T.W., and Sahakian,B.J., 1998. Evidence for specific cognitive
deficits in preclinical Huntington's disease. Brain 121 ( Pt 7), 1329-1341.
579. Troster,A.I., Fields,J.A., Testa,J.A., Paul,R.H., Blanco,C.R., Hames,K.A., Salmon,D.P.,
and Beatty,W.W., 1998. Cortical and subcortical influences on clustering and switching in
the performance of verbal fluency tasks. Neuropsychologia 36, 295-304.
580. Vuillaume,I., Vermersch,P., Destee,A., Petit,H., and Sablonniere,B., 1998. Genetic
polymorphisms adjacent to the CAG repeat influence clinical features at onset in
Huntington's disease. J.Neurol.Neurosurg.Psychiatry 64, 758-762.
581. Gomez-Tortosa,E., del,B.A., Garcia Ruiz,P.J., Pernaute,R.S., Benitez,J., Barroso,A.,
Jimenez,F.J., and Garcia,Y.J., 1998. Severity of cognitive impairment in juvenile and lateonset Huntington disease. Arch.Neurol. 55, 835-843.
582. Snowden,J.S., Craufurd,D., Griffiths,H.L., and Neary,D., 1998. Awareness of involuntary
movements in Huntington disease. Arch.Neurol. 55, 801-805.
583. Hausdorff,J.M., Cudkowicz,M.E., Firtion,R., Wei,J.Y., and Goldberger,A.L., 1998. Gait
variability and basal ganglia disorders: stride-to-stride variations of gait cycle timing in
Parkinson's disease and Huntington's disease. Mov Disord. 13, 428-437.
584. 1998. Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's
disease. The Huntington Study Group. Neurology 50, 1366-1373.
585. Jenkins,B.G., Rosas,H.D., Chen,Y.C., Makabe,T., Myers,R., MacDonald,M., Rosen,B.R.,
Beal,M.F., and Koroshetz,W.J., 1998. 1H NMR spectroscopy studies of Huntington's
disease: correlations with CAG repeat numbers. Neurology 50, 1357-1365.
586. Hoang,T.Q., Bluml,S., Dubowitz,D.J., Moats,R., Kopyov,O., Jacques,D., and Ross,B.D.,
1998. Quantitative proton-decoupled 31P MRS and 1H MRS in the evaluation of
Huntington's and Parkinson's diseases. Neurology 50, 1033-1040.
587. Messmer,K. and Reynolds,G.P., 1998. Increased peripheral benzodiazepine binding sites
in the brain of patients with Huntington's disease. Neurosci.Lett. 241, 53-56.
588. Arenas,J., Campos,Y., Ribacoba,R., Martin,M.A., Rubio,J.C., Ablanedo,P., and
Cabello,A., 1998. Complex I defect in muscle from patients with Huntington's disease.
Ann.Neurol. 43, 397-400.
589. Hahn-Barma,V., Deweer,B., Durr,A., Dode,C., Feingold,J., Pillon,B., Agid,Y., Brice,A.,
and Dubois,B., 1998. Are cognitive changes the first symptoms of Huntington's disease? A
study of gene carriers. J.Neurol.Neurosurg.Psychiatry 64, 172-177.
590. Antonini,A., Leenders,K.L., and Eidelberg,D., 1998. [11C]raclopride-PET studies of the
Huntington's disease rate of progression: relevance of the trinucleotide repeat length.
Ann.Neurol. 43, 253-255.
591. Macdonald,V., Halliday,G.M., Trent,R.J., and McCusker,E.A., 1997. Significant loss of
pyramidal neurons in the angular gyrus of patients with Huntington's disease.
Neuropathol.Appl.Neurobiol. 23, 492-495.
592. de,B.G., Tibben,A., Hermans,J., Maat,A., and Roos,R.A., 1998. Subtle involuntary
movements are not reliable indicators of incipient Huntington's disease. Mov Disord. 13,
96-99.
593. DudokdeWit,A.C., Tibben,A., Duivenvoorden,H.J., Niermeijer,M.F., Passchier,J., and
Trijsburg,R.W., 1998. Distress in individuals facing predictive DNA testing for autosomal
dominant late-onset disorders: comparing questionnaire results with in-depth interviews.
Rotterdam/Leiden Genetics Workgroup. Am.J.Med.Genet. 75, 62-74.
594. Backman,L., Robins-Wahlin,T.B., Lundin,A., Ginovart,N., and Farde,L., 1997. Cognitive
deficits in Huntington's disease are predicted by dopaminergic PET markers and brain
volumes. Brain 120 ( Pt 12), 2207-2217.
595. Bylsma,F.W., Moberg,P.J., Doty,R.L., and Brandt,J., 1997. Odor identification in
Huntington's disease patients and asymptomatic gene carriers. J.Neuropsychiatry
Clin.Neurosci. 9, 598-600.
596. Aylward,E.H., Anderson,N.B., Bylsma,F.W., Wagster,M.V., Barta,P.E., Sherr,M.,
Feeney,J., Davis,A., Rosenblatt,A., Pearlson,G.D., and Ross,C.A., 1998. Frontal lobe
volume in patients with Huntington's disease. Neurology 50, 252-258.
597. Ackermann,H., Hertrich,I., Daum,I., Scharf,G., and Spieker,S., 1997. Kinematic analysis
of articulatory movements in central motor disorders. Mov Disord. 12, 1019-1027.
598. Gray,J.M., Young,A.W., Barker,W.A., Curtis,A., and Gibson,D., 1997. Impaired
recognition of disgust in Huntington's disease gene carriers. Brain 120 ( Pt 11), 2029-2038.
599. Pirker,W., Asenbaum,S., Wenger,S., Kornhuber,J., Angelberger,P., Deecke,L.,
Podreka,I., and Brucke,T., 1997. Iodine-123-epidepride-SPECT: studies in Parkinson's
disease, multiple system atrophy and Huntington's disease. J.Nucl.Med. 38, 1711-1717.
600. de Boo, G.M., Tibben,A., Lanser,J.B., Jennekens-Schinkel,A., Hermans,J., MaatKievit,A., and Roos,R.A., 1997. Early cognitive and motor symptoms in identified carriers
of the gene for Huntington disease. Arch.Neurol. 54, 1353-1357.
601. Weeks,R.A., Ceballos-Baumann,A., Piccini,P., Boecker,H., Harding,A.E., and
Brooks,D.J., 1997. Cortical control of movement in Huntington's disease. A PET activation
study. Brain 120 ( Pt 9), 1569-1578.
602. Bartenstein,P., Weindl,A., Spiegel,S., Boecker,H., Wenzel,R., Ceballos-Baumann,A.O.,
Minoshima,S., and Conrad,B., 1997. Central motor processing in Huntington's disease. A
PET study. Brain 120 ( Pt 9), 1553-1567.
603. Munte,T.F., Ridao-Alonso,M.E., Preinfalk,J., Jung,A., Wieringa,B.M., Matzke,M.,
Dengler,R., and Johannes,S., 1997. An electrophysiological analysis of altered cognitive
functions in Huntington disease. Arch.Neurol. 54, 1089-1098.
604. Jason,G.W., Suchowersky,O., Pajurkova,E.M., Graham,L., Klimek,M.L., Garber,A.T.,
and Poirier-Heine,D., 1997. Cognitive manifestations of Huntington disease in relation to
genetic structure and clinical onset. Arch.Neurol. 54, 1081-1088.
605. Weeks, R.A., Cunningham,V.J., Piccini,P., Waters,S., Harding,A.E., and Brooks,D.J.,
1997. 11C-diprenorphine binding in Huntington's disease: a comparison of region of
interest analysis with statistical parametric mapping. J.Cereb.Blood Flow Metab 17, 943949.
606. Rubinsztein,D.C., Leggo,J., Chiano,M., Korn,S., Dodge,A., Norbury,G., Rosser,E., and
Craufurd,D., 1997. Homozygotes and heterozygotes for ciliary neurotrophic factor null
alleles do not show earlier onset of Huntington's disease. Neurology 49, 890-892.
607. Leone,O., Muglia,M., Gabriele,A.L., Annesi,G., Conforti,F.L., Imbrogno,E.,
Imbrogno,L., and Brancati,C., 1997. Analysis of the (CAG)n repeat at the IT15 locus in a
population from Calabria (southern Italy). Hum.Biol. 69, 653-662.
608. de Boo,G.M., Tibben,A., Lanser,J.B., Jennekens-Schinkel,A., Hermans,J., Vegter-van,d.,
V, and Roos,R.A., 1997. Intelligence indices in people with a high/low risk for developing
Huntington's disease. J.Med.Genet. 34, 564-568.
609. Murman,D.L., Giordani,B., Mellow,A.M., Johanns,J.R., Little,R.J., Hariharan,M., and
Foster,N.L., 1997. Cognitive, behavioral, and motor effects of the NMDA antagonist
ketamine in Huntington's disease. Neurology 49, 153-161.
610. van Vugt,J.P., Siesling,S., Vergeer,M., van,d., V, and Roos,R.A., 1997. Clozapine versus
placebo in Huntington's disease: a double blind randomised comparative study.
J.Neurol.Neurosurg.Psychiatry 63, 35-39.
611. Taylor,C.A. and Myers,R.H., 1997. Long-term impact of Huntington disease linkage
testing. Am.J.Med.Genet. 70, 365-370.
612. Abbruzzese,G., Buccolieri,A., Marchese,R., Trompetto,C., Mandich,P., and
Schieppati,M., 1997. Intracortical inhibition and facilitation are abnormal in Huntington's
disease: a paired magnetic stimulation study. Neurosci.Lett. 228, 87-90.
613. Georgiou,N., Bradshaw,J.L., Phillips,J.G., and Chiu,E., 1997. Effect of directed attention
in Huntington's disease. J.Clin.Exp.Neuropsychol. 19, 367-377.
614. Como,P.G., Rubin,A.J., O'Brien,C.F., Lawler,K., Hickey,C., Rubin,A.E., Henderson,R.,
McDermott,M.P., McDermott,M., Steinberg,K., and Shoulson,I., 1997. A controlled trial of
fluoxetine in nondepressed patients with Huntington's disease. Mov Disord. 12, 397-401.
615. Georgiou,N., Phillips,J.G., Bradshaw,J.L., Cunnington,R., and Chiu,E., 1997.
Impairments of movement kinematics in patients with Huntington's disease: a comparison
with and without a concurrent task. Mov Disord. 12, 386-396.
616. Coles,R., Leggo,J., and Rubinsztein,D.C., 1997. Analysis of the 5' upstream sequence of
the Huntington's disease (HD) gene shows six new rare alleles which are unrelated to the
age at onset of HD. J.Med.Genet. 34, 371-374.
617. Brinkman,R.R., Mezei,M.M., Theilmann,J., Almqvist,E., and Hayden,M.R., 1997. The
likelihood of being affected with Huntington disease by a particular age, for a specific CAG
size. Am.J.Hum.Genet. 60, 1202-1210.
618. Fellows,S., Schwarz,M., Schaffrath,C., Domges,F., and Noth,J., 1997. Disturbances of
precision grip in Huntington's disease. Neurosci.Lett. 226, 103-106.
619. Rubinsztein,D.C., Leggo,J., Chiano,M., Dodge,A., Norbury,G., Rosser,E., and
Craufurd,D., 1997. Genotypes at the GluR6 kainate receptor locus are associated with
variation in the age of onset of Huntington disease. Proc.Natl.Acad.Sci.U.S.A 94, 38723876.
620. Rich,J.B., Campodonico,J.R., Rothlind,J., Bylsma,F.W.,
Perseverations
during
paired-associate
learning
in
J.Clin.Exp.Neuropsychol. 19, 191-203.
and Brandt,J., 1997.
Huntington's
disease.
621. Alonso,M.E., Yescas,P., Cisneros,B., Martinez,C., Silva,G., Ochoa,A., and Montanez,C.,
1997. Analysis of the (CAG)n repeat causing Huntington's disease in a Mexican population.
Clin.Genet. 51, 225-230.
622. Reilmann,R., Rolf,L.H., and Lange,H.W., 1997. Huntington's disease: N-methyl-Daspartate receptor coagonist glycine is increased in platelets. Exp.Neurol. 144, 416-419.
623. Gabrieli,J.D., Stebbins,G.T., Singh,J., Willingham,D.B., and Goetz,C.G., 1997. Intact
mirror-tracing and impaired rotary-pursuit skill learning in patients with Huntington's
disease: evidence for dissociable memory systems in skill learning. Neuropsychology 11,
272-281.
624. Sieradzan,K., Mann,D.M., and Dodge,A., 1997. Clinical presentation and patterns of
regional cerebral atrophy related to the length of trinucleotide repeat expansion in patients
with adult onset Huntington's disease. Neurosci.Lett. 225, 45-48.
625. Ginovart,N., Lundin,A., Farde,L., Halldin,C., Backman,L., Swahn,C.G., Pauli,S., and
Sedvall,G., 1997. PET study of the pre- and post-synaptic dopaminergic markers for the
neurodegenerative process in Huntington's disease. Brain 120 ( Pt 3), 503-514.
626. Staffen,W., Hondl,N., Trinka,E., Zenzmaier,R., and Ladurner,G., 1997. SPET
investigations in extrapyramidal diseases using specific ligands. Nucl.Med.Commun. 18,
159-163.
627. Clark,C.M., Jacova,C., Klonoff,H., Kremer,B., Hayden,M., and Paty,D., 1997.
Pathological association and dissociation of functional systems in multiple sclerosis and
Huntington's disease. J.Clin.Exp.Neuropsychol. 19, 63-76.
628. Aylward,E.H., Li,Q., Stine,O.C., Ranen,N., Sherr,M., Barta,P.E., Bylsma,F.W.,
Pearlson,G.D., and Ross,C.A., 1997. Longitudinal change in basal ganglia volume in
patients with Huntington's disease. Neurology 48, 394-399.
629. Koroshetz,W.J., Jenkins,B.G., Rosen,B.R., and Beal,M.F., 1997. Energy metabolism
defects in Huntington's disease and effects of coenzyme Q10. Ann.Neurol. 41, 160-165.
630. Moberg,P.J. and Doty,R.L., 1997. Olfactory function in Huntington's disease patients and
at-risk offspring. Int.J.Neurosci. 89, 133-139.
631. Hausdorff,J.M., Mitchell,S.L., Firtion,R., Peng,C.K., Cudkowicz,M.E., Wei,J.Y., and
Goldberger,A.L., 1997. Altered fractal dynamics of gait: reduced stride-interval correlations
with aging and Huntington's disease. J.Appl.Physiol 82, 262-269.
632. Codori,A.M., Slavney,P.R., Young,C., Miglioretti,D.L., and Brandt,J., 1997. Predictors
of psychological adjustment to genetic testing for Huntington's disease. Health Psychol. 16,
36-50.
633. Tibben,A., Timman,R., Bannink,E.C., and Duivenvoorden,H.J., 1997. Three-year followup after presymptomatic testing for Huntington's disease in tested individuals and partners.
Health Psychol. 16, 20-35.
634. Harms,L., Meierkord,H., Timm,G., Pfeiffer,L., and Ludolph,A.C., 1997. Decreased Nacetyl-aspartate/choline ratio and increased lactate in the frontal lobe of patients with
Huntington's disease: a proton magnetic resonance spectroscopy study.
J.Neurol.Neurosurg.Psychiatry 62, 27-30.
635. Antonini,A., Leenders,K.L., Spiegel,R., Meier,D., Vontobel,P., Weigell-Weber,M.,
Sanchez-Pernaute,R., de Yebenez,J.G., Boesiger,P., Weindl,A., and Maguire,R.P., 1996.
Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene
carriers and patients with Huntington's disease. Brain 119 ( Pt 6), 2085-2095.
636. Campodonico,J.R., Codori,A.M., and Brandt,J., 1996. Neuropsychological stability over
two years in asymptomatic carriers of the Huntington's disease mutation.
J.Neurol.Neurosurg.Psychiatry 61, 621-624.
637. Aylward,E.H., Codori,A.M., Barta,P.E., Pearlson,G.D., Harris,G.J., and Brandt,J., 1996.
Basal ganglia volume and proximity to onset in presymptomatic Huntington disease.
Arch.Neurol. 53, 1293-1296.
638. Nance,M.A., Westphal,B., and Nugent,S., 1996. Diagnosis of patients presenting to a
Huntington disease (HD) clinic without a family history of HD. Neurology 47, 1578-1580.
639. Phillips,J.G., Bradshaw,J.L., Chiu,E., Teasdale,N., Iansek,R., and Bradshaw,J.A., 1996.
Bradykinesia and movement precision in Huntington's disease. Neuropsychologia 34, 12411245.
640. Cariello,L., de,C.T., Zanetti,L., Cuomo,T., Di,M.L., Campanella,G., Rinaldi,S.,
Zanetti,P., Di,L.R., and Varrone,S., 1996. Transglutaminase activity is related to CAG
repeat length in patients with Huntington's disease. Hum.Genet. 98, 633-635.
641. Sax,D.S., Powsner,R., Kim,A., Tilak,S., Bhatia,R., Cupples,L.A., and Myers,R.H., 1996.
Evidence of cortical metabolic dysfunction in early Huntington's disease by single-photonemission computed tomography. Mov Disord. 11, 671-677.
642. Mohr,E., Walker,D., Randolph,C., Sampson,M., and Mendis,T., 1996. Utility of clinical
trial batteries in the measurement of Alzheimer's and Huntington's dementia.
Int.Psychogeriatr. 8, 397-411.
643. Lawson,K., Wiggins,S., Green,T., Adam,S., Bloch,M., and Hayden,M.R., 1996. Adverse
psychological events occurring in the first year after predictive testing for Huntington's
disease. The Canadian Collaborative Study Predictive Testing. J.Med.Genet. 33, 856-862.
644. Sprengelmeyer,R., Young,A.W., Calder,A.J., Karnat,A., Lange,H., Homberg,V.,
Perrett,D.I., and Rowland,D., 1996. Loss of disgust. Perception of faces and emotions in
Huntington's disease. Brain 119 ( Pt 5), 1647-1665.
645. Lawrence,A.D., Sahakian,B.J., Hodges,J.R., Rosser,A.E., Lange,K.W., and
Robbins,T.W., 1996. Executive and mnemonic functions in early Huntington's disease.
Brain 119 ( Pt 5), 1633-1645.
646. Ranen,N.G., Peyser,C.E., Coyle,J.T., Bylsma,F.W., Sherr,M., Day,L., Folstein,M.F.,
Brandt,J., Ross,C.A., and Folstein,S.E., 1996. A controlled trial of idebenone in
Huntington's disease. Mov Disord. 11, 549-554.
647. Nance,M.A. and Sanders,G., 1996. Characteristics of individuals with Huntington disease
in long-term care. Mov Disord. 11, 542-548.
648. Georgiou,N., Bradshaw,J.L., Phillips,J.G., and Chiu,E., 1996. The effect of Huntington's
disease and Gilles de la Tourette's syndrome on the ability to hold and shift attention.
Neuropsychologia 34, 843-851.
649. Tegenthoff,M., Vorgerd,M., Juskowiak,F., Roos,V., and Malin,J.P., 1996. Postexcitatory
inhibition after transcranial magnetic single and double brain stimulation in Huntington's
disease. Electroencephalogr.Clin.Neurophysiol. 101, 298-303.
650. Timmers,H.J., Swaab,D.F., van de Nes,J.A., and Kremer,H.P., 1996. Somatostatin 1-12
immunoreactivity is decreased in the hypothalamic lateral tuberal nucleus of Huntington's
disease patients. Brain Res. 728, 141-148.
651. Woodruff-Pak,D.S. and Papka,M., 1996. Huntington's disease and eyeblink classical
conditioning: normal learning but abnormal timing. J.Int.Neuropsychol.Soc. 2, 323-334.
652. van Vugt,J.P., van Hilten,B.J., and Roos,R.A., 1996. Hypokinesia in Huntington's
disease. Mov Disord. 11, 384-388.
653. Weeks,R.A., Piccini,P., Harding,A.E., and Brooks,D.J., 1996. Striatal D1 and D2
dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease.
Ann.Neurol. 40, 49-54.
654. Zappacosta,B., Monza,D., Meoni,C., Austoni,L., Soliveri,P., Gellera,C., Alberti,R.,
Mantero,M., Penati,G., Caraceni,T., and Girotti,F., 1996. Psychiatric symptoms do not
correlate with cognitive decline, motor symptoms, or CAG repeat length in Huntington's
disease. Arch.Neurol. 53, 493-497.
655. Siemers,E., Foroud,T., Bill,D.J., Sorbel,J., Norton,J.A., Jr., Hodes,M.E., Niebler,G.,
Conneally,P.M., and Christian,J.C., 1996. Motor changes in presymptomatic Huntington
disease gene carriers. Arch.Neurol. 53, 487-492.
656. Claus,J.J. and Mohr,E., 1996. Attentional deficits in Alzheimer's, Parkinson's, and
Huntington's diseases. Acta Neurol.Scand. 93, 346-351.
657. Frank,E.M., McDade,H.L., and Scott,W.K., 1996. Naming in dementia secondary to
Parkinson's, Huntington's, and Alzheimer's diseases. J.Commun.Disord. 29, 183-197.
658. Hanes,K.R., Andrewes,D.G., Pantelis,C., and Chiu,E., 1996. Subcortical dysfunction in
schizophrenia: a comparison with Parkinson's disease and Huntington's disease.
Schizophr.Res. 19, 121-128.
659. Feigin,A., Kieburtz,K., Como,P., Hickey,C., Claude,K., Abwender,D., Zimmerman,C.,
Steinberg,K., and Shoulson,I., 1996. Assessment of coenzyme Q10 tolerability in
Huntington's disease. Mov Disord. 11, 321-323.
660. Kieburtz,K., Feigin,A., McDermott,M., Como,P., Abwender,D., Zimmerman,C.,
Hickey,C., Orme,C., Claude,K., Sotack,J., Greenamyre,J.T., Dunn,C., and Shoulson,I.,
1996. A controlled trial of remacemide hydrochloride in Huntington's disease. Mov Disord.
11, 273-277.
661. Harris,G.J., Aylward,E.H., Peyser,C.E., Pearlson,G.D., Brandt,J., Roberts-Twillie,J.V.,
Barta,P.E., and Folstein,S.E., 1996. Single photon emission computed tomographic blood
flow and magnetic resonance volume imaging of basal ganglia in Huntington's disease.
Arch.Neurol. 53, 316-324.
662. Gomez-Tortosa,E., del,B.A., Barroso,T., and Garcia Ruiz,P.J., 1996. Visual processing
disorders in patients with Huntington's disease and asymptomatic carriers. J.Neurol. 243,
286-292.
663. Taylor-Robinson,S.D.,
Weeks,R.A.,
Bryant,D.J.,
Sargentoni,J.,
Marcus,C.D.,
Harding,A.E., and Brooks,D.J., 1996. Proton magnetic resonance spectroscopy in
Huntington's disease: evidence in favour of the glutamate excitotoxic theory. Mov Disord.
11, 167-173.
664. Weigell-Weber,M., Schmid,W., and Spiegel,R., 1996. Psychiatric symptoms and CAG
expansion in Huntington's disease. Am.J.Med.Genet. 67, 53-57.
665. Sharma,P., Savy,L., Britton,J., Taylor,R., Howick,A., and Patton,M., 1996. Huntington's
disease: a molecular genetic and CT comparison. J.Neurol.Neurosurg.Psychiatry 60, 206208.
666. Brandt,J., Bylsma,F.W., Gross,R., Stine,O.C., Ranen,N., and Ross,C.A., 1996.
Trinucleotide repeat length and clinical progression in Huntington's disease. Neurology 46,
527-531.
667. Mandich,P., Di,M.E., Bellone,E., Ajmar,F., and Abbruzzese,G., 1996. Molecular analysis
of the IT15 gene in patients with apparently 'sporadic' Huntington's disease. Eur.Neurol. 36,
348-352.
668. Brandt,J., Bylsma,F.W., Aylward,E.H., Rothlind,J., and Gow,C.A., 1995. Impaired
source memory in Huntington's disease and its relation to basal ganglia atrophy.
J.Clin.Exp.Neuropsychol. 17, 868-877.
669. Tsai,T.T., Lasker,A., and Zee,D.S., 1995. Visual attention in Huntington's disease: the
effect of cueing on saccade latencies and manual reaction times. Neuropsychologia 33,
1617-1626.
670. Peyser,C.E., Folstein,M., Chase,G.A., Starkstein,S., Brandt,J., Cockrell,J.R., Bylsma,F.,
Coyle,J.T., McHugh,P.R., and Folstein,S.E., 1995. Trial of d-alpha-tocopherol in
Huntington's disease. Am.J.Psychiatry 152, 1771-1775.
671. Rebok,G.W., Bylsma,F.W., Keyl,P.M., Brandt,J., and Folstein,S.E., 1995. Automobile
driving in Huntington's disease. Mov Disord. 10, 778-787.
672. Albanese,A., Cassetta,E., Carretta,D., Bentivoglio,A.R., and Tonali,P., 1995. Acute
challenge with apomorphine in Huntington's disease: a double-blind study.
Clin.Neuropharmacol. 18, 427-434.
673. Filoteo,J.V., Delis,D.C., Roman,M.J., Demadura,T., Ford,E., Butters,N., Salmon,D.P.,
Paulsen,J., Shults,C.W., Swenson,M., and ., 1995. Visual attention and perception in
patients with Huntington's disease: comparisons with other subcortical and cortical
dementias. J.Clin.Exp.Neuropsychol. 17, 654-667.
674. Martin,W.R., Hoskinson,M., Kremer,B., Maguire,C., and McEwan,A., 1995. Functional
caudate imaging in symptomatic Huntington's disease: positron emission tomography
versus single-photon emission computed tomography. J.Neuroimaging 5, 227-232.
675. Georgiou,N., Bradshaw,J.L., Phillips,J.G., Bradshaw,J.A., and Chiu,E., 1995. The Simon
effect and attention deficits in Gilles de la Tourette's syndrome and Huntington's disease.
Brain 118 ( Pt 5), 1305-1318.
676. Bamford,K.A., Caine,E.D., Kido,D.K., Cox,C., and Shoulson,I., 1995. A prospective
evaluation of cognitive decline in early Huntington's disease: functional and radiographic
correlates. Neurology 45, 1867-1873.
677. Leblhuber,F., Peichl,M., Neubauer,C., Reisecker,F., Steinparz,F.X., Windhager,E., and
Maschek,W., 1995. Serum dehydroepiandrosterone and cortisol measurements in
Huntington's chorea. J.Neurol.Sci. 132, 76-79.
678. Claes,S., Van,Z.K., Legius,E., Dom,R., Malfroid,M., Baro,F., Godderis,J., and
Cassiman,J.J., 1995. Correlations between triplet repeat expansion and clinical features in
Huntington's disease. Arch.Neurol. 52, 749-753.
679. Ho,V.B., Chuang,H.S., Rovira,M.J., and Koo,B., 1995. Juvenile Huntington disease: CT
and MR features. AJNR Am.J.Neuroradiol. 16, 1405-1412.
680. Rosenberg,N.K., Sorensen,S.A., and Christensen,A.L., 1995. Neuropsychological
characteristics of Huntington's disease carriers: a double blind study. J.Med.Genet. 32, 600604.
681. Georgiou,N., Bradshaw,J.L., Phillips,J.G., Chiu,E., and Bradshaw,J.A., 1995. Reliance
on advance information and movement sequencing in Huntington's disease. Mov Disord.
10, 472-481.
682. Jankovic,J., Beach,J., and Ashizawa,T., 1995. Emotional and functional impact of DNA
testing on patients with symptoms of Huntington's disease. J.Med.Genet. 32, 516-518.
683. Jacobs,D.H., Shuren,J., and Heilman,K.M., 1995. Impaired perception of facial identity
and facial affect in Huntington's disease. Neurology 45, 1217-1218.
684. Turjanski,N., Weeks,R., Dolan,R., Harding,A.E., and Brooks,D.J., 1995. Striatal D1 and
D2 receptor binding in patients with Huntington's disease and other choreas. A PET study.
Brain 118 ( Pt 3), 689-696.
685. Lundervold,A.J. and Reinvang,I., 1995. Variability in cognitive function among persons
at high genetic risk of Huntington's disease. Acta Neurol.Scand. 91, 462-469.
686. Foroud,T., Siemers,E., Kleindorfer,D., Bill,D.J., Hodes,M.E., Norton,J.A.,
Conneally,P.M., and Christian,J.C., 1995. Cognitive scores in carriers of Huntington's
disease gene compared to noncarriers. Ann.Neurol. 37, 657-664.
687. Paulsen,J.S., Butters,N., Sadek,J.R., Johnson,S.A., Salmon,D.P., Swerdlow,N.R., and
Swenson,M.R., 1995. Distinct cognitive profiles of cortical and subcortical dementia in
advanced illness. Neurology 45, 951-956.
688. Lange,K.W., Sahakian,B.J., Quinn,N.P., Marsden,C.D., and Robbins,T.W., 1995.
Comparison of executive and visuospatial memory function in Huntington's disease and
dementia
of
Alzheimer
type
matched
for
degree
of
dementia.
J.Neurol.Neurosurg.Psychiatry 58, 598-606.
689. Blackmore,L., Simpson,S.A., and Crawford,J.R., 1995. Cognitive performance in UK
sample of presymptomatic people carrying the gene for Huntington's disease. J.Med.Genet.
32, 358-362.
690. Reilmann,R., Rolf,L.H., and Lange,H.W., 1995. Decreased plasma alanine and isoleucine
in Huntington's disease. Acta Neurol.Scand. 91, 222-224.
691. Phillips,J.G., Chiu,E., Bradshaw,J.L., and Iansek,R., 1995. Impaired movement
sequencing in patients with Huntington's disease: a kinematic analysis. Neuropsychologia
33, 365-369.
692. Feigin,A., Kieburtz,K., Bordwell,K., Como,P., Steinberg,K., Sotack,J., Zimmerman,C.,
Hickey,C., Orme,C., and Shoulson,I., 1995. Functional decline in Huntington's disease.
Mov Disord. 10, 211-214.
693. Durr,A., Dode,C., Hahn,V., Pecheux,C., Pillon,B., Feingold,J., Kaplan,J.C., Agid,Y., and
Brice,A., 1995. Diagnosis of "sporadic" Huntington's disease. J.Neurol.Sci. 129, 51-55.
694. Garcia Ruiz,P.J., Mena,M.A., Sanchez,B., V, Diaz,N.W., Gimenez,R.S., Benitez,J., and
Garcia de,Y.J., 1995. Cerebrospinal fluid homovanillic acid is reduced in untreated
Huntington's disease. Clin.Neuropharmacol. 18, 58-63.
695. Sprengelmeyer,R., Lange,H., and Homberg,V., 1995. The pattern of attentional deficits in
Huntington's disease. Brain 118 ( Pt 1), 145-152.
696. Swerdlow,N.R., Paulsen,J., Braff,D.L., Butters,N., Geyer,M.A., and Swenson,M.R.,
1995. Impaired prepulse inhibition of acoustic and tactile startle response in patients with
Huntington's disease. J.Neurol.Neurosurg.Psychiatry 58, 192-200.
697. Piolti,R., Appollonio,I., Perego,M., Pozzi,C., Rovati,L., Ferrarese,C., and Frattola,L.,
1995. Proglumide, a cholecystokinin receptor antagonist, reduces neuroleptic action in
Huntington's chorea. Eur.Neurol. 35, 344-348.
698. Sprengelmeyer,R., Canavan,A.G., Lange,H.W., and Homberg,V., 1995. Associative
learning in degenerative neostriatal disorders: contrasts in explicit and implicit
remembering between Parkinson's and Huntington's diseases. Mov Disord. 10, 51-65.
699. Giordani,B., Berent,S., Boivin,M.J., Penney,J.B., Lehtinen,S., Markel,D.S.,
Hollingsworth,Z., Butterbaugh,G., Hichwa,R.D., Gusella,J.F., and ., 1995. Longitudinal
neuropsychological and genetic linkage analysis of persons at risk for Huntington's disease.
Arch.Neurol. 52, 59-64.
700. Schwagerl,A.L., Mohan,P.S., Cataldo,A.M., Vonsattel,J.P., Kowall,N.W., and
Nixon,R.A., 1995. Elevated levels of the endosomal-lysosomal proteinase cathepsin D in
cerebrospinal fluid in Alzheimer disease. J.Neurochem. 64, 443-446.
701. Decruyenaere,M., Evers-Kiebooms,G., Boogaerts,A., Cassiman,J.J., Cloostermans,T.,
Demyttenaere,K., Dom,R., Fryns,J.P., and Van den,B.H., 1995. Predictive testing for
Huntington's disease: risk perception, reasons for testing and psychological profile of test
applicants. Genet.Couns. 6, 1-13.
702. Paulsen,J.S., Salmon,D.P., Monsch,A.U., Butters,N., Swenson,M.R., and Bondi,M.W.,
1995. Discrimination of cortical from subcortical dementias on the basis of memory and
problem-solving tests. J.Clin.Psychol. 51, 48-58.
703. Ackermann,H., Hertrich,I., and Hehr,T., 1995. Oral diadochokinesis in neurological
dysarthrias. Folia Phoniatr.Logop. 47, 15-23.
704. Silvestri,R., Raffaele,M., De,D.P., Tisano,A., Mento,G., Casella,C., Tripoli,M.C.,
Serra,S., and Di,P.R., 1995. Sleep features in Tourette's syndrome, neuroacanthocytosis and
Huntington's chorea. Neurophysiol.Clin. 25, 66-77.
705. Reilmann,R., Rolf,L.H., and Lange,H.W., 1994. Huntington's disease: the
neuroexcitotoxin aspartate is increased in platelets and decreased in plasma. J.Neurol.Sci.
127, 48-53.
706. James,C.M., Houlihan,G.D., Snell,R.G., Cheadle,J.P., and Harper,P.S., 1994. Late-onset
Huntington's disease: a clinical and molecular study. Age Ageing 23, 445-448.
707. Rosser,A. and Hodges,J.R., 1994. Initial letter and semantic category fluency in
Alzheimer's disease, Huntington's disease, and progressive supranuclear palsy.
J.Neurol.Neurosurg.Psychiatry 57, 1389-1394.
708. Tibben,A., Duivenvoorden,H.J., Niermeijer,M.F., Vegter-van,d., V, Roos,R.A., and
Verhage,F., 1994. Psychological effects of presymptomatic DNA testing for Huntington's
disease in the Dutch program. Psychosom.Med. 56, 526-532.
709. Kieburtz,K., MacDonald,M., Shih,C., Feigin,A., Steinberg,K., Bordwell,K.,
Zimmerman,C., Srinidhi,J., Sotack,J., Gusella,J., and ., 1994. Trinucleotide repeat length
and progression of illness in Huntington's disease. J.Med.Genet. 31, 872-874.
710. Illarioshkin,S.N., Igarashi,S., Onodera,O., Markova,E.D., Nikolskaya,N.N., Tanaka,H.,
Chabrashwili,T.Z., Insarova,N.G., Endo,K., Ivanova-Smolenskaya,I.A., and ., 1994.
Trinucleotide repeat length and rate of progression of Huntington's disease. Ann.Neurol. 36,
630-635.
711. van,d.S., I, Tibben,A., Roos,R.A., van de Kamp,J.J., and Niermeijer,M.F., 1994.
Predictive testing for Huntington disease: nonparticipants compared with participants in the
Dutch program. Am.J.Hum.Genet. 55, 618-625.
712. Benjamin,C.M., Adam,S., Wiggins,S., Theilmann,J.L., Copley,T.T., Bloch,M.,
Squitieri,F., McKellin,W., Cox,S., Brown,S.A., and ., 1994. Proceed with care: direct
predictive testing for Huntington disease. Am.J.Hum.Genet. 55, 606-617.
713. Shiwach,R., 1994. Psychopathology
Psychiatr.Scand. 90, 241-246.
in
Huntington's
disease
patients.
Acta
714. Shiwach,R.S. and Norbury,C.G., 1994. A controlled psychiatric study of individuals at
risk for Huntington's disease. Br.J.Psychiatry 165, 500-505.
715. Davis,M.B., Bateman,D., Quinn,N.P., Marsden,C.D., and Harding,A.E., 1994. Mutation
analysis in patients with possible but apparently sporadic Huntington's disease. Lancet 344,
714-717.
716. Milstien,S., Sakai,N., Brew,B.J., Krieger,C., Vickers,J.H., Saito,K., and Heyes,M.P.,
1994. Cerebrospinal fluid nitrite/nitrate levels in neurologic diseases. J.Neurochem. 63,
1178-1180.
717. Sax,D.S., Kornetsky,C., and Kim,A., 1994. Lack of hepatotoxicity with naltrexone
treatment. J.Clin.Pharmacol. 34, 898-901.
718. Pasquier,F., Van der,L.M., Lefebvre,V., Lefebvre,C., Bruyer,R., and Petit,H., 1994.
Motor memory and the preselection effect in Huntington's and Parkinson's disease.
Neuropsychologia 32, 951-968.
719. Hashimoto,T. and Yanagisawa,N., 1994. A comparison of the regularity of involuntary
muscle contractions in vascular chorea with that in Huntington's chorea, hemiballism and
parkinsonian tremor. J.Neurol.Sci. 125, 87-94.
720. Peavy,G., Jacobs,D., Salmon,D.P., Butters,N., Delis,D.C., Taylor,M., Massman,P.,
Stout,J.C., Heindel,W.C., Kirson,D., and ., 1994. Verbal memory performance of patients
with human immunodeficiency virus infection: evidence of subcortical dysfunction. The
HNRC Group. J.Clin.Exp.Neuropsychol. 16, 508-523.
721. Hertrich,I. and Ackermann,H., 1994. Acoustic analysis of speech timing in Huntington's
disease. Brain Lang 47, 182-196.
722. Rosser,A.E. and Hodges,J.R., 1994. The Dementia Rating Scale in Alzheimer's disease,
Huntington's disease and progressive supranuclear palsy. J.Neurol. 241, 531-536.
723. Boecker,H., Kuwert,T., Langen,K.J., Lange,H.W., Czech,N., Ziemons,K., Herzog,H.,
Shikare,S., Weindl,A., and Feinendegen,L.E., 1994. SPECT with HMPAO compared to
PET with FDG in Huntington disease. J.Comput.Assist.Tomogr. 18, 542-548.
724. Pillon,B., Deweer,B., Michon,A., Malapani,C., Agid,Y., and Dubois,B., 1994. Are
explicit memory disorders of progressive supranuclear palsy related to damage to
striatofrontal circuits? Comparison with Alzheimer's, Parkinson's, and Huntington's
diseases. Neurology 44, 1264-1270.
725. Taylor-Robinson,S.D.,
Weeks,R.A.,
Sargentoni,J.,
Marcus,C.D.,
Bryant,D.J.,
Harding,A.E., and Brooks,D.J., 1994. Evidence for glutamate excitotoxicity in Huntington's
disease with proton magnetic resonance spectroscopy. Lancet 343, 1170726. Aylward,E.H., Brandt,J., Codori,A.M., Mangus,R.S., Barta,P.E., and Harris,G.J., 1994.
Reduced basal ganglia volume associated with the gene for Huntington's disease in
asymptomatic at-risk persons. Neurology 44, 823-828.
727. Bonuccelli,U., Ceravolo,R., Maremmani,C., Nuti,A., Rossi,G., and Muratorio,A., 1994.
Clozapine in Huntington's chorea. Neurology 44, 821-823.
728. Trottier,Y., Biancalana,V., and Mandel,J.L., 1994. Instability of CAG repeats in
Huntington's disease: relation to parental transmission and age of onset. J.Med.Genet. 31,
377-382.
729. Morrison,P.J. and Nevin,N.C., 1994. Serum iron, total iron binding capacity and ferritin
in early Huntington disease patients. Ir.J.Med.Sci. 163, 236-237.
730. Lundervold,A.J., Karlsen,N.R., and Reinvang,I., 1994. Assessment of 'subcortical
dementia' in patients with Huntington's disease, Parkinson's disease, multiple sclerosis and
AIDS by a neuropsychological screening battery. Scand.J.Psychol. 35, 48-55.
731. Lundervold,A.J., Reinvang,I., and Lundervold,A., 1994. Characteristic patterns of verbal
memory function in patients with Huntington's disease. Scand.J.Psychol. 35, 38-47.
732. Bylsma,F.W., Peyser,C.E., Folstein,S.E., Folstein,M.F., Ross,C., and Brandt,J., 1994.
EEG power spectra in Huntington's disease: clinical and neuropsychological correlates.
Neuropsychologia 32, 137-150.
733. Homberg,V. and Huttunen,J., 1994. Muscle tone in Huntington's disease. J.Neurol.Sci.
121, 147-154.
734. Sedvall,G., Karlsson,P., Lundin,A., Anvret,M., Suhara,T., Halldin,C., and Farde,L., 1994.
Dopamine D1 receptor number--a sensitive PET marker for early brain degeneration in
Huntington's disease. Eur.Arch.Psychiatry Clin.Neurosci. 243, 249-255.
735. Fedoroff,J.P., Peyser,C., Franz,M.L., and Folstein,S.E., 1994. Sexual disorders in
Huntington's disease. J.Neuropsychiatry Clin.Neurosci. 6, 147-153.
736. Kandil,M.R., Tohamy,S.A., Fattah,M.A., Ahmed,H.N., and Farwiez,H.M., 1994.
Prevalence of chorea, dystonia and athetosis in Assiut, Egypt: a clinical and
epidemiological study. Neuroepidemiology 13, 202-210.
737. Pearson,S.J. and Reynolds,G.P., 1994. Neocortical neurotransmitter markers in
Huntington's disease. J.Neural Transm.Gen.Sect. 98, 197-207.
738. Lipe,H., Schultz,A., and Bird,T.D., 1993. Risk factors for suicide in Huntingtons disease:
a retrospective case controlled study. Am.J.Med.Genet. 48, 231-233.
739. Jensen,P., Sorensen,S.A., Fenger,K., and Bolwig,T.G., 1993. A study of psychiatric
morbidity in patients with Huntington's disease, their relatives, and controls. Admissions to
psychiatric hospitals in Denmark from 1969 to 1991. Br.J.Psychiatry 163, 790-797.
740. Jenkins,B.G., Koroshetz,W.J., Beal,M.F., and Rosen,B.R., 1993. Evidence for
impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR
spectroscopy. Neurology 43, 2689-2695.
741. Kremer,B., Squitieri,F., Telenius,H., Andrew,S.E., Theilmann,J., Spence,N.,
Goldberg,Y.P., and Hayden,M.R., 1993. Molecular analysis of late onset Huntington's
disease. J.Med.Genet. 30, 991-995.
742. Simpson,S.A., Davidson,M.J., and Barron,L.H., 1993. Huntington's disease in Grampian
region: correlation of the CAG repeat number and the age of onset of the disease.
J.Med.Genet. 30, 1014-1017.
743. Craufurd,D. and Dodge,A., 1993. Mutation size and age at onset in Huntington's disease.
J.Med.Genet. 30, 1008-1011.
744. Jahanshahi,M., Brown,R.G., and Marsden,C.D., 1993. A comparative study of simple and
choice reaction time in Parkinson's, Huntington's and cerebellar disease.
J.Neurol.Neurosurg.Psychiatry 56, 1169-1177.
745. Kuwert,T., Lange,H.W., Boecker,H., Titz,H., Herzog,H., Aulich,A., Wang,B.C.,
Nayak,U., and Feinendegen,L.E., 1993. Striatal glucose consumption in chorea-free
subjects at risk of Huntington's disease. J.Neurol. 241, 31-36.
746. MacMillan,J.C., Snell,R.G., Tyler,A., Houlihan,G.D., Fenton,I., Cheadle,J.P.,
Lazarou,L.P., Shaw,D.J., and Harper,P.S., 1993. Molecular analysis and clinical
correlations of the Huntington's disease mutation. Lancet 342, 954-958.
747. Tibben,A., Duivenvoorden,H.J., Vegter-van,d., V, Niermeijer,M.F., Frets,P.G., van de
Kamp,J.J., Roos,R.A., Rooijmans,H.G., and Verhage,F., 1993. Presymptomatic DNA
testing for Huntington disease: identifying the need for psychological intervention.
Am.J.Med.Genet. 48, 137-144.
748. Stine,O.C., Pleasant,N., Franz,M.L., Abbott,M.H., Folstein,S.E., and Ross,C.A., 1993.
Correlation between the onset age of Huntington's disease and length of the trinucleotide
repeat in IT-15. Hum.Mol.Genet. 2, 1547-1549.
749. Paulus,W., Schwarz,G., Werner,A., Lange,H., Bayer,A., Hofschuster,M., Muller,N., and
Zrenner,E., 1993. Impairment of retinal increment thresholds in Huntington's disease.
Ann.Neurol. 34, 574-578.